

Withdrawal/Redaction Sheet

Clinton Library

DOCUMENT NO. AND TYPE	SUBJECT/TITLE	DATE	RESTRICTION
001. email	From: Jeffrey Levi, To: Patricia Romani, Re: Mardi Gras [Personally Identifiable Information] [partial] (1 page)	02/20/1996	b(6)
002. email	From: Jeffrey Levi, To: Julie Demeo, Re: Mardi Gras [Personally Identifiable Information] [partial] (1 page)	02/20/1996	b(6)
003. email	From: Rosalyn Miller, To: Many Recipients, Re: Surprise Party!!!! (2 pages)	02/21/1996	Personal Misfile
004. email	From: Dorothy Karayannis, To: Many Recipients, Re: Thank You! (2 pages)	02/22/1996	Personal Misfile
005. email	From: Dorothy Karayannis, To: Many Recipients, Re: Surprise Birthday Breakfast (2 pages)	02/22/1996	Personal Misfile
006. email	From: Nancy-Ann Min, To: Jeffrey Levi, Re: ADAP Update [partial] (1 page)	02/23/1996	b(6)
007. email	From: Dorothy Karayannis, To: Many Recipients, Re: Brian's Party (2 pages)	02/23/1996	Personal Misfile

COLLECTION:

Clinton Presidential Records
Automated Records Management System [Email]
WHO ([Jeffrey Levi...])
OA/Box Number: 500000

FOLDER TITLE:

[02/19/1996 - 02/23/1996]

2018-0759-F

in397

RESTRICTION CODES

Presidential Records Act - [44 U.S.C. 2204(a)]

- P1 National Security Classified Information [(a)(1) of the PRA]
- P2 Relating to the appointment to Federal office [(a)(2) of the PRA]
- P3 Release would violate a Federal statute [(a)(3) of the PRA]
- P4 Release would disclose trade secrets or confidential commercial or financial information [(a)(4) of the PRA]
- P5 Release would disclose confidential advice between the President and his advisors, or between such advisors [(a)(5) of the PRA]
- P6 Release would constitute a clearly unwarranted invasion of personal privacy [(a)(6) of the PRA]

C. Closed in accordance with restrictions contained in donor's deed of gift.

PRM. Personal record misfile defined in accordance with 44 U.S.C. 2201(3).

RR. Document will be reviewed upon request.

Freedom of Information Act - [5 U.S.C. 552(b)]

- b(1) National security classified information [(b)(1) of the FOIA]
- b(2) Release would disclose internal personnel rules and practices of an agency [(b)(2) of the FOIA]
- b(3) Release would violate a Federal statute [(b)(3) of the FOIA]
- b(4) Release would disclose trade secrets or confidential or financial information [(b)(4) of the FOIA]
- b(6) Release would constitute a clearly unwarranted invasion of personal privacy [(b)(6) of the FOIA]
- b(7) Release would disclose information compiled for law enforcement purposes [(b)(7) of the FOIA]
- b(8) Release would disclose information concerning the regulation of financial institutions [(b)(8) of the FOIA]
- b(9) Release would disclose geological or geophysical information concerning wells [(b)(9) of the FOIA]

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:19-FEB-1996 14:31:04.32

SUBJECT: still more news

TO: Patsy Fleming (FLEMING_P) (WHO)

READ:19-FEB-1996 14:57:29.96

TEXT:

===== ATTACHMENT 1 =====

ATT CREATION TIME/DATE:15-FEB-1996 08:23:00.00

ATT BODYPART TYPE:E

ATT CREATOR: aidsnews

ATT SUBJECT: CDC AIDS Daily Summary 02/15/96

ATT TO: levi_j (levi_j@A1@CD)

TEXT:

AIDS Daily Summary
February 15, 1996

The Centers for Disease Control and Prevention (CDC) National AIDS Clearinghouse makes available the following information as a public service only. Providing this information does not constitute endorsement by the CDC, the CDC Clearinghouse, or any other organization. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC Clearinghouse should be cited as the source of this information.
Copyright 1996, Information, Inc., Bethesda, MD

"New York to Screen Boxers for H.I.V."

"Military HIV Ban Defended by Gingrich"

"Today's Debate: Mandatory AIDS Testing"

"Women-Friendly AIDS Protection"

"HIV Deadly Weapon?"

"Lawyer Gets Virulent in Case of HIV Cop"

"Voices: Should Professional Athletes Be Required to Be Tested
for the AIDS Virus?"

"IV Drug Use Compromises Integrity of Cell Membranes Prior to HIV
Infection"

"Modified Microbe May Boost TB Vaccine"

"The Challenge of Maternal-Infant Transmission of HIV"

"New York to Screen Boxers for H.I.V."

New York Times (02/15/96) P. B17; Sandomir, Richard

The New York State Athletic Commission announced Wednesday that boxers would be screened annually for HIV before fighting.

Nevada, Oregon, Washington, and Arizona are the only other states to currently require testing. The commission said it is implementing the test as a result of the finding that heavyweight Tommy Morrison has HIV. Floyd Patterson, the commission chairman, said, "because of the very nature of boxing, the risk of HIV transmission from blood-to-blood contact is there. We must do everything we can to protect the health and well-being of those who compete in New York." Past chairman Randy Gordon said he pushed for the mandate for seven years and was told that it would require new legislation. The new policy may be the result of broader interpretation of existing law under New York Gov. George E. Pataki. The American Civil Liberties Union has argued that the policy must be supported by medical evidence that boxers are at risk for HIV transmission, something which is currently being debated among experts. Related Stories: Washington Post (02/15/96) P. D4; USA Today (02/15/96) P. 1C

"Military HIV Ban Defended by Gingrich"

Washington Post (02/15/96) P. A7; Yang, John E.

Speaker of the House Newt Gingrich (R-Ga.) found fault with President Clinton and basketball player Earvin "Magic" Johnson for supporting a repeal of a new policy that would force the discharge of all HIV-positive military members. Gingrich charged on Wednesday that Clinton and Johnson do not understand combat, although Gingrich obtained deferments from military service himself. Gingrich said that "no one who has ever studied seriously how bad combat can get wants to have a person in your unit who's HIV-positive because you have a real danger of transferring blood." Current military policy, however, already prevents people with HIV from serving in combat. Gingrich made the comments in response to a letter from Johnson, who asked for support for Clinton's attempts to repeal the provision.

"Today's Debate: Mandatory AIDS Testing"

USA Today (02/15/96) P. 10A

A USA Today editorial, followed by a response from Bill Eastman of the California Athletic Commission, addresses the issue of mandatory HIV testing for athletes. The editorial calls the demands for mandatory testing "irrational." The editors claim that the risk of HIV transmission in the ring is trivial compared to the risk of brain damage and that boxing officials should focus more on the HIV risks boxers face outside the ring, such as unsafe sex and shared needles. In opposition, Eastman notes that HIV testing is a safety issue, that mucous and blood are commonly commingled between boxers in the ring. Even though the risk is low, he says, testing would offer protection. He says each sport should be considered individually. In California, a law to require the test for boxers has failed before but will now find support, Eastman predicts.

"Women-Friendly AIDS Protection"

USA Today (2/14/96) P. 9D; Painter, Kim

Scientists attempting to develop microbicides--vaginal creams or gels that women can use to protect themselves from AIDS and other sexually transmitted diseases--have several promising leads. Research is ongoing for products that might directly eliminate bacteria and viruses as well as others that might make the vaginal environment more able to resist infection. According to Sharon Hillier of the University of Pittsburgh, the aim is to discover "low-tech, user-friendly" compounds that are inexpensive and can be used without a partner's knowledge. Hillier is examining a vaginal suppository containing lactobacilli--bacteria that are found naturally in the vagina and are related to strains found in yogurt--while other researchers are working on products that would alter the acid balance of the vagina or coat cells to prevent infection. Related Story: Boston Globe (02/14) P. 56

"HIV Deadly Weapon?"

Houston Chronicle (02/14/96) P. 24A

In a rape trial in Austin, Texas, prosecutors in an aggravated sexual assault trial are trying to show that Jose Fonseca Najera's HIV-positive status constitutes a "deadly weapon." Police say the 16-year-old girl who Najera is accused of raping died of exposure three days after Najera forced her and a 15-year-old boy to spray each other with a hose and then locked them outside overnight in near-freezing conditions.

"Lawyer Gets Virulent in Case of HIV Cop"

Miami Herald (02/14/96) P. B1; Balmaseda, Liz

Miami Beach lawyer Joel Hirschhorn is threatening to sue the city for exposing Wyn Morris to HIV by allowing an HIV-positive police officer to serve. Ambrose Sims arrested Hirschhorn's client on Dec. 20 for battery on a police officer and resisting arrest, after Morris became angry when her car was towed from a drive-through teller lane at a bank. Thus far, Hirschhorn has attempted to damage Sim's record through allegations and reports to his personnel file. He has also charged that Sim's mind has been affected by HIV drugs.

"Voices: Should Professional Athletes Be Required to Be Tested for the AIDS Virus?"

USA Today (02/14/96) P. 12A

USA Today conducted a poll of its readers regarding the HIV testing of professional athletes in response to the news that boxer Tommy Morrison tested positive for the virus. Milt Richards of Albany, N.Y. said the tests should not be required, unless the "medical community can document the need for such testing for medical reasons." Eleven-year-old Kim Judd of Vernon, Wis. thinks the test should be mandatory as a matter of responsibility. Meanwhile, Ken Rice of Dellwood, Mo. said the test should not be required because athletes should be given the same rights as the rest of the public. Wanda Molina of Arecibo, P.R. said for sports where a lot of blood is shed, like boxing, the test is needed, but not in other sports. R. Scott Van Dyke

of Tulsa, Okla. said the test should be required for all sports.

"IV Drug Use Compromises Integrity of Cell Membranes Prior to HIV Infection"

Reuters (02/14/96)

Researchers in Switzerland have reported that intravenous drug use "compromises the biochemical and structural integrity of the membrane surface" of blood cells even before HIV infection. The researchers studied the blood cells of 101 injection drug users, including 91 who were HIV-positive, as well as the blood of a control group HIV-negative IV drug users. The scientists found that both groups had abnormal surface enzyme kinetics in their peripheral blood mononuclear cells.

"Modified Microbe May Boost TB Vaccine"

Science (01/26/96) Vol.271, No.5248, P. 447; Roush, Wade

A relatively harmless mycobacterium, bacille Calmette-Guerin (BCG), has been widely used as a vaccine against the tuberculosis (TB) organism because the similarity between their proteins appears to arm the body's immune system against a TB attack. BCG does not always remain protective, and now intercellular messengers called cytokines may be used to bolster the immune system. Researchers at the Whitehead Institute for Biomedical Research in Cambridge, Massachusetts, have engineered BCG to express several mouse cytokines that stimulate immune cells to attack an invader. They report that giving mice the engineered bacterium greatly improved their cells' immune responses to TB. Other researchers are praising the achievement, which raises the hopes for an improved TB vaccine, and could lead to better cancer therapies as well. While the procedure has been proven to work, Kenneth Stover, a molecular microbiologist at the Seattle firm PathoGenesis, says that "it's potentially exciting. There is definitely room for an improved BCG vaccine, and this may be a much cheaper, safer way to do it than adding cytokines as drugs."

"The Challenge of Maternal-Infant Transmission of HIV"

Journal of the Association of Nurses in AIDS Care (01/96-02/96)

Vol.7, No.1, P. 47; Gallagher, Maureen A.; Klima, Carrie

The AIDS Clinical Trials Group has published results of a study showing that women and infants taking AZT had a significantly lower rate of HIV transmission from mother to infant. However, nurses Maureen A. Gallagher and Carrie Klima contend that the weaknesses of the study must be considered when applying these results. When first tested, 8.3 percent of the infants born to women who received AZT were infected with HIV, compared to 25.5 percent in the placebo group. Due to this preliminary finding, an independent safety board recommended that no additional women be enrolled and that AZT be offered to all those in the study who were eligible for the drug. Some aspects of the study, including the long-term effects of the drug, are still unknown. Dr. Ronald Bayer has voiced concern about the lack of information about the long-term use of AZT among the 70 percent to 80 percent of children who were exposed to AZT but would not have been born with HIV. The results of the study also generate ethical

questions about the womens' and infants' rights, mandatory HIV testing, and equal access to health care. HIV-infected pregnant women should be properly counseled on transmission of HIV to the infant, and the use of AZT to control transmission, the authors conclude.

===== END ATTACHMENT 1 =====

===== ATTACHMENT 2 =====

ATT CREATION TIME/DATE:15-FEB-1996 17:31:00.00

ATT BODYPART TYPE:D

TEXT:

RFC-822-headers:

Received: from storm.eop.gov (storm.eop.gov)

by PMDF.EOP.GOV (PMDf V5.0-4 #6879) id <011190W0N6DC00G399@PMDf.EOP.GOV> for levi_j@a1.eop.gov; Thu, 15 Feb 1996 17:29:22 -0400 (EDT)

Received: from aspensys ("port 45812"@aspensys.aspensys.com)

by STORM.EOP.GOV (PMDf V5.0-6 #6879) id <011190XDIL16001MXV@STORM.EOP.GOV> for levi_j@a1.eop.gov; Thu, 15 Feb 1996 17:30:28 -0700 (MST)

Received: by aspensys (5.0/SMI-SVR4) id AA00347; Thu, 15 Feb 1996 17:23:46 +0500

Errors-to: martha_vander_kolk@smtpinet.aspensys.com

Precedence: bulk

Originator: aidsnews@cdcnac.aspensys.com

X-Comment: CDC National AIDS Clearinghouse

X-Listprocessor-version: 6.0c -- ListProcessor by Anastasios Kotsikonas

===== END ATTACHMENT 2 =====

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:19-FEB-1996 12:33:30.24

SUBJECT: daily news

TO: Patsy Fleming (FLEMING_P) (WHO)

READ:19-FEB-1996 13:03:37.76

TEXT:

===== ATTACHMENT 1 =====

ATT CREATION TIME/DATE:12-FEB-1996 02:25:00.00

ATT BODYPART TYPE:E

ATT CREATOR: aidsnews

ATT SUBJECT: CDC AIDS Daily Summary 02/12 /96

ATT TO: levi_j (levi_j@A1@CD)

TEXT:

AIDS Daily Summary
February 12, 1996

The Centers for Disease Control and Prevention (CDC) National AIDS Clearinghouse makes available the following information as a public service only. Providing this information does not constitute endorsement by the CDC, the CDC Clearinghouse, or any other organization. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC Clearinghouse should be cited as the source of this information.
Copyright 1995, Information, Inc., Bethesda, MD

"Medical Suspension Creates Concern"

"Ignoring a Proven Lifesaver"

"Shark, Frog Compounds Fight Sex Disease"

"Medicaid Cuts Keep Many AIDS Patients from New Treatments"

"Clinton Signs Defense Bill, Blasts AIDS Provision"

"Doctor Hopes to Repeat Baboon Cell Transplant"

"Man Accused of Giving HIV to Four is Slain"

"Blood Supply: Possibly Tainted Product Withdrawn"

"Reduction of HIV Concentration During Acute Infection:

Independence from a Specific Immune Response"

"Ship to Shore"

"Medical Suspension Creates Concern"

New York Times (02/12/96) P. C1; Eskenazi, Gerald

Tommy Morrison, the former World Boxing Organization heavyweight champion, was suspended by the Nevada Athletic Commission on Saturday for an undisclosed medical reason. Although no one would say so, the suspected reason is that Morrison tested positive for HIV. Nevada is the only major boxing state that requires a pre-fight HIV test. A commission official said that if the reason had been an injury he would have released it. Neither the official of Morrison's promoter would deny that the fighter had the virus. Related Stories: Washington Post (02/12/96) P.C1; Philadelphia Inquirer (02/12/96) P.D1

"Ignoring a Proven Lifesaver"

Washington Post (02/12/96) P. A19; Graham, Jim

In a letter to the editors of the Washington Post, Jim Graham, director of the Whitman-Walker Clinic in Washington D.C., asserts that the city's needle exchange program could be an effective tool in slowing the spread of HIV, but that it is failing. He claims that the program, which was one of the first, is restricted by bureaucracy and limited funds. Furthermore, he notes, the number of IV-drug users in the city with AIDS has tripled in the last three years. The pilot program has been stopped and no needles are currently being exchanged. Graham adds that the program's costs are modest, and points out that studies of other programs have shown that they are effective.

"Shark, Frog Compounds Fight Sex Disease"

Washington Times (02/12/96) P. A7

Substances from the dogfish shark and the African clawed frog may be used to fight sexually transmitted diseases, including AIDS, scientists said Sunday. Dr. Leonard Jacob of Magainin Pharmaceuticals of Plymouth Meeting, Pa., said the compounds, called magainins or squalamines, have already passed preliminary testing and are being tested, or soon will be tested in humans. The substances are derived from the defense systems of the animals.

"Medicaid Cuts Keep Many AIDS Patients from New Treatments"

New York Times (02/12/96) P. A14; Sharp, Victoria L.; Stoddard, Tom

In two separate letters to the editor, the authors argue that government funding is necessary for many AIDS patients, especially as costs for drugs are rising. In one, Dr. Victoria Sharp, of the Spellman Center for HIV-Related Disease at St. Clare's Hospital, claims that proposed New York state and federal cuts in Medicaid will result in a "two-tiered medical system that denies treatment to the poor." Tom Stoddard writes in the second letter that the estimated \$70,000 price tag cited by the newspaper for treatments for advanced AIDS patients is low. The hopes offered by new therapies, he says, are unattainable for some patients, even some with medical coverage. Stoddard argues that medical care should be extended to those who need it.

"Clinton Signs Defense Bill, Blasts AIDS Provision"

Washington Post (02/11/96) P. A8

President Clinton signed the Defense appropriations bill Saturday, despite its inclusion of a provision that requires the discharge of all HIV-positive military members. The president called the provision "blatantly discriminatory," and said he supports efforts in Congress to repeal it before it takes effect in six months. Rep. Robert K. Dornan (R-Calif.), who sponsored the measure, said that attempts to repeal it will fail. "Bill Clinton continues to ignore the needs and requirements of the military while deferring to the wishes of a vocal minority who donate heavily to his presidential campaign," Dornan said. Clinton has called the provision unconstitutionally discriminatory and has instructed Attorney General Janet Reno not to defend it in court.

"Doctor Hopes to Repeat Baboon Cell Transplant"

Washington Post (02/11/96) P. A9; Weiss, Rick

Suzanne Ildstad, the University of Pittsburgh surgeon who transplanted baboon bone marrow into an AIDS patient two months ago, said she wants to repeat the controversial procedure with another patient in the next six months. She said the transplant was not successful in getting the baboon cells to survive in the patient, but noted that it did result in the patient becoming healthier. Ildstad discussed the transplant at the annual meeting of the American Association for the Advancement of Science in Baltimore. She said that patient Jeff Getty's improved health could be the result of a small number of surviving baboon cells or of the chemotherapy and radiation Getty received before the transplant. Ildstad said she would increase the chemotherapy dose in the next transplant, which would have to be approved by the Food and Drug Administration.

"Man Accused of Giving HIV to Four is Slain"

Philadelphia Inquirer (02/10/96) P. A11; Rose, Lori Dodge

Robert Warren, a married man who was accused of infecting four girlfriends with HIV, was shot and killed, two weeks before he was to be tried for one of those cases. St. Louis police said that a motive was still uncertain, but that revenge and drugs were possibilities. Warren was charged in April with HIV-infecting one of his girlfriends, and was set free on bail. Police said that Warren was known to be popular with women and that one woman continued to date him even after learning he had HIV. Warren admitted he never wore condoms, and police noted that he did not seem sorry for spreading the virus, but was frustrated that the arrest had interrupted his usual lifestyle.

"Blood Supply: Possibly Tainted Product Withdrawn"

Toronto Globe and Mail (02/09/96) P. A4

The Canadian Red Cross says it is withdrawing two lots of the blood product intravenous immune globulin, for fear that it could be tainted with Creutzfeldt-Jakob disease. The manufacturer, Bayer Inc., requested the withdrawal of about 16,000 vials of the product, which is used to treat patients with immune deficiencies.

"Reduction of HIV Concentration During Acute Infection:
Independence from a Specific Immune Response"
Science (01/26/96) Vol.271, No.5248, P. 497; Phillips, Andrew N.

After HIV infection, the virus' concentration in the plasma increases, and then decreases a few weeks later. This decrease was thought to be the result of an HIV-specific immune response. A mathematical model of the population dynamics of early HIV infection was devised to investigate this relationship. Variables were used to represent activated, uninfected CD4 cells, latently infected cells, actively infected cells and free virions. Changes in the virus concentration and CD4 cell count were tracked over time. The patterns resulting from the model approximate those observed in patients, with a peak of virus concentration a few weeks after infection and a rapid decline in CD4 cells which then stabilizes. The decrease, according to the model, was a result of population dynamics, not an immune response. The model did not explain how CD4 cells are gradually depleted after HIV infection. The results of the model suggest that the appearance of an HIV-specific immune response results from the high level of virus but is not a major cause of the decline. This could explain why some patients may have a decline in virus concentration even without a specific immune response.

"Ship to Shore"

POZ (02/96-03/96) No.12, P. 38; Blotcher, Jay

Sue Saunders, who learned she was HIV-positive at the age of 58, had resigned herself to death, until--while visiting one of her four children on a farewell trip--she learned she had several more years to live. Five years later she enjoys gardening, movies and working out. Saunders lives in Fort Lauderdale and volunteers at her local PWA Coalition. She has also videotaped an interview, called "It Can Happen To Me," for the American Association for Retired Persons about living with HIV.

===== END ATTACHMENT 1 =====

===== ATTACHMENT 2 =====

ATT CREATION TIME/DATE:12-FEB-1996 11:33:00.00

ATT BODYPART TYPE:D

TEXT:

RFC-822-headers:

Received: from storm.eop.gov (storm.eop.gov)

by PMDF.EOP.GOV (PMDf V5.0-4 #6879) id <01114HJ94ITS00AVZV@PMDf.EOP.GOV> for levi_j@al.eop.gov; Mon, 12 Feb 1996 11:32:16 -0400 (EDT)

Received: from aspensys ("port 62401"@aspensys.aspensys.com)

by STORM.EOP.GOV (PMDf V5.0-4 #6879) id <01114HG4JZMO0012M3@STORM.EOP.GOV> for levi_j@al.eop.gov; Mon, 12 Feb 1996 11:29:45 -0700 (MST)

Received: by aspensys (5.0/SMI-SVR4) id AA23512; Mon, 12 Feb 1996 11:25:47 +0500

Errors-to: martha_vander_kolk@smtpinet.aspensys.com

Precedence: bulk

Originator: aidsnews@cdcnac.aspensys.com

X-Comment: CDC National AIDS Clearinghouse

X-Listprocessor-version: 6.0c -- ListProcessor by Anastasios Kotsikonas
===== END ATTACHMENT 2 =====

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:19-FEB-1996 14:33:06.55

SUBJECT: still even more news

TO: Patsy Fleming (FLEMING_P) (WHO)

READ:19-FEB-1996 16:03:37.26

TEXT:

===== ATTACHMENT 1 =====

ATT CREATION TIME/DATE:16-FEB-1996 03:53:00.00

ATT BODYPART TYPE:E

ATT CREATOR: aidsnews

ATT SUBJECT: CDC AIDS Daily Summary 02/16/96

ATT TO: levi_j (levi_j@A1@CD)

TEXT:

AIDS Daily Summary
February 16, 1996

The Centers for Disease Control and Prevention (CDC) National AIDS Clearinghouse makes available the following information as a public service only. Providing this information does not constitute endorsement by the CDC, the CDC Clearinghouse, or any other organization. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC Clearinghouse should be cited as the source of this information.
Copyright 1996, Information, Inc., Bethesda, MD

"AIDS Deaths Continue to Rise in 25-44 Age Group, U.S. Says"

"Remorse From a Heavyweight"

"Sequus Drug Is Approved"

"N.J. Gives Hemophiliacs Hope on AIDS Lawsuits"

"Ryan White's Legacy"

"Answers on Blood Seem Elusive"

"Empiric Therapy for AIDS-Related Pneumonia Appropriate in Selected Cases"

"Risk of Kaposi Sarcoma in Unmarried Men Similar in Pre-AIDS Era and AIDS Era"

"Gene Therapy Blocked by Strong Immune Response"

"Tokyo Professor Accused on Perjury Over Evidence of HIV Infection"

"Mortality Due to HIV Infection Among Persons Aged 25-44 Years-

United States, 1993 and 1994"

"AIDS Deaths Continue to Rise in 25-44 Age Group, U.S. Says"

New York Times (02/16/96) P. A22; Hilts, Philip J.

The number of lives lost to AIDS among 25-44 year-old American men and women of every race continued to increase in 1994. The disease has become the third leading cause of death for women in that age group and the leading cause of death for white men in that group. In 1994, there was a 30 percent rise in AIDS-related deaths among white women, a 28 percent increase among black women, and a 13 percent increase among black men. The new figures are based on a report published Thursday by the Centers for Disease Control and Prevention. AIDS cases among minorities and women are often linked to drug use and sex with infected drug users. The two are related because drug use impairs a person's judgment about having sex and some people trade sex for drugs and share needles used to inject drugs. The number of deaths from AIDS in the United States increased 9 percent in 1994 from the previous year, and has increased every year since the epidemic began 15 years ago. The number of new AIDS cases in 1994 was 63,000 and the number of new infections is estimated at 40,000 to 80,000. AIDS-related deaths in 1994 totaled 41,930. Related Stories: Philadelphia Inquirer (02/16/96) P. A3; Baltimore Sun (02/16/96) P. 2A

"Remorse From a Heavyweight"

Washington Post (02/16/96) P. A1; Romano, Lois

At a press conference in Tulsa, Okla., on Thursday, heavyweight boxer Tommy Morrison told his young fans to "no longer consider [him] a role model," after a second test confirmed that he is infected with HIV. Morrison said he "had the opportunity to be a role model, but blew it. Blew it with irresponsible, irrational, immature decisions." He stated that he will not fight again and urged required HIV tests for professional boxers. Furthermore, Morrison said that he has tried to contact people whom he might have infected, including both sparring and sexual partners. He said he does not know how he became HIV-infected but noted that part of his life was marked by "a very permissive, fast, reckless lifestyle." Related Stories: New York Times (02/16/96) P. B7; Philadelphia Inquirer (02/16/96) P. D1

"Sequus Drug Is Approved"

Wall Street Journal (02/16/96) P. B2

Sequus Pharmaceuticals has announced the receipt of regulatory approval to sell Doxil, a drug for the treatment of Kaposi's sarcoma, in 15 European countries. The approval, handed down by the European Committee on Proprietary and Medicinal Products, covers all members of the European Union, Sequus said. Doxil has been granted marketing approval from the U.S. Food and Drug Administration as a treatment for patients who cannot benefit from established therapy, but the European body has approved it as a first-line therapy as well.

"N.J. Gives Hemophiliacs Hope on AIDS Lawsuits"

Philadelphia Inquirer (02/16/96) P. B7; Conway, Chris

Hemophiliacs are again pushing for a New Jersey law that would give them more time to sue drug makers whose products infected them with HIV. State Sen. William Gormly has been working on a compromise with the governor to address the proposed bill's constitutionality. Gov. Whitman vetoed a similar proposal last year. The new plan would extend for an additional two years the state's two-year statute of limitations for HIV-infected hemophiliacs who want to sue. An Institute of Medicine report released last year found that manufacturers of plasma products were not doing adequate research into heat-treating their products to kill viruses because there was no competitive pressure.

"Ryan White's Legacy"

Philadelphia Inquirer (02/16/96) P. A24

A Philadelphia Inquirer editorial emphasizes the need for continued government funding for AIDS drugs for needy patients. The editors note that Congress has provided only limited funding for the Ryan White Act, which subsidizes Medicaid funds to provide drugs for AIDS patients. A recent survey showed that almost half of the states are facing a financial shortage in their programs that pay for AIDS drugs. The program in Pennsylvania enjoyed a surplus of money the last several years, but has now been reduced by the Ridge administration. The editors emphasize that funding the treatment of AIDS patients is not just a matter of compassion, but is also an investment. Effective medication, they note, enables people with AIDS to continue to work and to function.

"Answers on Blood Seem Elusive"

Toronto Globe and Mail (02/14/96) P. A7; Picard, Andre

Two years into the Canadian government inquiry of the tainted blood tragedy that left 1,200 Canadians infected with HIV, answers seem unlikely. The inquiry, being headed by Justice Horace Krever, is hampered by legal challenges, and many of those infected are concerned that Krever's report may never be published. The Canadian Red Cross and other parties are trying to remove any allegations of wrongdoing from the inquiry's findings. One element of hope is that the public is now more aware of the threats of tainted blood and as a result, is demanding a say as consumers. People who were infected, or lost loved ones as a result of the tainted blood, say their hope at the beginning of the inquiry has now turned to despair and disappointment.

"Empiric Therapy for AIDS-Related Pneumonia Appropriate in Selected Cases"

Reuters (02/15/96)

Researchers at the National Institutes of Health report that "if convenient, cost-effective diagnostic facilities are not readily available," empiric therapy for AIDS-related pneumonia is appropriate for some patients with HIV. Empiric oral therapy

against the common, treatable community-acquired pathogens is the usual treatment in individuals with healthy immune systems. However, Drs. Henry Masur and James Shelhamer note that in patients whose immune systems are compromised, "the range of potential pathogens is so broad" that doctors are reluctant to try empiric therapy. The researchers suggest, though, that an empiric approach is possible, and they recommend broad coverage of treatment.

"Risk of Kaposi Sarcoma in Unmarried Men Similar in Pre-AIDS Era and AIDS Era"

Reuters (02/15/96)

Researchers at the National Cancer Institute and the Danish Epidemiologic Science Center say the risks of Kaposi's sarcoma (KS) and non-Hodgkin's lymphoma in unmarried men have not increased significantly with the AIDS epidemic. Robert Biggar and Mads Melbye compared the risk of never being married with ever being married. They found no increased risk for KS, except between 1973 and 1976. The risk of non-Hodgkin lymphoma was slightly lower in single men before 1976, but the risk of anal cancer was more than five times higher for men aged 20-59 before the AIDS epidemic. The researchers suspect that the increased risk of anal cancer before AIDS was related to the risk of anal human papillomavirus infection in homosexual men.

"Gene Therapy Blocked by Strong Immune Response"

Lancet (02/03/96) Vol.347, No.8997, P. 314; McCarthy, Michael

A clinical trial in Seattle was conducted to determine whether genetically modified CD8 HIV-specific cytotoxic T lymphocytes (CTLs) could improve an HIV-infected patient's immune response. In prior studies with retrovirus vectors, gene-modified cells persisted over time without inducing an immune response. In the Seattle study, six HIV-positive patients were given the modified CD8 CTLs in four increasing doses. In five of the six patients, "there was effective transfer and persistence of modified CTLs after the first two infusions, but clearance after the last two doses," according to the researchers. The patients were found to have developed cytolytic reactivity to the modified cells. The results indicate the necessity of strategies that make the gene-modified cells less vulnerable to the host immune system.

"Tokyo Professor Accused on Perjury Over Evidence of HIV Infection"

Nature (02/01/96) Vol.379, No.6564, P. 388

A coalition in Tokyo has filed perjury claims against a Tokyo University scientist who served in the Ministry of Health and Welfare in the early 1980s and was responsible for policies on blood products. The 72-member group, which includes HIV-positive hemophiliacs, charges that public health professor Atsuaki Gunji lied when he gave evidence in a case the group brought against the government and pharmaceutical companies. Gunji had testified that he was unaware that HIV infection routes are like those of hepatitis B. The group says they have a document that was submitted to the Ministry's AIDS study group which indicates that

the routes of infection were similar. Gunji, however, claims that he never meant to lie, and denies that he did. The group has also sued the head of the AIDS study group, for "willful negligence" resulting in death.

"Mortality Due to HIV Infection Among Persons Aged 25-44 Years- United States, 1993 and 1994"

Morbidity and Mortality Weekly Report (02/16/96) Vol. 45, No. 6; Centers for Disease Control and Prevention

Death rates from HIV infection, the cause of AIDS, continued to increase in 1994, with over 70% of deaths occurring among Americans aged 25-44, according to provisional data from the National Center for Health Statistics. HIV remains the leading cause of death for Americans aged 25-44, and the rate of HIV-related deaths is increasing most rapidly among women and blacks. The death rate from HIV infection is now 4 times higher in black men 25-44 than in white men in the same age group, and the death rate among black women in this age group is 9 times higher than among white women. These findings demonstrate the ongoing impact of the AIDS epidemic on the premature loss of life. The full text document is available electronically through CDC NAC ONLINE, the CDC NAC Web page, <http://cdcnac.aspensys.com:86>, or gopher at cdcnac.aspensys.com. You may also order a paper copy by calling (800) 458-5231 and requesting publication number D213. One copy free per caller.

The CDC AIDS Daily Summary will not be published Monday, February 19, 1996, in observance of President's Day. Publication will resume Tuesday, February 20.

===== END ATTACHMENT 1 =====

===== ATTACHMENT 2 =====

ATT CREATION TIME/DATE:16-FEB-1996 13:00:00.00

ATT BODYPART TYPE:D

TEXT:

RFC-822-headers:

Received: from storm.eop.gov (storm.eop.gov)

by PMDF.EOP.GOV (PMDF V5.0-4 #6879) id <0111A5PYGT8G00781A@PMDf.EOP.GOV> for levi_j@a1.eop.gov; Fri, 16 Feb 1996 12:58:49 -0400 (EDT)

Received: from aspensys ("port 56324"@aspensys.aspensys.com)

by STORM.EOP.GOV (PMDF V5.0-6 #6879) id <0111A5RCTA2Q0000OS@STORM.EOP.GOV> for levi_j@a1.eop.gov; Fri, 16 Feb 1996 12:59:57 -0700 (MST)

Received: by aspensys (5.0/SMI-SVR4) id AA02808; Fri, 16 Feb 1996 12:53:14 +0500

Errors-to: martha_vander_kolk@smtpinet.aspensys.com

Precedence: bulk

Originator: aidsnews@cdcnac.aspensys.com

X-Comment: CDC National AIDS Clearinghouse

X-Listprocessor-version: 6.0c -- ListProcessor by Anastasios Kotsikonas

===== END ATTACHMENT 2 =====

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:19-FEB-1996 14:11:31.30

SUBJECT: more daily news

TO: Patsy Fleming (FLEMING_P) (WHO)

READ:19-FEB-1996 14:20:11.53

TEXT:

===== ATTACHMENT 1 =====

ATT CREATION TIME/DATE:15-FEB-1996 06:12:00.00

ATT BODYPART TYPE:E

ATT CREATOR: aidsnews

ATT SUBJECT: CDC AIDS Daily Summary 2/14/96

ATT TO: levi_j (levi_j@A1@CD)

TEXT:

AIDS Daily Summary
February 14, 1996

The Centers for Disease Control and Prevention (CDC) National AIDS Clearinghouse makes available the following information as a public service only. Providing this information does not constitute endorsement by the CDC, the CDC Clearinghouse, or any other organization. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC Clearinghouse should be cited as the source of this information.
Copyright 1995, Information, Inc., Bethesda, MD

"Morrison Ref HIV-Negative, Outcry for Testing Continues"

"Drug-Resistant TB Spreads"

"The FDA vs. Health Exams"

"Morrison's Partners Jolted by News"

"Biting Case Will Be Test for HIV Law"

"Japan Tobacco to Start Japan HIV Drug Test"

"Japan Minister Pledges to Resolve HIV Issue"

"Illinois Considering a Registry of Persons with HIV"

"Ribozymes Move Closer to Applications for AIDS Therapy"

"HIV and Dying: The Challenges of Caring"

"Morrison Ref HIV-Negative, Outcry for Testing Continues"

Washington Times (02/14/96) P. B1; Dahlberg, Tim

Mills Lane, the referee in Tommy Morrison's October fight with Lenox Lewis, has been tested for HIV because Morrison has admitted he has the virus. Lane's test came back negative. Meanwhile, boxing officials across the country are increasing their calls for more states to institute HIV testing for boxers. Lane said he knew there was only a very small chance that the virus could have been transmitted by Morrison, but that he wanted to be tested to reassure himself and his family. During the fight against Lewis, Morrison bled from hits around the eyes. "I had blood all over me," said Lane. It is not known whether Morrison was infected at that time. Lewis will be tested for the virus in Britain next month, as part of the country's requirements for his annual boxing license.

"Drug-Resistant TB Spreads"

Washington Post (02/14/96) P. A2

According to an article published in Wednesday's Journal of the American Medical Association, a family of potentially-fatal drug-resistant strains of tuberculosis (TB) that were first identified in New York in 1992 have spread to other cities in the United States and Europe. Researchers from the New York-based Public Health Research Institute who tracked the "W" strains of TB said that new drugs may be necessary to eliminate the bacteria, as the W strains do not respond to treatment with four of the most frequently used anti-TB medicines. In some cases, the strains are resistant to as many as seven drugs, they report. According to Barry N. Kreiswirth, director of the Institute's Tuberculosis Center, "The spread of this difficult-to-treat bacteria beyond New York City, where aggressive containment has been implemented, will have major implications for public health well into the 21st century."

"The FDA vs. Health Exams"

Investor's Business Daily (02/14/96) P. A2; Matias, Donna G.

In a guest editorial in the Investor's Business Daily, Donna Matias, attorney for the Institute of Justice, objects to the Food and Drug Administration's (FDA's) refusal to approve home-testing products for AIDS and other diseases. Matias notes that the FDA has refused for eight years to approve an HIV home-test kit that enables individuals to take their own blood and send it to a laboratory for testing. The user then calls a toll-free number within a week to get their results. If the results are negative, a recording informs the caller of his status. If positive, however, a counselor tells the caller and refers him to counseling or support groups. Currently, the FDA approves home test kits, but only if the maker guarantees that people with positive results will be forced to accept face-to-face counseling. Only about 27 percent of people in high-risk groups for HIV now get tested. If anonymous home-testing were available, studies suggest that at least 42 percent of those people would be tested. According to Matias, the FDA's unwillingness to approve certain home-testing kits intrudes "on the right of individuals to choose how they will obtain medical information about themselves" and also keeps many

from being tested.

"Morrison's Partners Jolted by News"

Washington Times (02/14/96) P. B5; Whitlock, Jason

Some women in Kansas City, Mo., are concerned about their HIV-status, following boxer Tommy Morrison's announcement that he has HIV. The fighter spent a lot of time in the city, partying with a number of women. A local AIDS hotline there has reported that it received an increased number of calls Monday, including calls from women who mentioned the Morrison case. Boxing matchmaker Peyton Sher said that three women called him personally, worried because they had been with Morrison.

"Biting Case Will Be Test for HIV Law"

Chicago Tribune (02/13/96) P. 1-7; Jimenez, Teresa

John Merritt of Chicago has been accused of biting someone and, under a new Illinois law for criminal transmission, of having HIV and biting someone. Merritt's HIV test results will be released in court on March 11. Merritt was arrested on Jan. 6 for biting an employee at a Sam's Club store while trying to flee the store. Merritt then told authorities that he had HIV, but refused to give a blood sample. The criminal transmission law has been controversial since it went into effect in 1989. A person could receive 3 to 7 years for the felony, if found to have engaged in an activity that could transmit the virus while knowing one has it. Prosecutors, however, must prove both that the defendant knew he had HIV and that he meant to transmit the virus.

"Japan Tobacco to Start Japan HIV Drug Test"

Reuters (02/14/96)

Japan Tobacco Inc. (JT) said Wednesday that it would launch in March Phase I clinical trials for the anti-HIV drug AG-1343, which it has developed with Agouron Pharmaceuticals Inc. A JT spokesman said that Phase II and Phase III trials of the drug started late last month in Europe and the United States, and noted that Phase I and pilot Phase II tests there have shown no serious after-effects. The drug has been found to resist development of HIV in the blood. Japan Tobacco expects to apply for approval from the U.S. Food and Drug Administration by September 1997 and to begin selling the drug by March 1998.

"Japan Minister Pledges to Resolve HIV Issue"

Reuters (02/14/96)

Japan's Health Minister told HIV-infected hemophiliacs Wednesday that he would try to facilitate an out-of-court settlement of their case against the government and five drug companies. About 50 of the 270 plaintiffs had begun a protest outside Naoto Kan's office earlier that day. Last week, the minister acknowledged for the first time that the ministry was aware in 1983 that there was a threat of HIV spreading through contaminated imported blood. The hemophiliacs, who contracted HIV through tainted blood in the late 1980s, have sued the state and five drug companies for failing to screen the blood for HIV.

"Illinois Considering a Registry of Persons with HIV"

Reuters (02/13/96)

The state of Illinois is considering keeping a confidential registry of persons infected with HIV, according to a report in AIDS Weekly Plus. The list would be protected from subpoena by a new state law. The Illinois State Medical Society has said that it supports the proposal, on the grounds that it would allow tracing of contacts and early detection of infection. However, the American Civil Liberties Union of Illinois and various AIDS groups oppose the idea, arguing that it would infringe on an individual's privacy and may discourage people from being tested. The proposed measure must be passed by both the Illinois House and Senate; a decision is expected around June.

"Ribozymes Move Closer to Applications for AIDS Therapy"

Chemical & Engineering News (01/29/96) Vol.74, No.5, P. 26;

Rawls, Rebecca

The first Phase I clinical trials using ribozymes to treat human disease will take place later this year, when researchers will insert genes for RNA into the blood of AIDS patients. These ribozymes are designed to destroy the RNA in HIV, a process which involves an enzyme-like cleavage reaction. Ribozymes work well in the test tube, but they have had limited success in tissue and culture experiments and in animal studies. Problems arise in getting the ribozyme to its target cell and to the target RNA before it is destroyed by ribonucleases in the cell. Gene therapy is one way to deal with these problems. In preclinical trials, researchers genetically modified stem cells, precursors to immune system cells, to give them anti-HIV ribozymes. The ribozymes cleave the HIV genome at different places. The studies showed that the treated cells could grow in culture into mature cells that are HIV-resistant. Next, researchers will try to add the genes for the anti-HIV ribozymes to cells from AIDS patients, to determine if the patients' cells can also be grown in culture and become resistant to the virus. If that works, the cells could then be reinfused into the AIDS patients.

"HIV and Dying: The Challenges of Caring"

Focus (01/96) Vol.11, No.2, P. 1; Rose, Avi

As an AIDS patient comes closer to dying, the number of caregivers involved may increase. The closest personal caregivers should be recognized as "family," whether or not they are legally bound to the patient, and should seek legal standing via a will and power of attorney. The closest caregivers may deny when a loved one is dying, and professionals should clearly, but gently, acknowledge the situation. Caregivers, however, should also remember to take care of themselves, including getting enough rest, nourishment, and exercise. Furthermore, a caregiver should seek support from other friends and family, or rely on professional caregivers when personal support is not available. Friends and family can be mobilized to take care of practical tasks like preparing meals, updating concerned people, taking care of children, handling family members, and taking care of pets. Primary caregivers need to do things that they feel are

helpful, to maintain a sense of competence. Caregivers should continue to fully respect the autonomy and decision-making power of the patient as long as possible. Moreover, making legal arrangements during the later stages of illness are empowering activities that are particularly useful when different parts of family are at odds with each other.

===== END ATTACHMENT 1 =====

===== ATTACHMENT 2 =====

ATT CREATION TIME/DATE:15-FEB-1996 15:19:00.00

ATT BODYPART TYPE:D

TEXT:

RFC-822-headers:

Received: from storm.eop.gov (storm.eop.gov)
by PMDF.EOP.GOV (PMDf V5.0-4 #6879) id <01118WB0R6I800FAJJ@PMDf.EOP.GOV> for
levi_j@a1.eop.gov; Thu, 15 Feb 1996 15:17:54 -0400 (EDT)

Received: from aspensys ("port 36268"@aspensys.aspensys.com)
by STORM.EOP.GOV (PMDf V5.0-6 #6879) id <01118WCEG2LA001MXV@STORM.EOP.GOV> for
levi_j@a1.eop.gov; Thu, 15 Feb 1996 15:19:00 -0700 (MST)

Received: by aspensys (5.0/SMI-SVR4) id AA13583; Thu, 15 Feb 1996 15:12:08 +0500

Errors-to: martha_vander_kolk@smtpinet.aspensys.com

Precedence: bulk

Originator: aidsnews@cdnac.aspensys.com

X-Comment: CDC National AIDS Clearinghouse

X-Listprocessor-version: 6.0c -- ListProcessor by Anastasios Kotsikonas

===== END ATTACHMENT 2 =====

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Dorothy L. Karayannis (KARAYANNIS_D) (OPD)

CREATION DATE/TIME:20-FEB-1996 18:00:03.03

SUBJECT: camera

TO: Jennifer L. Klein (KLEIN_J) (OPD)
READ:20-FEB-1996 18:01:40.43

TO: Cathy R. Mays (MAYS_C) (OPD)
READ:21-FEB-1996 09:15:01.45

TO: Rosalyn A. Miller (MILLER_RA) (OPD)
READ:21-FEB-1996 10:20:08.57

TO: Elizabeth E. Drye (DRYE_E) (OPD)
READ:20-FEB-1996 19:21:16.41

TO: Michael T. Schmidt (SCHMIDT_MT) (OPD)
READ:20-FEB-1996 18:41:10.78

TO: Stephen C. Warnath (WARNATH_S) (OPD)
READ:20-FEB-1996 19:00:13.55

TO: Paul J. Weinstein, Jr (WEINSTEIN_P) (OPD)
READ:20-FEB-1996 18:47:33.72

TO: Patsy Fleming (FLEMING_P) (WHO)
READ:20-FEB-1996 19:46:38.04

TO: Janet B. Abrams (ABRAMS_J) (VPO)
READ:20-FEB-1996 18:01:52.54

TO: Julie E. Demeo (DEMEO_J) (OPD)
READ:26-FEB-1996 08:20:06.82

TO: Diana M. Fortuna (FORTUNA_D) (OPD)
READ:20-FEB-1996 18:00:32.48

TO: Christopher C. Jennings (JENNINGS_C) (WHO)
READ:20-FEB-1996 20:50:14.47

TO: Jeffrey Levi (LEVI_J) (WHO)
READ:20-FEB-1996 19:32:16.10

TO: Gaynor R. McCown (MCCOWN_G) (OPD)
READ:20-FEB-1996 18:00:39.91

TO: Molly Brostrom (BROSTROM_M) (WHO)
READ:20-FEB-1996 18:05:09.33

TO: Patricia E. Romani (ROMANI_P) (WHO)
READ:20-FEB-1996 18:02:47.40

TO: Deborah L. Fine (FINE_D) (OPD)
READ:20-FEB-1996 19:09:43.34

TO: Dennis Burke (BURKE_D) (OPD)
READ:20-FEB-1996 18:07:15.71

TO: Denise Ricketson (RICKETSON_D) (OPD)
READ:21-FEB-1996 10:08:19.65

TEXT:
pat romani calling to see if anyone here has a camera for the
Mardi Gras party. Pls call her if you have one!!!!

**Clinton Presidential Records
Automated Records Management System
[EMAIL] and Tape Restoration Project [Email]**

This is not a presidential record. This is used as an administrative marker by the William J. Clinton Presidential Library Staff.

This marker identifies a responsive email, already made available within another collection.

Collection: 2007-0143-F

Bucket: WHO

Creation Date: 1996-02-20

Subject: CDC AIDS Daily Summary 02/20/96

Creator: aidsnews@aspensys.com@INET@EOPMRX

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:20-FEB-1996 11:46:39.48

SUBJECT: AETCs

TO: William G. White (WHITE_W) (OMB)

READ:20-FEB-1996 12:21:08.30

TEXT:

In her meeting with AIDS Action, Nancy-Ann apparently indicated that the AETCs would be getting less than the 96 request in our 97 budget -- but wasn't clear if that was accurate. Can you clarify?
thanks

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:20-FEB-1996 12:26:39.38

SUBJECT: RE: Letters

TO: Adam R. Kreisel (KREISEL_A) (WHO)

READ:20-FEB-1996 12:49:55.59

TEXT:
632-1096

Withdrawal/Redaction Marker

Clinton Library

DOCUMENT NO. AND TYPE	SUBJECT/TITLE	DATE	RESTRICTION
001. email	From: Jeffrey Levi, To: Patricia Romani, Re: Mardi Gras [Personally Identifiable Information] [partial] (1 page)	02/20/1996	b(6)

COLLECTION:

Clinton Presidential Records
Automated Records Management System [Email]
WHO ([Jeffrey Levi...])
OA/Box Number: 500000

FOLDER TITLE:

[02/19/1996 - 02/23/1996]

2018-0759-F
jn397

RESTRICTION CODES

Presidential Records Act - [44 U.S.C. 2204(a)]

- P1 National Security Classified Information [(a)(1) of the PRA]
- P2 Relating to the appointment to Federal office [(a)(2) of the PRA]
- P3 Release would violate a Federal statute [(a)(3) of the PRA]
- P4 Release would disclose trade secrets or confidential commercial or financial information [(a)(4) of the PRA]
- P5 Release would disclose confidential advice between the President and his advisors, or between such advisors [(a)(5) of the PRA]
- P6 Release would constitute a clearly unwarranted invasion of personal privacy [(a)(6) of the PRA]

C. Closed in accordance with restrictions contained in donor's deed of gift.

PRM. Personal record misfile defined in accordance with 44 U.S.C. 2201(3).

RR. Document will be reviewed upon request.

Freedom of Information Act - [5 U.S.C. 552(b)]

- b(1) National security classified information [(b)(1) of the FOIA]
- b(2) Release would disclose internal personnel rules and practices of an agency [(b)(2) of the FOIA]
- b(3) Release would violate a Federal statute [(b)(3) of the FOIA]
- b(4) Release would disclose trade secrets or confidential or financial information [(b)(4) of the FOIA]
- b(6) Release would constitute a clearly unwarranted invasion of personal privacy [(b)(6) of the FOIA]
- b(7) Release would disclose information compiled for law enforcement purposes [(b)(7) of the FOIA]
- b(8) Release would disclose information concerning the regulation of financial institutions [(b)(8) of the FOIA]
- b(9) Release would disclose geological or geophysical information concerning wells [(b)(9) of the FOIA]

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:20-FEB-1996 09:13:12.22

SUBJECT: Mardi Gras

TO: Patricia E. Romani (ROMANI_P) (WHO)

READ:20-FEB-1996 12:45:59.12

TEXT:

A favor -- could you clear in Richard Sorian for the 6 p.m. Mardi
Gras party -- dob (b)(6) Thanks.

[001]

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:20-FEB-1996 19:40:22.07

SUBJECT: RE: any word on who the bus lady should bill? thanks

TO: Wendy A. Heistad (HEISTAD_W) (WHO)

READ:20-FEB-1996 20:48:27.43

TEXT:

It should go to Richard Turner at Funders Concerned About AIDS

310 Madison Avenue, NY NY 10017

phone: 212-573-5533

fax: 212-949-1672

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 READ RECEIPT)

CREATOR: POSTMASTER (SYS)

CREATION DATE/TIME:20-FEB-1996 09:09:00.00

SUBJECT: Auto reply from DEMEO_J

TO: Jeffrey Levi (LEVI_J) (WHO)

READ:20-FEB-1996 09:11:08.30

TEXT:

I will be out of the office from 3:00pm Wednesday, February 14th through Friday, February 23rd. I will return to the office on Monday morning, February 26th.

If you need assistance while I am gone, please contact Pat Romani at x62249 or Dorothy Karayanis at x65571. I will also be checking my home voicemail periodically (202) 223-5220.

Thank you.

Withdrawal/Redaction Marker

Clinton Library

DOCUMENT NO. AND TYPE	SUBJECT/TITLE	DATE	RESTRICTION
002. email	From: Jeffrey Levi, To: Julie Demeo, Re: Mardi Gras [Personally Identifiable Information] [partial] (1 page)	02/20/1996	b(6)

COLLECTION:

Clinton Presidential Records
Automated Records Management System [Email]
WHO ([Jeffrey Levi...])
OA/Box Number: 500000

FOLDER TITLE:

[02/19/1996 - 02/23/1996]

2018-0759-F
jn397

RESTRICTION CODES

Presidential Records Act - [44 U.S.C. 2204(a)]

- P1 National Security Classified Information [(a)(1) of the PRA]
- P2 Relating to the appointment to Federal office [(a)(2) of the PRA]
- P3 Release would violate a Federal statute [(a)(3) of the PRA]
- P4 Release would disclose trade secrets or confidential commercial or financial information [(a)(4) of the PRA]
- P5 Release would disclose confidential advice between the President and his advisors, or between such advisors [(a)(5) of the PRA]
- P6 Release would constitute a clearly unwarranted invasion of personal privacy [(a)(6) of the PRA]

C. Closed in accordance with restrictions contained in donor's deed of gift.

PRM. Personal record misfile defined in accordance with 44 U.S.C. 2201(3).

RR. Document will be reviewed upon request.

Freedom of Information Act - [5 U.S.C. 552(b)]

- b(1) National security classified information [(b)(1) of the FOIA]
- b(2) Release would disclose internal personnel rules and practices of an agency [(b)(2) of the FOIA]
- b(3) Release would violate a Federal statute [(b)(3) of the FOIA]
- b(4) Release would disclose trade secrets or confidential or financial information [(b)(4) of the FOIA]
- b(6) Release would constitute a clearly unwarranted invasion of personal privacy [(b)(6) of the FOIA]
- b(7) Release would disclose information compiled for law enforcement purposes [(b)(7) of the FOIA]
- b(8) Release would disclose information concerning the regulation of financial institutions [(b)(8) of the FOIA]
- b(9) Release would disclose geological or geophysical information concerning wells [(b)(9) of the FOIA]

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:20-FEB-1996 09:09:07.88

SUBJECT: mardi gras

TO: Julie E. Demeo (DEMEO_J) (OPD)
READ:26-FEB-1996 08:19:49.24

TEXT:
Can you clear Richard Sorian (b)(6) for Mardi Gras tonight?
thanks.

[002]

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: William G. White (WHITE_W) (OMB)

CREATION DATE/TIME:20-FEB-1996 12:26:11.61

SUBJECT: RE: AETCs

TO: Jeffrey Levi (LEVI_J) (WHO)

READ:20-FEB-1996 12:27:11.97

TEXT:

According to my numbers, AIDS ETCS are getting the same level as the FY96 request (however, they may be nicked slightly due to the House's Administrative Reduction for HRSA.) I thought she knew that we were doing this. I didn't go to the meeting due to other madness, so I'm not sure what she was talking about.

This may be an example where the Budget Examiner makes policy and the PAD doesn't know about it.

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Adam R. Kreisel (KREISEL_A) (WHO)

CREATION DATE/TIME:20-FEB-1996 12:26:01.25

SUBJECT: RE: Letters

TO: Jeffrey Levi (LEVI_J) (WHO)

READ:20-FEB-1996 12:26:47.52

TEXT:

Thanks. What is your fax number.

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Adam R. Kreisel (KREISEL_A) (WHO)

CREATION DATE/TIME:20-FEB-1996 11:57:34.99

SUBJECT: Letters

TO: Jeffrey Levi (LEVI_J) (WHO)

READ:20-FEB-1996 12:26:16.34

TEXT:

Do you have language to respnd to letters on the DoD/HIV issue?
Leon received a letter from Fred Hochberg and I am trying to
figure out how to repond.

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:20-FEB-1996 12:23:28.56

SUBJECT: RE: Letters

TO: Adam R. Kreisel (KREISEL_A) (WHO)

READ:20-FEB-1996 12:23:47.15

TEXT:

We are drafting a form response on this issue. If you want to fax us Fred's letter, we can draft for you a personalized response as well.

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:21-FEB-1996 09:06:51.56

SUBJECT: draft press statement

TO: Gregory C. Simon (SIMON_G) Autoforward to: Remote Addressee (Gregory C.
Simon@LNGATE@EOPMRX) (VPO)
READ:NOT READ

TO: Lorraine A. Voles (VOLES_L) Autoforward to: Remote Addressee (Lorraine A.
Voles@LNGATE@EOPMRX) (VPO)
READ:NOT READ

CC: Toby A. Donenfeld (DONENF_T) Autoforward to: Remote Addressee (Toby
Donenfeld@LNGATE@EOPMRX) (VPO)
READ:NOT READ

TEXT:

I have faxed this to you as well -- for your edits, etc. It was a
great meeting -- thanks for all you did to make it work.

===== ATTACHMENT 1 =====

ATT CREATION TIME/DATE:21-FEB-1996 09:05:00.00

ATT BODYPART TYPE:p

ATT CREATOR: Jeffrey Levi

TEXT:

PRINTER FONT 14_POINT_ROMAN

Draft

PRINTER FONT 18_POINT_ROMAN

Vice President Meets With
Pharmaceutical Firms and AIDS
Researchers

PRINTER FONT 12_POINT_ROMAN

Vice President Gore met Tuesday with representatives of 12
pharmaceutical companies and leading AIDS researchers from the
National Institutes of Health, the Department of Defense, and the
Department of Veterans Affairs to discuss ways to accelerate
development of AIDS vaccines, therapeutics, and preventives.
The meeting was the first top

-level White House discussion of
AIDS drug development in the history of the epidemic. It
reflects the President's commitment to bring the AIDS epidemic to
an end. In his three years in office, the President has
increased funding for AIDS research by 26 percent, expedited AIDS
drug approval, and strengthened the Office of AIDS Research at
the National Institutes of Health.

[add VPOTUS quote here]
At the conclusion of the two

-hour meeting, the Vice President
announced the following steps:
? The Federal government will join with pharmaceutical
manufacturers, health insurance companies and other
third

-party payers, and patient advocacy organizations to
develop a collaborative system of clinical trials of AIDS
drugs that have been approved by the FDA under expedited
procedures to determine the long

-term effectiveness of those
drugs.
? The Vice President will work with international
organizations -- such as the World Bank -- to increase
investment in AIDS vaccine development.
? The Administration will increase support for the development
of microbicides to enable women to protect themselves from
HIV infection without relying on their sexual partners.
? The Vice President will facilitate ongoing discussions
between the government and the pharmaceutical industry to
identify areas of AIDS research that the government can
support in order to stimulate private sector investment in
the next generation of AIDS vaccines, therapeutics, and
microbicides.
? The Food and Drug Administration will pursue additional
measures to increase the number of anti

-HIV therapeutics
with pediatric indications.

PRINTER FONT 12_POINT_ROMAN_ITALIC
Draft

PRINTER FONT 12_POINT_ROMAN
Participants in Vice President's Meeting
with Pharmaceutical Companies and AIDS Researchers

The following pharmaceutical company representatives participated
in the February 20 meeting on AIDS drug development with Vice
President Gore:
Anne

-Marie Carrier
President, Chief Executive Officer
BIOSYN
Manuel Navia, PhD
Vice President, Senior Scientist
Vertex Pharmaceuticals Inc.

Michael Riordan
President, Chairman
Gilead Sciences
Joseph Pittelli
Senior Vice President for Clinical Research
Wyeth

-Ayerst Research
George Morrow
Group Vice President, Commercial Operations
Glaxo Wellcome, Inc.
Dan Hoth
Senior Vice President, Chief Operating Officer
Cell Genesys, Inc.
Peter Johnson
President, Chief Executive Officer
Agouron Pharmaceuticals, Inc.
Patrick Zenner
President, Chief Executive Officer
Hoffman

-La Roche
Whaijen Soo
Vice President for Clinical Science
Hoffman

-La Roche

Rajen Dalal
Vice President for Corporate Planning and Business Development
Chiron Corporation
David Pizzuti
Vice President for Anti

-Infective Development and Medical Affairs
Abbott Laboratories
Eve Slater
Senior Vice President for Clinical and Regulatory Development
Merck

===== END ATTACHMENT 1 =====

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:21-FEB-1996 10:25:03.26

SUBJECT: daily news

TO: Patsy Fleming (FLEMING_P) (WHO)

READ:22-FEB-1996 10:56:38.27

TEXT:

===== ATTACHMENT 1 =====

ATT CREATION TIME/DATE:21-FEB-1996 00:59:00.00

ATT BODYPART TYPE:E

ATT CREATOR: aidsnews

ATT SUBJECT: CDC AIDS Daily Summary 02/21/96

ATT TO: levi_j (levi_j@Al@CD)

TEXT:

AIDS Daily Summary
February 21, 1996

The Centers for Disease Control and Prevention (CDC) National AIDS Clearinghouse makes available the following information as a public service only. Providing this information does not constitute endorsement by the CDC, the CDC Clearinghouse, or any other organization. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC Clearinghouse should be cited as the source of this information.
Copyright 1996, Information, Inc., Bethesda, MD

"Genentech Inc. Forms a Firm for HIV Drug"
"Chiron Will Pay About \$120 Million For 49 Percent of Hoechst's Vaccine Business"
"A Vaccine for AIDS at Least 5 Years Away"
"'Dreaded-Disease' Policies Rise, But Some Say They're No Cure"
"Recurrent Varicella-Zoster Virus Infections Common in HIV-Positive Children"
"Skin Cancer and HPV 16 Infection Linked in AIDS Patient"
"Origin and Interstate Spread of a New York City Multidrug-Resistant Mycobacterium Tuberculosis Clone Family"
"Jobs at Risk for HIV-Infected Doctors"
"A Kinder, Gentler War Against Hepatitis B"
"An Epidemic's Evolution"

"Genentech Inc. Forms a Firm for HIV Drug"

Wall Street Journal (02/21/96) P. B6; King, Ralph T.

Genentech Inc. announced that it has created a separate company, Genevax Inc., to develop its HIV vaccine, gp120. The new company will ask for \$18 million from private investors for a pivotal-phase clinical trial for the vaccine. Genentech will contribute a total of \$2 million, giving it a 25 percent stake in the firm whose research will be supervised by Donald Francis, a public health expert who supervised the gp120 research at Genentech. Genentech had spent more than \$50 million on gp120, and had more than 100,000 doses ready for a trial that was halted in June 1994 when funding from the National Institutes of Health (NIH) was refused. A Genentech spokesman explained that forming the new company provided a way to perform the trial without government involvement. Last week NIH announced a new plan for AIDS vaccine development which included the use of a version of gp120 made by Chiron Corp. Related Story: Investor's Business Daily (02/21/96) P.A1

"Chiron Will Pay About \$120 Million For 49 Percent of Hoechst's Vaccine Business"

Wall Street Journal (02/21/96) P. B6; King, Ralph T.; Moore, Stephen D.

Chiron has agreed to buy 49 percent of Hoechst's vaccine business for about \$120 million, a move that should make it one of the top five vaccine suppliers worldwide and a strong player in Germany where the Hoechst subsidiary--Behringwerke AG--is based. The transaction will also make European vaccine markets more accessible to the biotechnology firm, which currently has several promising vaccines in development--including vaccines for genital herpes and cytomegalovirus--as well as new vaccines for hepatitis B and whooping cough already on the market. Hoechst, which is seeking to streamline its health-care operations, may form research alliances with Chiron in areas such as gene therapy and combinatorial chemistry. Under the terms of the agreement, Chiron will have an option to acquire the remaining 51 percent stake between 1998 and 2001. Related Story: New York Times (02/21) P. D5

"A Vaccine for AIDS at Least 5 Years Away"

Philadelphia Inquirer (02/19/96) P. C1; Vedantam, Shankar

AIDS researchers say there is little hope for an AIDS vaccine, which would be the only way to successfully deal with the disease, in the next five years. Anthony Fauci, director of the National Institute for Allergies and Infectious Diseases, said that even the AIDS vaccine furthest along in trials "will not be ready until 2001 or 2002," if it proves safe and effective. A vaccine prepares the immune system for infection, and wipes out the virus before a person gets sick. Therapeutic drugs, which are too expensive to be widely relied upon, have never eliminated a major disease. In addition, HIV's ability to rapidly mutate makes vaccine development especially difficult. Also, drug companies have been hesitant to pursue a vaccine because of the

technical difficulty and financial risk involved. AIDS is a particular threat to the developing world, where about 90 percent of new infections now occur. The vaccine with the most potential was developed by Pasteur Merieux-Connaught to defend against HIV-type B, the strain most common in the United States. Scientists are unsure whether a vaccine could protect against more than one strain of the virus, though Fauci said that if the vaccine proved successful, it would be fairly easy to make similar vaccines for others HIV types.

"'Dreaded-Disease' Policies Rise, But Some Say They're No Cure"
Wall Street Journal (02/21/96) P. C1; Jeffrey, Nancy Ann

"Limited benefit" health insurance policies to cover cancer, heart disease, and hospital stays are being offered in employee-pay-all programs, usually as supplements to an employer's comprehensive health plan. Consumer advocates warn against policies that cover a specific disease, however they note hospital-stay policies can be beneficial for seriously ill individuals. American Family Life Assurance Co., or Alfac Inc., offers two hospital plans which pay \$100 or \$200 a day for the first 30 days in the hospital and \$200 or \$400 a day for the next 150 days. The benefits are usually paid in cash, and can be used for food, rent, a private hospital room, or anything else not covered by regular insurance. For example, David Petersen, president of Affording Care, a nonprofit in New York, has been in the hospital for 44 days since testing positive for HIV in 1988. He pays \$1,400 a year for six hospital policies, and has used the benefits to help pay his monthly \$7,000 drug bill. Other methods of paying for disease costs include disability insurance, accelerated death benefits, and very high-deductible health insurance.

"Recurrent Varicella-Zoster Virus Infections Common in HIV-Positive Children"
Reuters (02/20/96)

Varicella-zoster virus infection in HIV-infected children tends to be recurrent and persistent. Hospitalization and morbidity are often attributed to the disease in these children, according to researchers at the Harbor-UCLA Medical Center in Torrance, Calif. Dr. Margaret Keller led the study of 117 cases of varicella-zoster infection in 73 HIV-positive children and found that 53 percent had recurrent episodes of infection. Keller's team also found that the number of episodes of varicella-zoster infection was strongly associated to low CD4+ cell counts. Keller concluded that new preventative and therapeutic therapies are needed to deal with the infection.

"Skin Cancer and HPV 16 Infection Linked in AIDS Patient"
Reuters (02/20/96)

Evidence of a relationship between human Papillomavirus infection and squamous cell carcinoma in an AIDS patient was reported by Dr. Hunter Maclean and colleagues at the Western General Hospital in Scotland. There, a 42-year-old AIDS patient was diagnosed with squamous cell carcinoma on the eyelid. The researchers

identified the human Papillomavirus infection using polymerase chain analysis, noting that squamous cell carcinoma is the third most common malignancy in HIV patients. Maclean therefore recommends that the carcinoma be considered in the diagnostic tests for HIV patients with eyelid lesions.

"Origin and Interstate Spread of a New York City Multidrug-Resistant Mycobacterium Tuberculosis Clone Family"
Journal of the American Medical Association (02/14/96) Vol.275, No.6, P. 452; Bifani, Pablo J.; Plikaytis, Bonnie B.; Kapur, Vivek; et al.

The resurgence of tuberculosis (TB) in the United States can be attributed to the AIDS epidemic, immigration from countries where TB is prevalent, and the discontinuation of TB control measures. A number of drug-resistant strains of the disease have been identified in New York City, and the number of TB patients in the city has tripled from 1978 through 1992. In this study, Bifani et al. analyzed multidrug-resistant strains of TB to determine if they were new genetic clones of Mycobacterium tuberculosis or unrelated organisms. Samples of M. tuberculosis were taken from 1,943 patients in New York and samples of multidrug-resistant isolates were taken from six patients elsewhere in the United States. Multidrug-resistant isolates of M. tuberculosis were found in 273 New York City patients as well as patients from Florida, Nevada, and Georgia. The strains of tuberculosis found in these patients were closely related at the molecular level. According to the researchers, the data suggest that these organisms are the product of a single ancestral M. tuberculosis cell. Numerous strains of bacteria have resulted from the sequential clonal expansion of this one cell. Cases of multidrug-resistant TB associated with HIV have a mortality rate of up to 90 percent.

"Jobs at Risk for HIV-Infected Doctors"
American Medical News (02/05/96) Vol.39, No.5, P. 1; Kent, Christina

Five years after Florida dentist David Acer was found to have transmitted HIV to his patients, the debate about whether HIV-positive health care workers should be allowed to continue to work with patients continues. The incident led to the development of new policies that some argue are unfair to HIV-infected health care workers. Medical and public health experts say that the risk of an HIV-infected health care worker spreading the virus to patients is small. The Acer case is the only known instance of a professional infecting a patient. The Centers for Disease Control and Prevention instituted a policy in 1991 that states that HIV-infected health care workers should avoid any "exposure-prone" procedures not approved by a panel of experts that has reviewed their case. The American Medical Association argued that there was no scientific basis for identifying such procedures. Medical groups also objected to the provision suggested by Congress that health care workers who perform such procedures be required to tell patients if they are HIV-positive. Most state policies do not require such

notification. Health care workers feel that disclosing their HIV status could lead to job discrimination. Fear of discrimination could also prevent workers from reporting on-the-job infections.

"A Kinder, Gentler War Against Hepatitis B"

Science News (02/03/96) Vol.149, No.5, P. 69; Travis, J.

Cytotoxic T lymphocytes (CTLs) kill viruses by attaching themselves to infected cells and releasing toxins that kill the cell and the virus. Francis Chisari of the Scripps Research Institute has found that, in fighting hepatitis B, CTLs release compounds that stimulate infected cells to destroy the virus, leaving the cell itself intact. A vaccine for hepatitis B exists, but it is not widely available. To determine CTLs mechanism of action, Chisari and his colleagues developed mice that make the virus. They found that injecting the mice with CTLs that target the cells producing the viral proteins causes the mice to almost rid themselves of the virus. The CTLs killed only about 5 percent of the targeted cells, leading researchers to conclude that the CTLs recognize infected cells and release two compounds that stimulate antiviral activity in them. The stimulated cells make proteins that disrupt the virus' ability to replicate. Chisari says that human cells may try to inhibit the virus in a similar way and that what they now know about the CTLs' role against hepatitis B could be applied to other viruses, including HIV.

"An Epidemic's Evolution"

Newsweek (02/05/96) Vol.127, No.6, P. 72; Will, George F.

In Newsweek magazine, columnist George F. Will writes that good news about the AIDS epidemic in America is, according to data from Philip Rosenberg, published in Science magazine, that the previous estimate of the incidence of AIDS was too high and that the epidemic is slowing down. The bad news is that the incidence is still high and that the epidemic is now spreading to new segments of the population. The AIDS epidemic started in the white homosexual male population in the late 1970s and early 1980s, centered in large cities. Now the epidemic is increasing in racial minority populations and women, and is spreading to rural areas, especially in the South. It is spreading increasingly through drug use and heterosexual sex, despite aggressive public education about the disease. The fact that AIDS has become endemic is surprising, Will notes, because HIV is difficult to acquire and almost completely preventable. Hopes for fighting AIDS lie in the fact that the epidemic is driven by behavior that can be changed. But, comparing AIDS to lung-cancer and other smoking-related diseases lessens that hope. Smoking involves the pull of nicotine, as AIDS often involves sex and drug use. Thirty-two years after the first surgeon general's warning linking smoking and cancer, smoking has become less common, but has also become concentrated in the poor and under-educated populations, a trend that AIDS appears to be following, Will concludes.

===== END ATTACHMENT 1 =====

===== ATTACHMENT 2 =====

ATT CREATION TIME/DATE:21-FEB-1996 10:07:00.00

ATT BODYPART TYPE:D

TEXT:

RFC-822-headers:

Received: from storm.eop.gov (storm.eop.gov)

by PMDF.EOP.GOV (PMDf V5.0-4 #6879) id <0111GZ47P3S000HYZB@PMDf.EOP.GOV> for
levi_j@al.eop.gov; Wed, 21 Feb 1996 10:05:03 -0400 (EDT)

Received: from aspensys ("port 53858"@aspensys.aspensys.com)

by STORM.EOP.GOV (PMDf V5.0-6 #6879) id <0111GZ5NUODM0000OS@STORM.EOP.GOV> for
levi_j@al.eop.gov; Wed, 21 Feb 1996 10:06:12 -0700 (MST)

Received: by aspensys (5.0/SMI-SVR4) id AA22594; Wed, 21 Feb 1996 09:59:26 +0500

Errors-to: martha_vander_kolk@smtpinet.aspensys.com

Precedence: bulk

Originator: aidsnews@cdcnac.aspensys.com

X-Comment: CDC National AIDS Clearinghouse

X-Listprocessor-version: 6.0c -- ListProcessor by Anastasios Kotsikonas

===== END ATTACHMENT 2 =====

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:21-FEB-1996 11:00:41.63

SUBJECT: draft statement

TO: Heidi Kukis (KUKIS_H) Autoforward to: Remote Addressee (Heidi
Kukis@LNGATE@EOPMRX) (VPO)
READ:NOT READ

TEXT:

===== ATTACHMENT 1 =====

ATT CREATION TIME/DATE:21-FEB-1996 10:59:00.00

ATT BODYPART TYPE:p

ATT CREATOR: Jeffrey Levi

TEXT:
PRINTER FONT 14_POINT_ROMAN
Draft

PRINTER FONT 18_POINT_ROMAN
Vice President Meets With
Pharmaceutical Firms and AIDS
Researchers

PRINTER FONT 12_POINT_ROMAN
Vice President Gore met Tuesday with representatives of 12
pharmaceutical companies and leading AIDS researchers from the
National Institutes of Health, the Department of Defense, and the
Department of Veterans Affairs to discuss ways to accelerate
development of AIDS vaccines, therapeutics, and preventives.
The meeting was the first top

-level White House discussion of
AIDS drug development in the history of the epidemic. It
reflects the President's commitment to bring the AIDS epidemic to
an end. In his three years in office, the President has
increased funding for AIDS research by 26 percent, expedited AIDS
drug approval, and strengthened the Office of AIDS Research at
the National Institutes of Health.
[add VPOTUS quote here]
At the conclusion of the two

-hour meeting, the Vice President
announced the following steps:
? The Federal government will join with pharmaceutical
manufacturers, health insurance companies and other
third

-party payers, and patient advocacy organizations to develop a collaborative system of clinical trials of AIDS drugs that have been approved by the FDA under expedited procedures to determine the long

-term effectiveness of those drugs.

? The Vice President will work with international organizations -- such as the World Bank -- to increase investment in AIDS vaccine development.

? The Administration will increase support for the development of microbicides to enable women to protect themselves from HIV infection without relying on their sexual partners.

? The Vice President will facilitate ongoing discussions between the government and the pharmaceutical industry to identify areas of AIDS research that the government can support in order to stimulate private sector investment in the next generation of AIDS vaccines, therapeutics, and microbicides.

? The Food and Drug Administration will pursue additional measures to increase the number of anti

-HIV therapeutics with pediatric indications.

PRINTER FONT 12_POINT_ROMAN_ITALIC
Draft

PRINTER FONT 12_POINT_ROMAN
Participants in Vice President's Meeting
with Pharmaceutical Companies and AIDS Researchers

The following pharmaceutical company representatives participated in the February 20 meeting on AIDS drug development with Vice President Gore:
Anne

-Marie Corrier
President, Chief Executive Officer
BIOSYN
Manuel Navia, PhD
Vice President, Senior Scientist
Vertex Pharmaceuticals Inc.
Michael Riordan
President, Chairman
Gilead Sciences
Joseph Pittelli
Senior Vice President for Clinical Research
Wyeth

-Ayerst Research
George Morrow

Group Vice President, Commercial Operations
Glaxo Wellcome, Inc.
Dan Hoth
Senior Vice President, Chief Operating Officer
Cell Genesys, Inc.
Peter Johnson
President, Chief Executive Officer
Agouron Pharmaceuticals, Inc.
Patrick Zenner
President, Chief Executive Officer
Hoffman

-La Roche
Whaijen Soo
Vice President for Clinical Science
Hoffman

-La Roche

Rajen Dalal
Vice President for Corporate Planning and Business Development
Chiron Corporation
David Pizzuti
Vice President for Anti

-Infective Development and Medical Affairs
Abbott Laboratories
Eve Slater
Senior Vice President for Clinical and Regulatory Development
Merck

===== END ATTACHMENT 1 =====

RECORD TYPE: PRESIDENTIAL (EXTERNAL MAIL)

CREATOR: CN=Lorraine A. Voles/O=OVP@OVP@LNGATE@EOPMRX

CREATION DATE/TIME:21-FEB-1996 11:31:00.00

SUBJECT: Re: draft press statement

TO: LEVI_J (LEVI_J@A1@CD) (WHO)

READ:21-FEB-1996 11:33:29.08

TEXT:

Message Creation Date was at 21-FEB-1996 11:30:00

Toby, please get me a hard copy of this for some reason I can't detach

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:21-FEB-1996 19:36:55.35

SUBJECT: lawsuits

TO: Patsy Fleming (FLEMING_P) (WHO)

READ:22-FEB-1996 11:06:33.09

TEXT:

===== ATTACHMENT 1 =====

ATT CREATION TIME/DATE:21-FEB-1996 19:34:00.00

ATT BODYPART TYPE:B

ATT CREATOR: Jeffrey Levi

ATT SUBJECT: lawsuits

ATT TO: Jeremy D. Benami (BENAMI_J)

TEXT:

I ran into Marvin Krislov who told me that Chai Feldblum believes we have essentially a 3-4 weeks window before lawsuits will be filed. I presume that should factor into our legislative strategy and the timeline VA is on.

On the good news front, Marilyn Yager has gotten an endorsement of repeal from the Air Force Association. It would seem if you seek out support, it might actually be forthcoming.

===== END ATTACHMENT 1 =====

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Carol H. Rasco (RASCO_C) (WHO)

CREATION DATE/TIME:21-FEB-1996 09:50:22.91

SUBJECT: RE: fyi re VP meeting

TO: Jeffrey Levi (LEVI_J) (WHO)

READ:21-FEB-1996 10:08:31.93

CC: Jeremy D. Benami (BENAMI_J) (WHO)

READ:21-FEB-1996 09:50:37.91

CC: Elizabeth E. Drye (DRYE_E) (OPD)

READ:21-FEB-1996 12:08:36.92

CC: Patsy Fleming (FLEMING_P) (WHO)

READ:22-FEB-1996 10:54:58.89

TEXT:

I can't get it to transfer...please fax me a hard copy.

RECORD TYPE: PRESIDENTIAL (EXTERNAL MAIL)

CREATOR: aidsnews@aspensys.com@INET@EOPMRX

CREATION DATE/TIME:21-FEB-1996 10:05:00.00

SUBJECT: CDC AIDS Daily Summary 02/21/96

TO: levi_j (levi_j@A1@CD) (WHO)

READ:21-FEB-1996 10:22:57.31

TEXT:

AIDS Daily Summary
February 21, 1996

The Centers for Disease Control and Prevention (CDC) National AIDS Clearinghouse makes available the following information as a public service only. Providing this information does not constitute endorsement by the CDC, the CDC Clearinghouse, or any other organization. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC Clearinghouse should be cited as the source of this information.
Copyright 1996, Information, Inc., Bethesda, MD

"Genentech Inc. Forms a Firm for HIV Drug"
"Chiron Will Pay About \$120 Million For 49 Percent of Hoechst's Vaccine Business"
"A Vaccine for AIDS at Least 5 Years Away"
"'Dreaded-Disease' Policies Rise, But Some Say They're No Cure"
"Recurrent Varicella-Zoster Virus Infections Common in HIV-Positive Children"
"Skin Cancer and HPV 16 Infection Linked in AIDS Patient"
"Origin and Interstate Spread of a New York City Multidrug-Resistant Mycobacterium Tuberculosis Clone Family"
"Jobs at Risk for HIV-Infected Doctors"
"A Kinder, Gentler War Against Hepatitis B"
"An Epidemic's Evolution"

"Genentech Inc. Forms a Firm for HIV Drug"
Wall Street Journal (02/21/96) P. B6; King, Ralph T.

Genentech Inc. announced that it has created a separate company, Genevax Inc., to develop its HIV vaccine, gp120. The new company will ask for \$18 million from private investors for a pivotal-phase clinical trial for the vaccine. Genentech will contribute a total of \$2 million, giving it a 25 percent stake in the firm whose research will be supervised by Donald Francis, a public health expert who supervised the gp120 research at Genentech. Genentech had spent more than \$50 million on gp120, and had more than 100,000 doses ready for a trial that was halted in June 1994 when funding from the National Institutes of Health

(NIH) was refused. A Genentech spokesman explained that forming the new company provided a way to perform the trial without government involvement. Last week NIH announced a new plan for AIDS vaccine development which included the use of a version of gp120 made by Chiron Corp. Related Story: Investor's Business Daily (02/21/96) P.A1

"Chiron Will Pay About \$120 Million For 49 Percent of Hoechst's Vaccine Business"

Wall Street Journal (02/21/96) P. B6; King, Ralph T.; Moore, Stephen D.

Chiron has agreed to buy 49 percent of Hoechst's vaccine business for about \$120 million, a move that should make it one of the top five vaccine suppliers worldwide and a strong player in Germany where the Hoechst subsidiary--Behringwerke AG--is based. The transaction will also make European vaccine markets more accessible to the biotechnology firm, which currently has several promising vaccines in development--including vaccines for genital herpes and cytomegalovirus--as well as new vaccines for hepatitis B and whooping cough already on the market. Hoechst, which is seeking to streamline its health-care operations, may form research alliances with Chiron in areas such as gene therapy and combinatorial chemistry. Under the terms of the agreement, Chiron will have an option to acquire the remaining 51 percent stake between 1998 and 2001. Related Story: New York Times (02/21) P. D5

"A Vaccine for AIDS at Least 5 Years Away"

Philadelphia Inquirer (02/19/96) P. C1; Vedantam, Shankar

AIDS researchers say there is little hope for an AIDS vaccine, which would be the only way to successfully deal with the disease, in the next five years. Anthony Fauci, director of the National Institute for Allergies and Infectious Diseases, said that even the AIDS vaccine furthest along in trials "will not be ready until 2001 or 2002," if it proves safe and effective. A vaccine prepares the immune system for infection, and wipes out the virus before a person gets sick. Therapeutic drugs, which are too expensive to be widely relied upon, have never eliminated a major disease. In addition, HIV's ability to rapidly mutate makes vaccine development especially difficult. Also, drug companies have been hesitant to pursue a vaccine because of the technical difficulty and financial risk involved. AIDS is a particular threat to the developing world, where about 90 percent of new infections now occur. The vaccine with the most potential was developed by Pasteur Merieux-Connaught to defend against HIV-type B, the strain most common in the United States. Scientists are unsure whether a vaccine could protect against more than one strain of the virus, though Fauci said that if the vaccine proved successful, it would be fairly easy to make similar vaccines for others HIV types.

"'Dreaded-Disease' Policies Rise, But Some Say They're No Cure"

Wall Street Journal (02/21/96) P. C1; Jeffrey, Nancy Ann

"Limited benefit" health insurance policies to cover cancer,

heart disease, and hospital stays are being offered in employee-pay-all programs, usually as supplements to an employer's comprehensive health plan. Consumer advocates warn against policies that cover a specific disease, however they note hospital-stay policies can be beneficial for seriously ill individuals. American Family Life Assurance Co., or Alfac Inc., offers two hospital plans which pay \$100 or \$200 a day for the first 30 days in the hospital and \$200 or \$400 a day for the next 150 days. The benefits are usually paid in cash, and can be used for food, rent, a private hospital room, or anything else not covered by regular insurance. For example, David Petersen, president of Affording Care, a nonprofit in New York, has been in the hospital for 44 days since testing positive for HIV in 1988. He pays \$1,400 a year for six hospital policies, and has used the benefits to help pay his monthly \$7,000 drug bill. Other methods of paying for disease costs include disability insurance, accelerated death benefits, and very high-deductible health insurance.

"Recurrent Varicella-Zoster Virus Infections Common in HIV-Positive Children"
Reuters (02/20/96)

Varicella-zoster virus infection in HIV-infected children tends to be recurrent and persistent. Hospitalization and morbidity are often attributed to the disease in these children, according to researchers at the Harbor-UCLA Medical Center in Torrance, Calif. Dr. Margaret Keller led the study of 117 cases of varicella-zoster infection in 73 HIV-positive children and found that 53 percent had recurrent episodes of infection. Keller's team also found that the number of episodes of varicella-zoster infection was strongly associated to low CD4+ cell counts. Keller concluded that new preventative and therapeutic therapies are needed to deal with the infection.

"Skin Cancer and HPV 16 Infection Linked in AIDS Patient"
Reuters (02/20/96)

Evidence of a relationship between human Papillomavirus infection and squamous cell carcinoma in an AIDS patient was reported by Dr. Hunter Maclean and colleagues at the Western General Hospital in Scotland. There, a 42-year-old AIDS patient was diagnosed with squamous cell carcinoma on the eyelid. The researchers identified the human Papillomavirus infection using polymerase chain analysis, noting that squamous cell carcinoma is the third most common malignancy in HIV patients. Maclean therefore recommends that the carcinoma be considered in the diagnostic tests for HIV patients with eyelid lesions.

"Origin and Interstate Spread of a New York City Multidrug-Resistant Mycobacterium Tuberculosis Clone Family"
Journal of the American Medical Association (02/14/96) Vol.275, No.6, P. 452; Bifani, Pablo J.; Plikaytis, Bonnie B.; Kapur, Vivek; et al.

The resurgence of tuberculosis (TB) in the United States can be attributed to the AIDS epidemic, immigration from countries where

TB is prevalent, and the discontinuation of TB control measures. A number of drug-resistant strains of the disease have been identified in New York City, and the number of TB patients in the city has tripled from 1978 through 1992. In this study, Bifani et al. analyzed multidrug-resistant strains of TB to determine if they were new genetic clones of *Mycobacterium tuberculosis* or unrelated organisms. Samples of *M. tuberculosis* were taken from 1,943 patients in New York and samples of multidrug-resistant isolates were taken from six patients elsewhere in the United States. Multidrug-resistant isolates of *M. tuberculosis* were found in 273 New York City patients as well as patients from Florida, Nevada, and Georgia. The strains of tuberculosis found in these patients were closely related at the molecular level. According to the researchers, the data suggest that these organisms are the product of a single ancestral *M. tuberculosis* cell. Numerous strains of bacteria have resulted from the sequential clonal expansion of this one cell. Cases of multidrug-resistant TB associated with HIV have a mortality rate of up to 90 percent.

"Jobs at Risk for HIV-Infected Doctors"

American Medical News (02/05/96) Vol.39, No.5, P. 1; Kent, Christina

Five years after Florida dentist David Acer was found to have transmitted HIV to his patients, the debate about whether HIV-positive health care workers should be allowed to continue to work with patients continues. The incident led to the development of new policies that some argue are unfair to HIV-infected health care workers. Medical and public health experts say that the risk of an HIV-infected health care worker spreading the virus to patients is small. The Acer case is the only known instance of a professional infecting a patient. The Centers for Disease Control and Prevention instituted a policy in 1991 that states that HIV-infected health care workers should avoid any "exposure-prone" procedures not approved by a panel of experts that has reviewed their case. The American Medical Association argued that there was no scientific basis for identifying such procedures. Medical groups also objected to the provision suggested by Congress that health care workers who perform such procedures be required to tell patients if they are HIV-positive. Most state policies do not require such notification. Health care workers feel that disclosing their HIV status could lead to job discrimination. Fear of discrimination could also prevent workers from reporting on-the-job infections.

"A Kinder, Gentler War Against Hepatitis B"

Science News (02/03/96) Vol.149, No.5, P. 69; Travis, J.

Cytotoxic T lymphocytes (CTLs) kill viruses by attaching themselves to infected cells and releasing toxins that kill the cell and the virus. Francis Chisari of the Scripps Research Institute has found that, in fighting hepatitis B, CTLs release compounds that stimulate infected cells to destroy the virus, leaving the cell itself intact. A vaccine for hepatitis B exists, but it is not widely available. To determine CTLs

mechanism of action, Chisari and his colleagues developed mice that make the virus. They found that injecting the mice with CTLs that target the cells producing the viral proteins causes the mice to almost rid themselves of the virus. The CTLs killed only about 5 percent of the targeted cells, leading researchers to conclude that the CTLs recognize infected cells and release two compounds that stimulate antiviral activity in them. The stimulated cells make proteins that disrupt the virus' ability to replicate. Chisari says that human cells may try to inhibit the virus in a similar way and that what they now know about the CTLs' role against hepatitis B could be applied to other viruses, including HIV.

"An Epidemic's Evolution"

Newsweek (02/05/96) Vol.127, No.6, P. 72; Will, George F.

In Newsweek magazine, columnist George F. Will writes that good news about the AIDS epidemic in America is, according to data from Philip Rosenberg, published in Science magazine, that the previous estimate of the incidence of AIDS was too high and that the epidemic is slowing down. The bad news is that the incidence is still high and that the epidemic is now spreading to new segments of the population. The AIDS epidemic started in the white homosexual male population in the late 1970s and early 1980s, centered in large cities. Now the epidemic is increasing in racial minority populations and women, and is spreading to rural areas, especially in the South. It is spreading increasingly through drug use and heterosexual sex, despite aggressive public education about the disease. The fact that AIDS has become endemic is surprising, Will notes, because HIV is difficult to acquire and almost completely preventable. Hopes for fighting AIDS lie in the fact that the epidemic is driven by behavior that can be changed. But, comparing AIDS to lung-cancer and other smoking-related diseases lessens that hope. Smoking involves the pull of nicotine, as AIDS often involves sex and drug use. Thirty-two years after the first surgeon general's warning linking smoking and cancer, smoking has become less common, but has also become concentrated in the poor and under-educated populations, a trend that AIDS appears to be following, Will concludes.

===== ATTACHMENT 1 =====

ATT CREATION TIME/DATE:21-FEB-1996 10:07:00.00

ATT BODYPART TYPE:D

TEXT:

RFC-822-headers:

Received: from storm.eop.gov (storm.eop.gov)

by PMDF.EOP.GOV (PMDf V5.0-4 #6879) id <0111GZ47P3S000HYZB@PMDf.EOP.GOV> for levi_j@al.eop.gov; Wed, 21 Feb 1996 10:05:03 -0400 (EDT)

Received: from aspensys ("port 53858"@aspensys.aspensys.com)

by STORM.EOP.GOV (PMDf V5.0-6 #6879) id <0111GZ5NUODM0000OS@STORM.EOP.GOV> for levi_j@al.eop.gov; Wed, 21 Feb 1996 10:06:12 -0700 (MST)

Received: by aspensys (5.0/SMI-SVR4) id AA22594; Wed, 21 Feb 1996 09:59:26 +0500

Errors-to: martha_vander_kolk@smtpinet.aspensys.com

Precedence: bulk

Originator: aidsnews@cdcnac.aspensys.com

X-Comment: CDC National AIDS Clearinghouse

X-Listprocessor-version: 6.0c -- ListProcessor by Anastasios Kotsikonas

===== END ATTACHMENT 1 =====

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:21-FEB-1996 19:43:01.93

SUBJECT: Press statement on VP meeting

TO: FAX (9-783-0328,Abby Dilley) (TLXA1MAIL_ \F:9-783-0328\C:Abby Dilley\\)
READ:NOT READ

TO: FAX (9-201-485-7769,Mary Boland) (TLXA1MAIL_ \F:9-201-485-7769\C:Mary Boland\\)
READ:NOT READ

TO: FAX (9-404-639-8616,Bruce Weniger) (TLXA1MAIL_ \F:9-404-639-8616\C:Bruce Weniger\\)
READ:NOT READ

TO: FAX (9-810-939-7172,Kathy Gerus) (TLXA1MAIL_ \F:9-810-939-7172\C:Kathy Gerus\\)
READ:NOT READ

TEXT:

PRINTER FONT 12_POINT_COURIER
THE WHITE HOUSE
OFFICE OF THE VICE PRESIDENT

FOR IMMEDIATE RELEASE CONTACT: 202

-456

-7035

WEDNESDAY, February 21, 1996

Vice President Gore Says Meeting
With Pharmaceutical Firms,
AIDS Researchers, An Important Step
in Fight Against Disease

WASHINGTON -- Highlighting his and President Clinton's commitment to AIDS drug development, Vice President Gore met Tuesday (2/20) with pharmaceutical company representatives and leading government researchers. He said the private and public sectors should accelerate their joint effort to find and develop as quickly as possible AIDS vaccines, therapeutics, and microbicides.

Attending the meeting were representatives of 11 pharmaceutical companies and leading AIDS researchers and officials from the National Institutes of Health, the Department of Defense, and the Food and Drug Administration. They discussed ways to accelerate the development of AIDS vaccines, therapeutics, and microbicides.

"This meeting was an important step in strengthening the government

-industry partnership that is essential to finding and developing effective treatments -- and ultimately a cure -- for AIDS," Vice President Gore said. "We are committed to marshalling our best minds and resources in the fight against AIDS."

At the December 6, 1995, White House Conference on HIV and AIDS, President Clinton asked Vice President Gore to convene this meeting to "identify all the ways in which we might accelerate the development of vaccines, therapeutics, and microbicides that can protect people from HIV and the infections it causes." The meeting reflects President Clinton's commitment to bring the AIDS epidemic to an end.

In his three years in office, President Clinton has increased funding for AIDS research by 26 percent, expedited AIDS drug approval, and strengthened the Office of AIDS Research at the National Institutes of Health.
At the conclusion of the two

-hour meeting, Vice President Gore announced the following steps:

The Administration will join with pharmaceutical manufacturers, health insurance companies and other third-party payers, and patient advocacy organizations to develop a collaborative system of clinical trials of AIDS drugs that have been approved by the FDA under expedited procedures to determine the best uses and the long

-term effectiveness of those drugs.

The Administration will work with international organizations -- such as the World Bank -- to increase investment in AIDS vaccine development and trials worldwide. The Administration will help facilitate the development of microbicides to enable women to protect themselves from HIV infection.

The Vice President will facilitate ongoing discussions between the government and the pharmaceutical industry to identify promising areas of AIDS research that the government can support in order to stimulate private sector investment in the next generation of AIDS vaccines, therapeutics, and microbicides.

The Food and Drug Administration will pursue additional measures to increase the number of anti

-HIV therapeutics with pediatric indications.

Participants in Vice President Gore's Meeting
with Pharmaceutical Companies and AIDS Researchers

2/20/96

The following pharmaceutical company representatives participated in the February 20 meeting on AIDS drug development with Vice President Gore:

Anne

-Marie Corner
President, Chief Executive Officer
BIOSYN
Manuel Navia, PhD
Vice President, Senior Scientist
Vertex Pharmaceuticals Inc.
Michael Riordan
President, Chairman
Gilead Sciences
Joseph Pittelli
Senior Vice President for Clinical Research

Wyeth

-Ayerst Research
George Morrow
Group Vice President, Commercial Operations
Glaxo Wellcome, Inc.
Dan Hoth
Senior Vice President, Chief Operating Officer
Cell Genesys, Inc.
Peter Johnson
President, Chief Executive Officer
Agouron Pharmaceuticals, Inc.
Patrick Zenner
President, Chief Executive Officer
Hoffman

-La Roche
Rajen Dalal
Vice President for Corporate Planning and Business Development
Chiron Corporation
David Pizzuti
Vice President for Anti

-Infective Development and Medical Affairs
Abbott Laboratories
Eve Slater
Senior Vice President for Clinical and Regulatory Development
Merck

##

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:21-FEB-1996 15:48:06.24

SUBJECT: Press statement on VP meeting with drug industry

TO: FAX (918028657701,Terje Anderson) (TLXA1MAIL_ \F:918028657701\C:Terje Anderson\\)
READ:NOT READ

TO: FAX (914154873089,Regina Aragon) (TLXA1MAIL_ \F:914154873089\C:Regina Aragon\\)
READ:NOT READ

TO: FAX (912014857769,Mary Boland) (TLXA1MAIL_ \F:910214857769\C:Mary Boland\\)
READ:NOT READ

TO: FAX (914157770869,Nick Bollman) (TLXA1MAIL_ \F:914157770869\C:Nick Bollman\\)
READ:NOT READ

TO: FAX (913122362321,Bob Fogel) (TLXA1MAIL_ \F:913122362321\C:Bob Fogel\\)
READ:NOT READ

TO: FAX (918109397170,Kathy Gerus) (TLXA1MAIL_ \F:918109397170\C:Kathy Gerus\\)
READ:NOT READ

TO: FAX (918189060766,Ed Gould) (TLXA1MAIL_ \F:918189060766\C:Ed Gould\\)
READ:NOT READ

TO: FAX (98333472,Phyllis Greenberger) (TLXA1MAIL_ \F:98333472\C:Phyllis Greenberger\\)
READ:NOT READ

TO: FAX (93712815,Bob Hattoy) (TLXA1MAIL_ \F:93712815\C:Bob Hattoy\\)
READ:NOT READ

TO: FAX (913106529655,Scott Hitt) (TLXA1MAIL_ \F:913106529655\C:Scott Hitt\\)
READ:NOT READ

TO: FAX (915059866120,Jeremy Landau) (TLXA1MAIL_ \F:915059866120\C:Jeremy Landau\\)
READ:NOT READ

TO: FAX (916128223042,Carole LaFavor) (TLXA1MAIL_ \F:916128223042\C:Carole LaFavor\\)
READ:NOT READ

TO: FAX (912137640060,Alexandra Levine) (TLXA1MAIL_ \F:912137640060\C:Alexandra Levine\\)
READ:NOT READ

TO: FAX (914155753935,Steve Lew) (TLXA1MAIL_ \F:914155753935\C:Steve Lew\\)
READ:NOT READ

TO: FAX (912132320018,Altagracia Perez) (TLXA1MAIL_ \F:912132320018\C:Altagracia Perez\\)
READ:NOT READ

TO: FAX (95460738,Alexander Robinson) (TLXA1MAIL_ \F:95460738\C:Alexander Robinson\\)
READ:NOT READ

TO: FAX (914152554784,Ben Schatz) (TLXA1MAIL_ \F:914152554784\C:Ben Schatz\\)
READ:NOT READ

TO: FAX (913145261684,Charles Troupe) (TLXA1MAIL_ \F:913145261684\C:Charles Troupe\\)
READ:NOT READ

TO: FAX (914048729661,Sandy Thurman) (TLXA1MAIL_ \F:914048729661\C:Sandy Thurman\\)
READ:NOT READ

TO: Remote Addressee (bgw2@NIP1.EM.CDC.GOV@INET@EOPMRX)
READ:NOT READ

TO: FAX (912126140057,Debra Fraser Howz (TLXA1MAIL_ \F:912126140057\C:Debra Fraser Howze\\)
READ:NOT READ

TO: FAX (912124598061,Stephen Abel) (TLXA1MAIL_ \F:912124598061\C:Stephen Abel\\)
READ:NOT READ

TO: FAX (912126447485,Tonio Burgos) (TLXA1MAIL_ \F:912126447485\C:Tonio Burgos\\)
READ:NOT READ

TO: FAX (917028775342,Jerry Cade) (TLXA1MAIL_ \F:917028775342\C:Jerry Cade\\)
READ:NOT READ

TO: FAX (915124732829,Tom Henderson) (TLXA1MAIL_ \F:915124732829\C:Tom Henderson\\)
READ:NOT READ

TO: FAX (914154766042,Helen Miramontes) (TLXA1MAIL_ \F:914154766042\C:Helen Miramontes\\)
READ:NOT READ

TO: FAX (915102737879,Michael Rankin) (TLXA1MAIL_ \F:915102737879\C:Michael Rankin\\)
READ:NOT READ

TO: FAX (916122930706,Rick Stafford) (TLXA1MAIL_ \F:916122930706\C:Rick Stafford\\)
READ:NOT READ

TEXT:

PRINTER FONT 12_POINT_COURIER
THE WHITE HOUSE
OFFICE OF THE VICE PRESIDENT

FOR IMMEDIATE RELEASE CONTACT: 202

-456

-7035

WEDNESDAY, February 21, 1996

Vice President Gore Says Meeting
With Pharmaceutical Firms,

AIDS Researchers, An Important Step
in Fight Against Disease

WASHINGTON -- Highlighting his and President Clinton's commitment to AIDS drug development, Vice President Gore met Tuesday (2/20) with pharmaceutical company representatives and leading government researchers. He said the private and public sectors should accelerate their joint effort to find and develop as quickly as possible AIDS vaccines, therapeutics, and microbicides.

Attending the meeting were representatives of 11 pharmaceutical companies and leading AIDS researchers and officials from the National Institutes of Health, the Department of Defense, and the Food and Drug Administration. They discussed ways to accelerate the development of AIDS vaccines, therapeutics, and microbicides.

"This meeting was an important step in strengthening the government

-industry partnership that is essential to finding and developing effective treatments -- and ultimately a cure -- for AIDS," Vice President Gore said. "We are committed to marshalling our best minds and resources in the fight against AIDS."

At the December 6, 1995, White House Conference on HIV and AIDS, President Clinton asked Vice President Gore to convene this meeting to "identify all the ways in which we might accelerate the development of vaccines, therapeutics, and microbicides that can protect people from HIV and the infections it causes." The meeting reflects President Clinton's commitment to bring the AIDS epidemic to an end.

In his three years in office, President Clinton has increased funding for AIDS research by 26 percent, expedited AIDS drug approval, and strengthened the Office of AIDS Research at the National Institutes of Health.

At the conclusion of the two

-hour meeting, Vice President Gore announced the following steps:

The Administration will join with pharmaceutical manufacturers, health insurance companies and other third-party payers, and patient advocacy organizations to develop a collaborative system of clinical trials of AIDS drugs that have been approved by the FDA under expedited procedures to determine the best uses and the long

-term effectiveness of those drugs.

The Administration will work with international organizations -- such as the World Bank -- to increase investment in AIDS vaccine development and trials worldwide. The Administration will help facilitate the development of microbicides to enable women to protect themselves from HIV

infection.

The Vice President will facilitate ongoing discussions between the government and the pharmaceutical industry to identify promising areas of AIDS research that the government can support in order to stimulate private sector investment in the next generation of AIDS vaccines, therapeutics, and microbicides.

The Food and Drug Administration will pursue additional measures to increase the number of anti

-HIV therapeutics

with pediatric indications.

Participants in Vice President Gore's Meeting
with Pharmaceutical Companies and AIDS Researchers

2/20/96

The following pharmaceutical company representatives participated in the February 20 meeting on AIDS drug development with Vice President Gore:

Anne

-Marie Carrier

President, Chief Executive Officer

BIOSYN

Manuel Navia, PhD

Vice President, Senior Scientist

Vertex Pharmaceuticals Inc.

Michael Riordan

President, Chairman

Gilead Sciences

Joseph Pittelli

Senior Vice President for Clinical Research

Wyeth

-Ayerst Research

George Morrow

Group Vice President, Commercial Operations

Glaxo Wellcome, Inc.

Dan Hoth

Senior Vice President, Chief Operating Officer

Cell Genesys, Inc.

Peter Johnson

President, Chief Executive Officer

Agouron Pharmaceuticals, Inc.

Patrick Zenner

President, Chief Executive Officer

Hoffman

-La Roche

Rajen Dalal

Vice President for Corporate Planning and Business Development

Chiron Corporation

David Pizzuti

Vice President for Anti

-Infective Development and Medical Affairs
Abbott Laboratories
Eve Slater
Senior Vice President for Clinical and Regulatory Development
Merck

##

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Marsha Scott (SCOTT_M) (WHO)

CREATION DATE/TIME:21-FEB-1996 15:06:40.15

SUBJECT: New York

TO: Jeffrey Levi (LEVI_J) (WHO)

READ:21-FEB-1996 15:33:34.03

TEXT:

Let's get this New York mess off our plate. We need to get Kevin Thurm and his lawyers over here with you, Patsy, Peg Clark and myself to discuss how to make the additions to the AIDS Council. Call me and let's talk about how best to do this. Thanks

RECORD TYPE: PRESIDENTIAL (EXTERNAL MAIL)

CREATOR: aidsnews@aspensys.com@INET@EOPMRX

CREATION DATE/TIME:21-FEB-1996 11:39:00.00

SUBJECT: New Conference Listings 02/21/96

TO: levi_j (levi_j@A1@CD) (WHO)

READ:21-FEB-1996 11:41:41.28

TEXT:

CDC National AIDS Clearinghouse
Conference Calendar Database

NEW CONFERENCE LISTINGS
February 21, 1996

The Clearinghouse's Conference Calendar Database contains information about upcoming conferences related to HIV and AIDS.

NAC ONLINE users can search this database by selecting "Clearinghouse Databases" from the NAC ONLINE main menu. When asked to enter a database name, specify "CONF" to search the Calendar.

To access the NAC ONLINE BBS, set your communications software to dial (800) 851-7245, and set the options for 8 data bits, N parity, 1 stop bit, full duplex, and complete a new user questionnaire. Only non-profit organizations, government agencies, educational institutions, and health departments are given full access to NAC ONLINE and the NAC databases.

Overnight, 13 new listings were loaded to the Conference Calendar Database. Their records follow:

TITLE: Comprehensive Management of HIV Disease: A Clinical
Preceptorship for Physicians
DATE: March 14-15, 1996
LOCATION: New Orleans, LA
SPONSOR(S): Delta Region AIDS Education and Training Center
CONTACT: Delta Region AIDS Education and Training Center, LSU Medical
Center, 136 S. Roman St, 3rd Fl., New Orleans, LA 70112, (504)
568-3855, FAX: (504) 568-7893
EVENT TYPE: Training
TOPICS: Opportunistic infections. Case management. Asymptomatic
infection. Tuberculosis (TB). Pneumocystis carinii pneumonia
(PCP). Pediatrics. Legal issues. Women. Psychiatry.
Dermatology. Treatment.
NOTES: Fee: \$150. Accommodations, (504) 524-2460. Continuing
education

credits available.

TITLE: HIV in Children and Families Today
DATE: March 25-27, 1996
LOCATION: Secaucus, NJ
SPONSOR(S): National Pediatric and Family HIV Resource Center
CONTACT: Maggie Garcia or Julie Plunkett, 15 S. 9th St., Newark, NJ
07107, (201) 268-8251, (800) 362-0071
EVENT TYPE: Conference
TOPICS: Treatment. Perinatal transmission. Opportunistic infections.

Clinical trials. Adolescents. Counseling. Nutrition. Home
care. Cultural factors. Families.

NOTES: Fee: \$250 before March 11; \$285 after March 11.

TITLE: Advances in Internal Medicine
DATE: May 20-24, 1996
LOCATION: San Francisco, CA
SPONSOR(S): Department of Medicine, University of California, San
Francisco
School of Medicine
CONTACT: University of California San Francisco, Postgraduate Programs,
Department of Medicine, UCSF Box 0656, San Francisco, CA
94143-0656, (415) 476-5808, (415) 476-5208
EVENT TYPE: Conference
TOPICS: Sexually transmitted diseases (STDs). Women. Cancer.
Tuberculosis (TB). Hepatitis.
NOTES: Fee: \$675 for physicians; \$475 for allied health
professionals,
medical house staff officers with letter of verification.
Accommodations, (415) 296-7465. Continuing medical education
credits available.

TITLE: Positive Living for US (PLUS) Seminar
DATE: March 29-31, 1996
LOCATION: San Francisco, CA
SPONSOR(S): National Task Force on AIDS Prevention
CONTACT: National Task Force on AIDS Prevention, (415) 356-8129
EVENT TYPE: Seminar
TOPICS: Treatment. Alternative therapies. Stress management.
Nutrition. Insurance policies. Legal issues. Sexuality.
Substance abuse.
NOTES: No fee.

TITLE: AIDS Candlelight Memorial and Mobilization: AIDS
Discrimination
is a Global Epidemic
DATE: May 19, 1996

LOCATION: International Event,
SPONSOR(S): International AIDS Candlelight Memorial and Mobilization
CONTACT: International AIDS Candlelight Memorial and Mobilization,
584-B

Castro St., San Francisco, CA 94114-1465, (415) 863-4676, FAX:
(415) 863-4740, Internet email: candle@hooked.net, World Wide
Web Page: <http://www.hooked.net/users/candle>

EVENT TYPE: Memorial

TOPICS: Memorials. Grief.

NOTES: This event is an international memorial observed in
communities
across the globe.

TITLE: Strictly Positive

DATE: May 18, 1996

LOCATION: Orlando, FL

SPONSOR(S): Hope and Heal Center of Central Florida; Comprehensive Care
Associates, Inc.; Mail Rx; Walt Disney World Co.; Walt Disney
World Dolphin

CONTACT: Hope and Heal Center of Central Florida, Inc., 1935 Woodcrest
Dr., Winter Park, FL 32792, (407) 645-2577, FAX: (407)
645-1570

EVENT TYPE: Conference

TOPICS: Alternative therapies. Attitudes. Mental health.

NOTES: No fee. Sponsorships available.

TITLE: The Changing Faces of AIDS: The HIV-Affected Family

DATE: February 22-23, 1996

LOCATION: San Antonio, TX

SPONSOR(S): University Health System

CONTACT: Lorraine T. Hester, Director, Education Resource Center,
University Health System, 4502 Medical Dr., San Antonio, TX
78229-4493, (210) 616-2355, FAX: (210) 616-3908

EVENT TYPE: Conference

TOPICS: Physicians. Care givers. Treatment. Nutrition. Death or
dying. Wasting syndrome. Nutrition. Families. Substance
abuse. Case management. Hospitals. Home care.

NOTES: Fee: \$119; \$99 for University Health System employees.
Continuing education credits available.

TITLE: Pain in AIDS: Mechanisms and Management Strategies

DATE: February 24, 1996

LOCATION: Los Angeles, CA

SPONSOR(S): HIV Institute at Davies Medical Center

CONTACT: HIV Institute at Davies Medical Center, (415) 565-6660 or
(415)

565-6153

EVENT TYPE: Symposium

TOPICS: Case management. Therapeutic drugs.

NOTES: Fee: \$15.

TITLE: Mantoux Tuberculin Skin Test Course
DATE: February 26, 1996
LOCATION: Newark, NJ
SPONSOR(S): New Jersey Medical School National Tuberculosis Center
CONTACT: New Jersey Medical School National Tuberculosis Center,
UMDNJ-Continuing Education, P.O. Box 573, Newark, NJ 07101,
(201) 982-4267, (800) 227-4852, FAX: (201) 982-7128
EVENT TYPE: Training
TOPICS: Tuberculosis (TB). Diagnostic tests. Treatment.
NOTES: Fee: \$25. Respiratory therapists and public health
representatives only.

TITLE: Exploring Death and Spirituality
DATE: May 12-15, 1996
LOCATION: London, CA - Canada
SPONSOR(S): King's College
CONTACT: Dr. John D. Morgan, 266 Epworth Ave., King's College, London,
Ontario, NGA 2M3, Canada, (519) 432-7946, FAX: (519) 432- 0200
EVENT TYPE: Conference
TOPICS: Death or dying. Grief. Bereavement. Spirituality.
NOTES: Fee dependent upon date of registration, attendance of special
events, and lodging.

TITLE: Vital Aging: Vision, Policy, Practice; 46th Conference and
Vital Aging Expo
DATE: April 24-28, 1996
LOCATION: Washington, DC
SPONSOR(S): National Council on the Aging, Incorporated (NCOA)
CONTACT: National Council on the Aging, Incorporated, (NCOA) Department
5087, Washington, DC 20061-5087, (202) 479-6991, FAX: (202)
479-0735
EVENT TYPE: Conference
TOPICS: Age factors. Caregivers.
NOTES: Fee dependent upon membership status, date of registration,
and
professional status, such as full time student or retired NCOA
member.

TITLE: Going for the Gold: Economic Dynamics of Health Education and
Health Promotion
DATE: April 26-28, 1996
LOCATION: Washington, DC
SPONSOR(S): Association of State and Territorial Directors of Health
Promotion and Public Health Education (ASTDHPHE)
CONTACT: John M. Cahill, Director, Bureau of Community Relations, New
York State Health Department, Albany, NY 12237, (518) 474-
5370,
FAX: (518) 486-2361

EVENT TYPE: Conference
TOPICS: Public awareness. Community health education. Community health planning. Community organizations.

TITLE: Angiogenesis Antagonists
DATE: April 1-3, 1996
LOCATION: Boston, MA
SPONSOR(S): Cambridge Healthtech Institute (CHI); The Angiogenesis Foundation
CONTACT: Cambridge Healthtech Institute, 1037 Chestnut St., Newton Upper Falls, MA 02164, (617) 630-1300, FAX: (617) 630-1325, Internet email: chi@healthtech.com, World Wide Web site: <http://www.healthtech.com>.
EVENT TYPE: Conference

Information about additional conferences is welcome. Please send E-Mail to Flynn McLean (through NAC ONLINE, or fmclean@cdcnac.aspensys.com via the Internet) at the CDC National AIDS Clearinghouse; include the title, dates, site, sponsoring agency, contact information, registration fee, and topics to be discussed at the conference.

===== ATTACHMENT 1 =====
ATT CREATION TIME/DATE:21-FEB-1996 11:41:00.00

ATT BODYPART TYPE:D

TEXT:
RFC-822-headers:
Received: from storm.eop.gov (storm.eop.gov)
by PMDF.EOP.GOV (PMDf V5.0-4 #6879) id <0111H2EV0ZVK002L1F@PMDf.EOP.GOV> for
levi_j@a1.eop.gov; Wed, 21 Feb 1996 11:39:08 -0400 (EDT)
Received: from aspensys ("port 61075"@aspensys.aspensys.com)
by STORM.EOP.GOV (PMDf V5.0-6 #6879) id <0111H2GAF8OI0000OS@STORM.EOP.GOV> for
levi_j@a1.eop.gov; Wed, 21 Feb 1996 11:40:17 -0700 (MST)
Received: by aspensys (5.0/SMI-SVR4) id AA05543; Wed, 21 Feb 1996 11:33:23 +0500
Errors-to: martha_vander_kolk@smtpinet.aspensys.com
Precedence: bulk
Originator: aidsnews@cdcnac.aspensys.com
X-Comment: CDC National AIDS Clearinghouse
X-Listprocessor-version: 6.0c -- ListProcessor by Anastasios Kotsikonas
===== END ATTACHMENT 1 =====

Withdrawal/Redaction Marker

Clinton Library

DOCUMENT NO. AND TYPE	SUBJECT/TITLE	DATE	RESTRICTION
--------------------------	---------------	------	-------------

003. email	From: Rosalyn Miller, To: Many Recipients, Re: Surprise Party!!!! (2 pages)	02/21/1996	Personal Misfile
------------	---	------------	------------------

COLLECTION:

Clinton Presidential Records
Automated Records Management System [Email]
WHO ([Jeffrey Levi...])
OA/Box Number: 500000

FOLDER TITLE:

[02/19/1996 - 02/23/1996]

2018-0759-F
jn397

RESTRICTION CODES

Presidential Records Act - [44 U.S.C. 2204(a)]

P1 National Security Classified Information [(a)(1) of the PRA]
P2 Relating to the appointment to Federal office [(a)(2) of the PRA]
P3 Release would violate a Federal statute [(a)(3) of the PRA]
P4 Release would disclose trade secrets or confidential commercial or financial information [(a)(4) of the PRA]
P5 Release would disclose confidential advice between the President and his advisors, or between such advisors [(a)(5) of the PRA]
P6 Release would constitute a clearly unwarranted invasion of personal privacy [(a)(6) of the PRA]

C. Closed in accordance with restrictions contained in donor's deed of gift.

PRM. Personal record misfile defined in accordance with 44 U.S.C. 2201(3).

RR. Document will be reviewed upon request.

Freedom of Information Act - [5 U.S.C. 552(b)]

b(1) National security classified information [(b)(1) of the FOIA]
b(2) Release would disclose internal personnel rules and practices of an agency [(b)(2) of the FOIA]
b(3) Release would violate a Federal statute [(b)(3) of the FOIA]
b(4) Release would disclose trade secrets or confidential or financial information [(b)(4) of the FOIA]
b(6) Release would constitute a clearly unwarranted invasion of personal privacy [(b)(6) of the FOIA]
b(7) Release would disclose information compiled for law enforcement purposes [(b)(7) of the FOIA]
b(8) Release would disclose information concerning the regulation of financial institutions [(b)(8) of the FOIA]
b(9) Release would disclose geological or geophysical information concerning wells [(b)(9) of the FOIA]

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:21-FEB-1996 16:54:43.66

SUBJECT: press release on VP meeting

TO: Marsha Scott (SCOTT_M) (WHO)

READ:22-FEB-1996 18:04:33.65

TEXT:

PRINTER FONT 12_POINT_COURIER
THE WHITE HOUSE
OFFICE OF THE VICE PRESIDENT

FOR IMMEDIATE RELEASE CONTACT: 202

-456

-7035

WEDNESDAY, February 21, 1996

Vice President Gore Says Meeting
With Pharmaceutical Firms,
AIDS Researchers, An Important Step
in Fight Against Disease

WASHINGTON -- Highlighting his and President Clinton's commitment to AIDS drug development, Vice President Gore met Tuesday (2/20) with pharmaceutical company representatives and leading government researchers. He said the private and public sectors should accelerate their joint effort to find and develop as quickly as possible AIDS vaccines, therapeutics, and microbicides.

Attending the meeting were representatives of 11 pharmaceutical companies and leading AIDS researchers and officials from the National Institutes of Health, the Department of Defense, and the Food and Drug Administration. They discussed ways to accelerate the development of AIDS vaccines, therapeutics, and microbicides.

"This meeting was an important step in strengthening the government

-industry partnership that is essential to finding and developing effective treatments -- and ultimately a cure -- for AIDS," Vice President Gore said. "We are committed to marshalling our best minds and resources in the fight against AIDS."

At the December 6, 1995, White House Conference on HIV and AIDS, President Clinton asked Vice President Gore to convene this meeting to "identify all the ways in which we might accelerate the development of vaccines, therapeutics, and microbicides that

can protect people from HIV and the infections it causes." The meeting reflects President Clinton's commitment to bring the AIDS epidemic to an end.

In his three years in office, President Clinton has increased funding for AIDS research by 26 percent, expedited AIDS drug approval, and strengthened the Office of AIDS Research at the National Institutes of Health.

At the conclusion of the two

-hour meeting, Vice President Gore announced the following steps:

The Administration will join with pharmaceutical manufacturers, health insurance companies and other third-party payers, and patient advocacy organizations to develop a collaborative system of clinical trials of AIDS drugs that have been approved by the FDA under expedited procedures to determine the best uses and the long

-term effectiveness of those drugs.

The Administration will work with international organizations -- such as the World Bank -- to increase investment in AIDS vaccine development and trials worldwide. The Administration will help facilitate the development of microbicides to enable women to protect themselves from HIV infection.

The Vice President will facilitate ongoing discussions between the government and the pharmaceutical industry to identify promising areas of AIDS research that the government can support in order to stimulate private sector investment in the next generation of AIDS vaccines, therapeutics, and microbicides.

The Food and Drug Administration will pursue additional measures to increase the number of anti

-HIV therapeutics with pediatric indications.

Participants in Vice President Gore's Meeting
with Pharmaceutical Companies and AIDS Researchers
2/20/96

The following pharmaceutical company representatives participated in the February 20 meeting on AIDS drug development with Vice President Gore:

Anne

-Marie Corner
President, Chief Executive Officer
BIOSYN
Manuel Navia, PhD
Vice President, Senior Scientist
Vertex Pharmaceuticals Inc.
Michael Riordan

President, Chairman
Gilead Sciences
Joseph Pittelli
Senior Vice President for Clinical Research

Wyeth

-Ayerst Research
George Morrow
Group Vice President, Commercial Operations
Glaxo Wellcome, Inc.
Dan Hoth
Senior Vice President, Chief Operating Officer
Cell Genesys, Inc.
Peter Johnson
President, Chief Executive Officer
Agouron Pharmaceuticals, Inc.
Patrick Zenner
President, Chief Executive Officer
Hoffman

-La Roche
Rajen Dalal
Vice President for Corporate Planning and Business Development
Chiron Corporation
David Pizzuti
Vice President for Anti

-Infective Development and Medical Affairs
Abbott Laboratories
Eve Slater
Senior Vice President for Clinical and Regulatory Development
Merck

##

RECORD TYPE: PRESIDENTIAL (EXTERNAL MAIL)

CREATOR: KSF@s-3.com@INET@EOPMRX

CREATION DATE/TIME:21-FEB-1996 14:05:00.00

SUBJECT: Pres. Advisory Council Meeting

TO: 'SMTP:LEVI_J@a1.eop.gov' (LEVI_J@A1@CD) (WHO)

READ:21-FEB-1996 14:31:11.38

TEXT:

The Radisson at Alexandria is able to give us the preferred dates of Thursday, April 25 and Friday, April 26 for the council meeting. The rooms aren't very large, but I think they will work. Please let me know if you would like to run over and take a look at the hotel before we finalize the contract.

Thanks.

Scott also told me that they are not doing the working lunch thing -- so, they won't need another room for lunch....

===== ATTACHMENT 1 =====

ATT CREATION TIME/DATE:21-FEB-1996 14:07:00.00

ATT BODYPART TYPE:D

TEXT:

RFC-822-headers:

Received: from storm.eop.gov (storm.eop.gov)

by PMDF.EOP.GOV (PMDf V5.0-4 #6879) id <0111H7IQCVB400KD2N@PMDf.EOP.GOV> for LEVI_J@a1.eop.gov; Wed, 21 Feb 1996 14:05:48 -0400 (EDT)

Received: from SSSHQ5 ("port 2134"@206.65.240.10)

by STORM.EOP.GOV (PMDf V5.0-6 #6879) id <0111H7K86ZP40000OS@STORM.EOP.GOV> for LEVI_J@a1.eop.gov; Wed, 21 Feb 1996 14:07:01 -0700 (MST)

X-Mailer: Worldtalk (NetConnex V3.50c)/MIME

===== END ATTACHMENT 1 =====

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:21-FEB-1996 12:19:45.87

SUBJECT: Re VP press statement

TO: Elizabeth E. Drye (DRYE_E) (OPD)

READ:21-FEB-1996 12:21:18.16

TEXT:

I just got the final version done by the VP's office -- when I get a cleaner version I will fax it you -- but they added reference to the government officials present -- specifically mentioning FDA. At least someone was more on top of this than I was.

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Heidi Kukis (KUKIS_H) (VPO)

CREATION DATE/TIME:21-FEB-1996 15:18:33.67

SUBJECT: gore press release -- thanks for doing first draft

TO: Jeffrey Levi (LEVI_J) (WHO)

READ:21-FEB-1996 15:33:49.02

TEXT:

THE WHITE HOUSE
OFFICE OF THE VICE PRESIDENT

FOR IMMEDIATE RELEASE CONTACT: 202-456-7035
WEDNESDAY, February 21, 1996

Vice President Gore Says Meeting
With Pharmaceutical Firms,
AIDS Researchers, An Important Step
in Fight Against Disease

WASHINGTON -- Highlighting his and President Clinton's commitment to AIDS drug development, Vice President Gore met Tuesday (2/20) with pharmaceutical company representatives and leading government researchers. He said the private and public sectors should accelerate their joint effort to find and develop as quickly as possible AIDS vaccines, therapeutics, and microbicides.

Attending the meeting were representatives of 11 pharmaceutical companies and leading AIDS researchers and officials from the National Institutes of Health, the Department of Defense, and the Food and Drug Administration. They discussed ways to accelerate the development of AIDS vaccines, therapeutics, and microbicides.

"This meeting was an important step in strengthening the government-industry partnership that is essential to finding and developing effective treatments -- and ultimately a cure -- for AIDS," Vice President Gore said. "We are committed to marshalling our best minds and resources in the fight against AIDS."

At the December 6, 1995, White House Conference on HIV and AIDS, President Clinton asked Vice President Gore to convene this meeting to "identify all the ways in which we might accelerate the development of vaccines, therapeutics, and microbicides that can protect people from HIV and the infections it causes." The meeting reflects President Clinton's commitment to bring the AIDS epidemic to an end.

In his three years in office, President Clinton has increased funding for AIDS research by 26 percent, expedited AIDS drug approval, and strengthened the Office of AIDS Research at the National Institutes of Health.

At the conclusion of the two-hour meeting, Vice President Gore

announced the following steps:

The Administration will join with pharmaceutical manufacturers, health insurance companies and other third-party payers, and patient advocacy organizations to develop a collaborative system of clinical trials of AIDS drugs that have been approved by the FDA under expedited procedures to determine the best uses and the long-term effectiveness of those drugs.

The Administration will work with international organizations -- such as the World Bank -- to increase investment in AIDS vaccine development and trials worldwide. The Administration will help facilitate the development of microbicides to enable women to protect themselves from HIV infection.

The Vice President will facilitate ongoing discussions between the government and the pharmaceutical industry to identify promising areas of AIDS research that the government can support in order to stimulate private sector investment in the next generation of AIDS vaccines, therapeutics, and microbicides.

The Food and Drug Administration will pursue additional measures to increase the number of anti-HIV therapeutics with pediatric indications.

Participants in Vice President Gore's Meeting
with Pharmaceutical Companies and AIDS Researchers
2/20/96

The following pharmaceutical company representatives participated in the February 20 meeting on AIDS drug development with Vice President Gore:

Anne-Marie Carrier
President, Chief Executive Officer
BIOSYN
Manuel Navia, PhD
Vice President, Senior Scientist
Vertex Pharmaceuticals Inc.
Michael Riordan
President, Chairman
Gilead Sciences
Joseph Pittelli
Senior Vice President for Clinical Research
Wyeth-Ayerst Research
George Morrow
Group Vice President, Commercial Operations
Glaxo Wellcome, Inc.
Dan Hoth
Senior Vice President, Chief Operating Officer
Cell Genesys, Inc.
Peter Johnson
President, Chief Executive Officer
Agouron Pharmaceuticals, Inc.
Patrick Zenner
President, Chief Executive Officer
Hoffman-La Roche
Rajen Dalal

Vice President for Corporate Planning and Business Development

Chiron Corporation

David Pizzuti

Vice President for Anti-Infective Development and Medical Affairs

Abbott Laboratories

Eve Slater

Senior Vice President for Clinical and Regulatory Development

Merck

##

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:21-FEB-1996 19:36:25.90

SUBJECT: lawsuits

TO: Jeremy D. Benami (BENAMI_J) (WHO)

READ:22-FEB-1996 08:29:22.47

TEXT:

I ran into Marvin Krislov who told me that Chai Feldblum believes we have essentially a 3-4 weeks window before lawsuits will be filed. I presume that should factor into our legislative strategy and the timeline VA is on.

On the good news front, Marilyn Yager has gotten an endorsement of repeal from the Air Force Association. It would seem if you seek out support, it might actually be forthcoming.

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Rosalyn A. Miller (MILLER_RA) (OPD)

CREATION DATE/TIME:21-FEB-1996 11:41:26.65

SUBJECT: New Pager for

TO: Ian R. Van Praagh (VANPRAAGH_I) (WHO)
READ:21-FEB-1996 11:46:01.89

TO: Cathy R. Mays (MAYS_C) (OPD)
READ:21-FEB-1996 11:43:48.61

TO: Bruce N. Reed (REED_B) (WHO)
READ:21-FEB-1996 12:13:42.98

TO: Gaynor R. McCown (MCCOWN_G) (OPD)
READ:21-FEB-1996 11:45:59.39

TO: Michael T. Schmidt (SCHMIDT_MT) (OPD)
READ:21-FEB-1996 11:56:37.57

TO: Paul J. Weinstein, Jr (WEINSTEIN_P) (OPD)
READ:21-FEB-1996 12:12:46.40

TO: Patsy Fleming (FLEMING_P) (WHO)
READ:22-FEB-1996 10:57:30.33

TO: Jennifer L. Klein (KLEIN_J) (OPD)
READ:21-FEB-1996 12:11:23.32

TO: Jeffrey Levi (LEVI_J) (WHO)
READ:21-FEB-1996 11:41:59.17

TO: Stephen C. Warnath (WARNATH_S) (OPD)
READ:21-FEB-1996 12:33:16.05

TO: Julie E. Demeo (DEMEO_J) (OPD)
READ:26-FEB-1996 08:20:26.23

TO: Christopher C. Jennings (JENNINGS_C) (WHO)
READ:21-FEB-1996 17:16:24.09

TO: Diana M. Fortuna (FORTUNA_D) (OPD)
READ:21-FEB-1996 11:52:02.11

TO: Janet B. Abrams (ABRAMS_J) (VPO)
READ:21-FEB-1996 11:41:27.10

TO: Molly Brostrom (BROSTROM_M) (WHO)
READ:21-FEB-1996 11:41:51.68

TO: Patricia E. Romani (ROMANI_P) (WHO)
READ:21-FEB-1996 11:51:12.52

TO: Denise Ricketson (RICKETSON_D) (OPD)
READ:21-FEB-1996 12:20:13.77

TO: Dorothy L. Karayannis (KARAYANNIS_D) (OPD)
READ:21-FEB-1996 11:57:31.22

TO: Jeremy D. Benami (BENAMI_J) (WHO)
READ:21-FEB-1996 12:06:52.51

TO: Dennis Burke (BURKE_D) (OPD)
READ:21-FEB-1996 11:57:39.52

TO: Deborah L. Fine (FINE_D) (OPD)
READ:21-FEB-1996 12:03:09.87

TO: Elizabeth E. Drye (DRYE_E) (OPD)
READ:21-FEB-1996 12:16:58.70

TEXT:

Please note that as of today, Paul Weinstein's new pager number is 4839. He has just been issued the same type pager that all of us have (Motorola). It should take about a day for the OASIS system to reflect this change; but until then you can page him through the Signal Operator.
Thanks.

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:21-FEB-1996 09:10:04.89

SUBJECT: fyi re VP meeting

TO: Carol H. Rasco (RASCO_C) (WHO)

READ:21-FEB-1996 09:48:44.26

TO: Jeremy D. Benami (BENAMI_J) (WHO)

READ:21-FEB-1996 09:18:38.59

TO: Elizabeth E. Drye (DRYE_E) (OPD)

READ:21-FEB-1996 10:08:26.80

CC: Patsy Fleming (FLEMING_P) (WHO)

READ:22-FEB-1996 10:53:27.23

TEXT:

The VP's meeting with the drug companies was a great success.
Thought the attached draft press statement would summarize for you
what occurred.

===== ATTACHMENT 1 =====

ATT CREATION TIME/DATE:21-FEB-1996 09:08:00.00

ATT BODYPART TYPE:p

ATT CREATOR: Jeffrey Levi

TEXT:

PRINTER FONT 14_POINT_ROMAN
Draft

PRINTER FONT 18_POINT_ROMAN
Vice President Meets With
Pharmaceutical Firms and AIDS
Researchers

PRINTER FONT 12_POINT_ROMAN
Vice President Gore met Tuesday with representatives of 12
pharmaceutical companies and leading AIDS researchers from the
National Institutes of Health, the Department of Defense, and the
Department of Veterans Affairs to discuss ways to accelerate
development of AIDS vaccines, therapeutics, and preventives.
The meeting was the first top

-level White House discussion of
AIDS drug development in the history of the epidemic. It
reflects the President's commitment to bring the AIDS epidemic to
an end. In his three years in office, the President has
increased funding for AIDS research by 26 percent, expedited AIDS
drug approval, and strengthened the Office of AIDS Research at

the National Institutes of Health.

[add VPOTUS quote here]

At the conclusion of the two

-hour meeting, the Vice President announced the following steps:

? The Federal government will join with pharmaceutical manufacturers, health insurance companies and other third

-party payers, and patient advocacy organizations to develop a collaborative system of clinical trials of AIDS drugs that have been approved by the FDA under expedited procedures to determine the long

-term effectiveness of those drugs.

? The Vice President will work with international organizations -- such as the World Bank -- to increase investment in AIDS vaccine development.

? The Administration will increase support for the development of microbicides to enable women to protect themselves from HIV infection without relying on their sexual partners.

? The Vice President will facilitate ongoing discussions between the government and the pharmaceutical industry to identify areas of AIDS research that the government can support in order to stimulate private sector investment in the next generation of AIDS vaccines, therapeutics, and microbicides.

? The Food and Drug Administration will pursue additional measures to increase the number of anti

-HIV therapeutics with pediatric indications.

PRINTER FONT 12_POINT_ROMAN_ITALIC
Draft

PRINTER FONT 12_POINT_ROMAN
Participants in Vice President's Meeting
with Pharmaceutical Companies and AIDS Researchers

The following pharmaceutical company representatives participated in the February 20 meeting on AIDS drug development with Vice President Gore:
Anne

-Marie Corrier
President, Chief Executive Officer
BIOSYN
Manuel Navia, PhD
Vice President, Senior Scientist

Vertex Pharmaceuticals Inc.
Michael Riordan
President, Chairman
Gilead Sciences
Joseph Pittelli
Senior Vice President for Clinical Research
Wyeth

-Ayerst Research
George Morrow
Group Vice President, Commercial Operations
Glaxo Wellcome, Inc.
Dan Hoth
Senior Vice President, Chief Operating Officer
Cell Genesys, Inc.
Peter Johnson
President, Chief Executive Officer
Agouron Pharmaceuticals, Inc.
Patrick Zenner
President, Chief Executive Officer
Hoffman

-La Roche
Whaijen Soo
Vice President for Clinical Science
Hoffman

-La Roche

Rajen Dalal
Vice President for Corporate Planning and Business Development
Chiron Corporation
David Pizzuti
Vice President for Anti

-Infective Development and Medical Affairs
Abbott Laboratories
Eve Slater
Senior Vice President for Clinical and Regulatory Development
Merck

===== END ATTACHMENT 1 =====

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:21-FEB-1996 08:55:39.95

SUBJECT: daily news

TO: Patsy Fleming (FLEMING_P) (WHO)

READ:22-FEB-1996 10:53:01.83

TEXT:

===== ATTACHMENT 1 =====

ATT CREATION TIME/DATE:20-FEB-1996 06:32:00.00

ATT BODYPART TYPE:E

ATT CREATOR: aidsnews

ATT SUBJECT: CDC AIDS Daily Summary 02/20/96

ATT TO: levi_j (levi_j@Al@CD)

TEXT:

AIDS Daily Summary
February 20, 1996

The Centers for Disease Control and Prevention (CDC) National AIDS Clearinghouse makes available the following information as a public service only. Providing this information does not constitute endorsement by the CDC, the CDC Clearinghouse, or any other organization. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC Clearinghouse should be cited as the source of this information.
Copyright 1996, Information, Inc., Bethesda, MD

"Jury Rejects Man's Claim that Dentist Gave Him HIV"
"Combination Strategy Reinvigorates Search for AIDS Vaccine"
"Global Warming Plague Looming? Wrong"
"Lab Chimpanzee With AIDS Is Euthanized"
"Model Soldier With HIV Assails Congress for Forcing Her Out"
"Across the USA: Iowa/Nebraska"
"Killing Not About AIDS, Police Say"
"PM Target of Postcard Protest"
"Overhauling AIDS Research: Views from the Community"
"Beating the Odds"

"Jury Rejects Man's Claim that Dentist Gave Him HIV"
Baltimore Sun (02/17/96) P. 2A

In Northampton, Mass., a jury rejected a man's claim that he got HIV from his dentist. The jury found that the dentist, Anthony E. Breglio, was negligent in his treatment of the dental tools he used on the patient. They decided, though, that the negligence did not cause the patient's infection. Related Story: Los Angeles Times (02/18/96) P.A25

"Combination Strategy Reinvigorates Search for AIDS Vaccine"
New York Times (02/20/96) P. C5; Altman, Lawrence K.

Developing an AIDS vaccine has proven a particularly difficult task. About 20 experimental vaccines have been studied since 1987, but none have reached the third stage of testing. However, a new vaccine--a combination of two genetically engineered vaccines--has the potential to make it to the third stage. One of those two vaccines contains proteins from the surface of HIV, while the other contains a weakened form of the canarypox virus, which has also been used to develop an experimental rabies vaccine. A 1994 study of the canarypox vaccine was not allowed because a panel said additional data was needed. Now researchers have found that preliminary tests of the two vaccines tested in 1994 may have been flawed. At issue is a test to detect neutralizing antibodies, which are produced as a protective immunological reaction to a vaccine. The canarypox vaccine would be the first to be tested--perhaps as early as late 1997--under the new plan for greater cooperation between government and industry.

"Global Warming Plague Looming? Wrong"
USA Today (02/19/96) P. 11A; Snow, Tony

In USA Today, columnist Tony Snow discusses Vice President Gore's recent warning that global warming will cause an increase in infectious diseases. Snow notes that the data Gore bases his opinion on--a series of papers published in the Journal of the American Medical Association--do not take into account certain factors that might lead to a perceived increase in the infectious disease rate. The measurement of AIDS cases, for instance, inflates the rate because such cases were not even measured prior in 1982. Snow contends that the real problem is not global warming, but slow action on the part of the U.S. Food and Drug Administration in approving new drugs, especially biotech-based drugs.

"Lab Chimpanzee With AIDS Is Euthanized"
New York Times (02/19/96) P. A12

The laboratory chimpanzee that developed AIDS was euthanized after researchers found that it could not be treated for the disease. Researchers at the Yerkes Primate Research Center announced just two weeks ago that the chimp was the first to develop AIDS. The center's director said the animal was terminally ill and that no new information would be gained by keeping it alive. In Defense of Animals, an animal rights group, agreed with the decision to euthanize, but criticized the use of chimpanzees in AIDS research.

"Model Soldier With HIV Assails Congress for Forcing Her Out"
Baltimore Sun (02/19/96) P. 6A

Under the new defense appropriations bill, a 24-year old soldier who has been recognized for her excellent service and leadership potential will be forced out of the army in six months because of her HIV-positive status. "Jasmine" says she was infected through unprotected sex with a man with whom she no longer has contact. The woman is angry with Congress for forcing her discharge, because she says, she is still able to work and is not sick. She claims that the ban "is more crippling than the disease itself." The new law will provide HIV-infected service members with medical benefits but such personnel will lose any retirement benefits they have accumulated. President Clinton has said he will try to repeal the ban and has told the Justice Department not to defend the policy in court.

"Across the USA: Iowa/Nebraska"
USA Today (02/19/96) P. 8A

In Iowa, state health officials have decided to end anonymous HIV testing, a move which AIDS activists say will keep people from getting tested. In Nebraska, meanwhile, the state Supreme Court has decided that a juvenile court judge had to return a boy to his foster mother, who has AIDS, and father, or tell the court why she will not. State officials want the foster child to be placed in another home.

"Killing Not About AIDS, Police Say"
St. Louis Post-Dispatch (02/15/96) P. A1; Bryan, Bill
St. Louis police say a man accused of infecting others with HIV was killed for a drug-related motive rather than revenge for the infections. Robert Warren III had been accused of infecting three women with the virus, and was waiting for his trial when he was shot and killed Feb. 8 behind a known drug house. A suspect in the killing has been arrested.

"PM Target of Postcard Protest"
Toronto Globe and Mail (02/16/96) P. A4

In Canada, advocacy groups and people who were infected by tainted blood have targeted Prime Minister Jean Chretien for a postcard protest. They are calling for the Prime Minister to stop the legal challenges that are slowing the government's inquiry into the tragedy. The Canadian Hemophilia Society will launch a similar protest next month. The Canadian Red Cross, pharmaceutical companies, and others requested a judicial review of the inquiry after they were notified of potential findings of misconduct that could be levied against them in the final report.

"Overhauling AIDS Research: Views from the Community"
Science (02/02/96) Vol.271, No.5249, P. 590; Cohen, Jon

An intensive review of the National Institutes of Health's (NIH's) \$1.4 billion AIDS budget, which is being conducted by more than 100 scientists and AIDS activists, is expected to be released in March. Drafts of reports by the group's subpanels reveal that the evaluation will recommend more critical

evaluation of whether clinical trials for new drugs and vaccines should be started; efforts to attract better scientists to AIDS research; and the elimination of spending out of the AIDS budget for research that is not directly related to AIDS. A panel which examined the NIH's studies on the cause of AIDS and the mechanism of HIV found that much of the research supported was "of dubious quality and relevance." The panel also found that some researchers did not cooperate with their colleagues on the use of resources. A panel reviewing vaccine research reported that more incentive was needed to interest the private sector and that too much money was going for irrelevant research. In addition, a panel reviewing AIDS clinical trials recommended the incorporation of all four current clinical trial networks into the AIDS Clinical Trials Group. Members of the review groups say they hope to issue a tough final report, which could influence the 1997 budget request.

"Beating the Odds"

U.S. News & World Report (02/12/96) Vol.120, No.6, P. 60; Brink, Susan

The public's perception of HIV has changed dramatically since 1991, when Earvin "Magic" Johnson retired from professional basketball after learning he had HIV. Fear of AIDS was widespread, and in 1992 when Johnson tried to return to the sport he was criticized and rejected. Now he has been welcomed back to the sport and applauded by the American public for returning. Increased medical knowledge and public education of HIV and AIDS have improved the public's acceptance of people with the virus. People with the virus are living longer, thanks to new drugs, and society has learned that the virus cannot be transmitted through casual contact, dispelling fears about interacting with people with HIV. AIDS has also increasingly infiltrated class, race and gender barriers, thereby dissolving stereotypes about the disease. The 1990 Americans With Disabilities Act protects those with HIV from discrimination. Doctors and researchers have learned that most people with the virus develop symptoms of AIDS after seven to nine years, but that some do not for 10 years or more. Scientists have also found that the amount of virus in a patient's blood is a good predictor of their future health. Overall, the public's attitude toward people with HIV and AIDS has improved, something that is evident from polls, trends in the media, and politics.

===== END ATTACHMENT 1 =====

===== ATTACHMENT 2 =====

ATT CREATION TIME/DATE:20-FEB-1996 15:40:00.00

ATT BODYPART TYPE:D

TEXT:

RFC-822-headers:

Received: from storm.eop.gov (storm.eop.gov)

by PMDF.EOP.GOV (PMDf V5.0-4 #6879) id <0111FWH9YKE800JS5O@PMDf.EOP.GOV> for
levi_j@al.eop.gov; Tue, 20 Feb 1996 15:38:29 -0400 (EDT)

Received: from aspenys ("port 48384"@aspenys.aspenys.com)
by STORM.EOP.GOV (PMDf V5.0-6 #6879) id <0111FWIQFXDC0000OS@STORM.EOP.GOV> for
levi_j@a1.eop.gov; Tue, 20 Feb 1996 15:39:41 -0700 (MST)
Received: by aspenys (5.0/SMI-SVR4) id AA14604; Tue, 20 Feb 1996 15:32:52 +0500
Errors-to: martha_vander_kolk@smtpinet.aspenys.com
Precedence: bulk
Originator: aidsnews@cdcnac.aspenys.com
X-Comment: CDC National AIDS Clearinghouse
X-Listprocessor-version: 6.0c -- ListProcessor by Anastasios Kotsikonas
===== END ATTACHMENT 2 =====

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Marilyn Yager (YAGER_M) (WHO)

CREATION DATE/TIME:22-FEB-1996 12:01:07.35

SUBJECT: RE: today's 3 p.m. meeting

TO: Jeffrey Levi (LEVI_J) (WHO)

READ:22-FEB-1996 12:06:21.98

TEXT:

no, that's fine. Is there any update I should be aware of from your meeting last week with John Hilly and the groups?

Withdrawal/Redaction Marker

Clinton Library

DOCUMENT NO. AND TYPE	SUBJECT/TITLE	DATE	RESTRICTION
--------------------------	---------------	------	-------------

004. email	From: Dorothy Karayannis, To: Many Recipients, Re: Thank You! (2 pages)	02/22/1996	Personal Misfile
------------	---	------------	------------------

COLLECTION:

Clinton Presidential Records
Automated Records Management System [Email]
WHO ([Jeffrey Levi...])
OA/Box Number: 500000

FOLDER TITLE:

[02/19/1996 - 02/23/1996]

2018-0759-F
jn397

RESTRICTION CODES

Presidential Records Act - [44 U.S.C. 2204(a)]

P1 National Security Classified Information [(a)(1) of the PRA]
P2 Relating to the appointment to Federal office [(a)(2) of the PRA]
P3 Release would violate a Federal statute [(a)(3) of the PRA]
P4 Release would disclose trade secrets or confidential commercial or financial information [(a)(4) of the PRA]
P5 Release would disclose confidential advice between the President and his advisors, or between such advisors [(a)(5) of the PRA]
P6 Release would constitute a clearly unwarranted invasion of personal privacy [(a)(6) of the PRA]

C. Closed in accordance with restrictions contained in donor's deed of gift.
PRM. Personal record misfile defined in accordance with 44 U.S.C. 2201(3).
RR. Document will be reviewed upon request.

Freedom of Information Act - [5 U.S.C. 552(b)]

b(1) National security classified information [(b)(1) of the FOIA]
b(2) Release would disclose internal personnel rules and practices of an agency [(b)(2) of the FOIA]
b(3) Release would violate a Federal statute [(b)(3) of the FOIA]
b(4) Release would disclose trade secrets or confidential or financial information [(b)(4) of the FOIA]
b(6) Release would constitute a clearly unwarranted invasion of personal privacy [(b)(6) of the FOIA]
b(7) Release would disclose information compiled for law enforcement purposes [(b)(7) of the FOIA]
b(8) Release would disclose information concerning the regulation of financial institutions [(b)(8) of the FOIA]
b(9) Release would disclose geological or geophysical information concerning wells [(b)(9) of the FOIA]

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:22-FEB-1996 12:06:06.52

SUBJECT: RE: today's 3 p.m. meeting

TO: Marilyn Yager (YAGER_M) (WHO)

READ:22-FEB-1996 12:19:06.61

TEXT:

He committed to working collaboratively with the groups -- especially re targeting key members whose support is needed; he promised that he and other senior WH officials would be involved, including POTUS when needed, in the effort to achieve repeal.

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:22-FEB-1996 17:48:02.75

SUBJECT: Outreach re OAR

TO: Marsha Scott (SCOTT_M) (WHO)

READ:22-FEB-1996 18:19:56.78

TEXT:

Oy. I have spoken to:

Gregg Gonsalvez (TAG)

Christine Lubinski for AIDS Action

Winnie

Alexander Robinson

I have a call into Jane Silver who is out of town and will probably call to harangue me tonight.

So far, so good.

Jeff

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:22-FEB-1996 14:21:07.26

SUBJECT: AIDS groups

TO: Marilyn Yager (YAGER_M) (WHO)

READ:22-FEB-1996 14:31:37.25

TO: Marsha Scott (SCOTT_M) (WHO)

READ:22-FEB-1996 18:09:28.17

TEXT:

my life has changed, it looks like I'll be at the 3 p.m. meeting.

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Marilyn Yager (YAGER_M) (WHO)

CREATION DATE/TIME:22-FEB-1996 14:26:01.85

SUBJECT: RE: AIDS groups

TO: Jeffrey Levi (LEVI_J) (WHO)

READ:22-FEB-1996 14:42:01.29

CC: Marsha Scott (SCOTT_M) (WHO)

READ:22-FEB-1996 18:09:34.36

TEXT:

great, see you there. We are walking over at about 2:45pm. Todd Stern is going to do the legal overview.

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:22-FEB-1996 16:46:43.94

SUBJECT: RE: weekly

TO: Deborah L. Fine (FINE_D) (OPD)

READ:22-FEB-1996 17:53:34.10

CC: Patsy Fleming (FLEMING_P) (WHO)

READ:22-FEB-1996 17:25:19.25

TEXT:

The AIDS Policy Office worked with the Office of the Vice President in preparation for the Vice President's meeting on Tuesday with pharmaceutical companies. This was one of the commitments made by the President at the White House Conference on HIV and AIDS. Additional dialogue promoting public-private collaboration in development of AIDS drugs, vaccines, and microbicides will follow. In addition, as a result of these discussions, the government will be pursuing a collaboration with drug companies, third party payors and patient advocacy groups for financial support of clinical trials.

Patsy Fleming and the AIDS policy staff participated in further discussions regarding coordination of the Administration's response to the Dornan amendment on HIV-positive servicemembers.

DoD has agreed to delay the discharge proceedings as long as possible, with no one discharged before the mandated date of August 31st. VA has still not developed the benefits package; we are hoping to encourage them to move more expeditiously.

Patsy Fleming, Carol Rasco, and Tom Henderson, member of the Presidential Advisory Council on HIV/AIDS, went to Dallas and Fort Worth to visit four community-based AIDS organizations and conduct a two-hour town hall meeting with local residents. The organizations included AIDS Services of Dallas, a housing problem for people living with AIDS; AIDS Resource Center, a social service provider; Welcome House, a program to assist HIV-positive women who have stopped using drugs; and the Health Education Learning Project, a youth-oriented education and prevention program. This is the first of a series of such visits featuring Administration officials and Advisory Council members.

Patsy Fleming spoke at the National Black Gay and Lesbian Leadership Forum in Dallas.

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:22-FEB-1996 12:26:46.98

SUBJECT: stationery

TO: Remote Addressee (KSF@s-3.com@INET@EOPMRX)
READ:NOT READ

CC: Remote Addressee (ScottHitt@aol.com@INET@EOPMRX)
READ:NOT READ

TEXT:

Can we develop some letterhead for the Advisory Council? Is there
an inexpensive way to do this -- so we don't incur costs but they
have something that looks official?

Let me know.

Thanks.

RECORD TYPE: PRESIDENTIAL (EXTERNAL MAIL)

CREATOR: aidsnews@aspensys.com@INET@EOPMRX

CREATION DATE/TIME:22-FEB-1996 10:18:00.00

SUBJECT: CDC AIDS Daily Summary 02/22/96

TO: levi_j (levi_j@A1@CD) (WHO)

READ:22-FEB-1996 11:15:01.42

TEXT:

AIDS Daily Summary
February 22, 1996

The Centers for Disease Control and Prevention (CDC) National AIDS Clearinghouse makes available the following information as a public service only. Providing this information does not constitute endorsement by the CDC, the CDC Clearinghouse, or any other organization. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC Clearinghouse should be cited as the source of this information.
Copyright 1996, Information, Inc., Bethesda, MD

"Approval of DaunoXome Set by European Countries"
"Patients' Groups Jump Into the Battle Over Proposals to Restructure the FDA"
"Genentech to Spin Off AIDS Research Unit"
"FDA Chief Warns Against Some Parts of Overhaul Legislation"
"Culture, et Cetera: Excuse Me"
"Singapore HIV Infection Rises 29 Percent in 1995"
"Teens Flush with Cash in Toilet Giveaway"
"HIV Antiviral Effects of Hyperbaric Oxygen Therapy"
"NIH Agrees to Temporary By-Pass of AIDS Office in Allocation of Grants"
"Continued Sexual Risk Behavior Among HIV Seropositive, Drug-Using Men: Atlanta, Washington D.C., San Juan, Puerto Rico"

"Approval of DaunoXome Set by European Countries"
Wall Street Journal (02/22/96) P. B4

NeXstar Pharmaceuticals Inc. has announced that 10 European Community countries including Austria, Belgium, Denmark, Germany, Greece, Ireland, Italy, Luxembourg, the Netherlands, and Portugal will allow the marketing of DaunoXome, a new drug used to treat Kaposi's sarcoma in AIDS patients. Sweden and the United Kingdom had earlier approved the drug. Food and Drug Administration approval for DaunoXome is currently pending in the United States.

"Patients' Groups Jump Into the Battle Over Proposals to Restructure the FDA"

Wall Street Journal (02/22/96) P. B5; McGinley, Laurie

Patients' groups are now joining the debate on reforming the Food and Drug Administration (FDA) but are taking positions on both sides of the issue. Defending the FDA is the Patients' Coalition, made up of more than 50 national nonprofit groups, including the American Cancer Society, the Arthritis Foundation, the National Hemophilia Foundation, AIDS Action Council, and Gay Men's Health Crisis. While this group says reform proposals would weaken the agency and put consumers at risk, other patient groups are pushing for change. Derek Link, a spokesman for the Patients' Coalition, objects to proposals that would place tight deadlines on drug approvals, which could require the FDA to use outside, private reviewers. But Ellen Stovall, of the National Coalition for Cancer Survivors, said the legislation is needed to require the agency to speed drug approvals and to allow companies to publish information on alternative, unapproved uses of approved drugs. The Patients' Coalition was formed after a number of nonprofit health groups disagreed with proposals that industry groups described as good for consumers. However, some AIDS groups--including the National AIDS Treatment Advocacy Project--claim that the coalition is too cautious.

"Genentech to Spin Off AIDS Research Unit"

Journal of Commerce (02/22/96) P. 5B

Genentech Inc. plans to create a new company, Genenvax Inc., to further develop a potential AIDS vaccine. Genentech has already spent \$100 million and 10 years on its gp120 vaccine. Donald Francis, who supervised early AIDS research at the Centers for Disease Control and Prevention, will head the new company.

"FDA Chief Warns Against Some Parts of Overhaul Legislation"

Washington Post (02/22/96) P. A23; Schwartz, John

FDA Commissioner David A. Kessler told members of the Senate Labor and Human Resources Committee on Wednesday that the agency was successfully reforming itself and that certain provisions of Sen. Nancy Kassebaum's (R-Kan.) reform bill could adversely affect public health. Under consideration was a portion of the bill that would require the FDA to take action within four months on applications for new drugs to treat life-threatening diseases or other conditions for which no treatment exists, and within six months for all other products. Kessler said that the agency is already approving new drugs for AIDS and other life-threatening illnesses in less time than the Kassebaum bill stipulates. The session scheduled for Thursday will consider another portion of the bill that would permit drug manufactures to distribute to physicians peer-reviewed studies of unapproved uses of approved drugs. Related Story: Washington Times (02/22) P. B6

"Culture, et Cetera: Excuse Me"

Washington Times (02/22/96) P. A2; Barnicle, Mike

In a letter to the editor, reprinted in the Washington Times from the Boston Globe, columnist Mike Barnicle objects to President's Clinton's attempt to restore disability, retirement, and health benefits to HIV-infected military personnel who will be

discharged under a new law. Barnicle argues that Clinton wants the protections because, although he signed the bill, "he can't stand the thought of a single person not liking him." Furthermore, he writes that, in light of current AIDS education efforts, "if you get the disease today due to sexual behavior or drug use, then you are either a complete moron or a degenerate junkie," and that taxpayers should not have to pay for benefits for such individuals.

"Singapore HIV Infection Rises 29 Percent in 1995" Reuters (02/22/96)

Singapore reported that 111 new cases of HIV were reported in 1995, a 29 percent increase over 1994's figures. According to the Ministry of Health, 419 cases of HIV have been reported in Singapore since 1985, the year that statistics were first gathered. To date, 179 of these people have developed AIDS and 124 have died. All but one of the HIV-infections reported in 1995 were transmitted through sexual contact, 76 percent of which occurred through heterosexual transmission. Males accounted for 91 percent of the cases.

"Teens Flush with Cash in Toilet Giveaway" Chicago Tribune (02/18/96) P. 16-5E; Horowitz, Donna

In Larkspur, Calif., teenage volunteers have raised \$7,050 for the Marin AIDS Project by giving away water-conserving toilets. The AIDS group provides services to people with AIDS and offers AIDS prevention education. To encourage people to conserve water, the Marin Municipal Water District underwrote the cost of the toilets, which reduce water bills and keep the costs down for importing water, while the teens organized and advertised the giveaways and collected the old toilets, which will be crushed and used for road construction. The teens received \$15 for each new toilet they distributed.

"HIV Antiviral Effects of Hyperbaric Oxygen Therapy" Journal of the Association of Nurses in AIDS Care (01/96-02/96) Vol.7, No.1, P. 43; Reillo, Michelle R.; Altieri, Raymond J.

Researchers have theorized that hyperbaric oxygen (HBO) therapy inhibits HIV. To test this theory, Reillo and Altieri conducted laboratory tests with HIV-infected plasma and peripheral blood mononuclear cells (PBMCs), comparing the viral load before and after treatment. The viral load was lower after the treatment, and few viruses entered the uninfected PBMCs that were exposed to HBO. The therapy was also tested in patients and appeared to eliminate traceable HIV virus in their plasma. The therapy was found to relieve the fatigue associated with HIV infection without the toxic side effects brought on by antiviral drugs. The preliminary results offer evidence of HBO's potential to fight HIV in the laboratory and the body. Additional research is necessary to study the mechanism of the treatment.

"NIH Agrees to Temporary By-Pass of AIDS Office in Allocation of Grants" Nature (02/08/96) Vol.379, No.6565, P. 475; Wadman, Meredith

In an effort to get AIDS research funding back on schedule after two government shutdowns, the National Institutes of Health (NIH) has made a preliminary decision to take away budget control held by the Office of AIDS Research (OAR). If the decision is made final, AIDS funding would go directly to the individual institutes. Officials from the Clinton Administration, which has supported the OAR, note that the decision is not final. A spokesman from the White House National AIDS Policy Office said the president is "absolutely and firmly" committed to keeping the OAR's budgetary role. AIDS activists claim that the decision would take away all the OAR's authority and would make the results of a forthcoming evaluation of the NIH's AIDS research efforts meaningless. The House voted in August to remove the OAR's budgetary authority, but the Senate voted to keep it. A temporary funding provision is unclear about the AIDS office's current role. Officials at the Department of Health and Human Services, NIH's parent agency, say they are still trying to reach a final decision. A spokesman for Rep. John Porter (R-Ill.), who chairs the appropriation subcommittee in charge of the NIH budget, says the committee thinks that "science, not politics, should make all judgments about scientific research."

"Continued Sexual Risk Behavior Among HIV Seropositive, Drug-Using Men: Atlanta, Washington D.C., San Juan, Puerto Rico" Morbidity and Mortality Weekly Report (02/23/96) Vol. 45, No. 7; Centers for Disease Control and Prevention

A new study looking at sexual practices of male drug-users who are infected with HIV underscores the need for intensified prevention efforts for this risk group. Previous research reveals that a number of infected men who use drugs continue to practice high-risk sexual behaviors. To look at factors that may contribute to these behaviors, this report compares two groups of HIV-positive, drug-using men--those who report unprotected sex and those who abstain or practice safer sex. The study found no significant differences in demographic characteristics, health status, or drug use behavior, but did identify an opportunity for improved prevention. Most of these men are linked to ongoing community programs which provide drug treatment, mental services, health care, and psychological support. The challenge is to ensure that these programs also address the critical need for these individuals to reduce risky sexual behaviors. This article will be available tomorrow, February 23, from the Centers for Disease Control and Prevention National AIDS Clearinghouse World Wide Web page, <http://cdcnac.aspcsys.com:86>, the CDC National AIDS Clearinghouse listserv, and CDC NAC ONLINE.

===== ATTACHMENT 1 =====
ATT CREATION TIME/DATE:22-FEB-1996 10:20:00.00

ATT BODYPART TYPE:D

TEXT:

RFC-822-headers:

Received: from storm.eop.gov (storm.eop.gov)

by PMDF.EOP.GOV (PMDf V5.0-4 #6879) id <0111IDVFJVU800JG4C@PMDf.EOP.GOV> for

levi_j@al.eop.gov; Thu, 22 Feb 1996 10:18:39 -0400 (EDT)
Received: from aspensys ("port 45022"@aspensys.aspensys.com)
by STORM.EOP.GOV (PMDf V5.0-6 #6879) id <0111IDWUCFDW0000OS@STORM.EOP.GOV> for
levi_j@al.eop.gov; Thu, 22 Feb 1996 10:19:48 -0700 (MST)
Received: by aspensys (5.0/SMI-SVR4) id AA29827; Thu, 22 Feb 1996 10:12:51 +0500
Errors-to: martha_vander_kolk@smtpinet.aspensys.com
Precedence: bulk
Originator: aidsnews@cdcnac.aspensys.com
X-Comment: CDC National AIDS Clearinghouse
X-Listprocessor-version: 6.0c -- ListProcessor by Anastasios Kotsikonas
===== END ATTACHMENT 1 =====

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:22-FEB-1996 08:10:16.63

SUBJECT: council letter

TO: Remote Addressee (KSF@s-3.com@INET@EOPMRX)
READ:NOT READ

TEXT:

(1) I think the Radisson will be OK -- if you don't hear from me later today, let's go forward with it (I want to run it by Patsy). I don't think they'll be thrilled being out of town -- but welcome to living within the budget!!

(2) Attached is a letter to go from the Council to all the members of congress. Do you have the capacity to generate this?

Thanks.

===== ATTACHMENT 1 =====

ATT CREATION TIME/DATE:22-FEB-1996 08:07:00.00

ATT BODYPART TYPE:p

ATT CREATOR: Jeffrey Levi

TEXT:

PRINTER FONT 12_POINT_ROMAN

WHALES AND OCEANOGRAPHIC TESTING:

The Scripps Oceanographic Institute is tracking the speed of sound through the ocean as part of an effort to track warming of the oceans. This involves a low frequency sound source moored, at a significant depth, 88 kilometres off the California coast and there has been some concern expressed about potential negative effects on marine mammals -- particularly whales. Three humpback whales died late last year and the deaths occurred at approximately the same time that preliminary sound source tests were conducted. NMFS subsequently determined that the whales deaths were apparently unrelated to the sound source tests. As such, the National Marine Fisheries Service (NMFS) issued a permit to Scripps while simultaneously ensuring that the effects, if any, are discovered. The first bi

-monthly report to NMFS
required under the permit was received on January 22, 1996 and indicates the research is proceeding without incident. Finally, Scripps intends to apply for a modification to the permit to allow the use of an alternative sound source over a 12

-day period
in June 1996. Public review of such a request will be required in addition to agency review.

===== END ATTACHMENT 1 =====

Withdrawal/Redaction Marker

Clinton Library

DOCUMENT NO. AND TYPE	SUBJECT/TITLE	DATE	RESTRICTION
005. email	From: Dorothy Karayannis, To: Many Recipients, Re: Surprise Birthday Breakfast (2 pages)	02/22/1996	Personal Misfile

COLLECTION:

Clinton Presidential Records
Automated Records Management System [Email]
WHO ([Jeffrey Levi...])
OA/Box Number: 500000

FOLDER TITLE:

[02/19/1996 - 02/23/1996]

2018-0759-F
jn397

RESTRICTION CODES

Presidential Records Act - [44 U.S.C. 2204(a)]

- P1 National Security Classified Information [(a)(1) of the PRA]
- P2 Relating to the appointment to Federal office [(a)(2) of the PRA]
- P3 Release would violate a Federal statute [(a)(3) of the PRA]
- P4 Release would disclose trade secrets or confidential commercial or financial information [(a)(4) of the PRA]
- P5 Release would disclose confidential advice between the President and his advisors, or between such advisors [(a)(5) of the PRA]
- P6 Release would constitute a clearly unwarranted invasion of personal privacy [(a)(6) of the PRA]

C. Closed in accordance with restrictions contained in donor's deed of gift.

PRM. Personal record misfile defined in accordance with 44 U.S.C. 2201(3).

RR. Document will be reviewed upon request.

Freedom of Information Act - [5 U.S.C. 552(b)]

- b(1) National security classified information [(b)(1) of the FOIA]
- b(2) Release would disclose internal personnel rules and practices of an agency [(b)(2) of the FOIA]
- b(3) Release would violate a Federal statute [(b)(3) of the FOIA]
- b(4) Release would disclose trade secrets or confidential or financial information [(b)(4) of the FOIA]
- b(6) Release would constitute a clearly unwarranted invasion of personal privacy [(b)(6) of the FOIA]
- b(7) Release would disclose information compiled for law enforcement purposes [(b)(7) of the FOIA]
- b(8) Release would disclose information concerning the regulation of financial institutions [(b)(8) of the FOIA]
- b(9) Release would disclose geological or geophysical information concerning wells [(b)(9) of the FOIA]

RECORD TYPE: PRESIDENTIAL (EXTERNAL MAIL)

CREATOR: bgw2@NIP1.EM.CDC.GOV@INET@EOPMRX

CREATION DATE/TIME:22-FEB-1996 17:55:00.00

SUBJECT: Message for Patsy Fleming, ONAP

TO: 'Levi, Jeff (ONAP, White House)' (LEVI_J@A1@CD) (WHO)

READ:23-FEB-1996 09:06:29.22

CC: Brummer, Barbara (ACP/J&J) (bbrumme@ompus.jnj.com@INET@EOPMRX)

READ:NOT READ

TEXT:

Dear Jeff,

Please pass to Patsy this note below from Dr. Barbara Brummer, chief executive officer of the Advanced Care Products subsidiary company of Johnson & Johnson, which has more than half the world's market for vaginal products and has committed to anti-HIV microbicide R&D.

I shared with her the press release about the Vice-President's meeting with pharmaceutical companies, and she felt left out and would seem to appreciate participating in future discussions. Her fax is: 908-524-1705, tel 524-1640. (I suspect companies in drug and vaccine development were considered higher priority on the Vice-President's invitation list.)

Thanks,
Bruce

From: OPCRARNF.BBRUMME
To: bgw2
Subject: RE: Press statement on VP meeting with d
Date: Thursday, 22 February 1996 09:55

Microsoft Mail v3.0 IPM.Microsoft Mail.Note
From: Brummer, Barbara x1640
To: BGW3
Cc: McGee, Susan x3132
Subject: RE: Press statement on VP meeting with d
Date: 1996-02-22 09:53
Priority:
Message ID: E8DFB082
Conversation ID: E8DFB082

--

Bruce,

I was very disappointed to note that we missed this meeting. I'm not sure how we were not aware but, I want to make sure that we participate in future meetings. As you know Advanced Care Products, a division of Ortho Pharmaceutical (J&J) has made a commitment to research in this area. We have met with a number of the top researchers in this area and are working with several organizations. I have made it clear to our people that we cannot afford to miss any of these gatherings in order to take advantage of opportunities and information gathering.

Barbara

From: BGW3

Subject: FW: Press statement on VP meeting with d

Date: Wednesday, February 21, 1996 11:56PM

SUBJECT: FW: Press statement on VP meeting with drug industry

===== ATTACHMENT 1 =====

ATT CREATION TIME/DATE:22-FEB-1996 17:57:00.00

ATT BODYPART TYPE:D

TEXT:

RFC-822-headers:

Received: from storm.eop.gov (storm.eop.gov)

by PMDF.EOP.GOV (PMDf V5.0-4 #6879) id <0111ITTDFO0000JKUQ@PMDf.EOP.GOV> for
LEVI_J@a1.eop.gov; Thu, 22 Feb 1996 17:55:06 -0400 (EDT)

Received: from msmtp ("port 65396"@msmail.em.cdc.gov)

by STORM.EOP.GOV (PMDf V5.0-6 #6879) id <0111ITUUQ8AM000MRE@STORM.EOP.GOV> for
LEVI_J@a1.eop.gov; Thu, 22 Feb 1996 17:56:18 -0700 (MST)

Received: from SmtOut.em.cdc.gov by msmtp (5.0/SMI-SVR4) id AA12117; Thu,
22 Feb 1996 17:59:28 -0500

Received: by SmtOut.em.cdc.gov with Microsoft Mail id

<312C7678@SmtOut.em.cdc.gov>; Thu, 22 Feb 1996 17:58:16 -0500 (EST)

===== END ATTACHMENT 1 =====

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:22-FEB-1996 12:19:14.18

SUBJECT: your fax

TO: Remote Addressee (ScottHitt@aol.com@INET@EOPMRX)
READ:NOT READ

TEXT:

Maybe if I initiate this you can reply to me and it will come through.

Thanks for the note. It was wonderful to be away. I am not sure how wonderful it is to be back.

There is more stuff going on re the OAR; we thought we were doing something good with the Shalala letters; it doesn't seem to have been heard that way; we are meeting with Steve Morin today to try to clarify where we are; we will meet with TAG et al. next week.

The problem seems to be that in our letter to Porter and Specter, we talked about FY 97 and not FY 96 -- giving the impression that we have given up on FY 96. In fact, we have had to distribute the FY 96 money without the consolidated appropriation; we would, of course, be supportive of an effort to restore that account in a new continuing resolution. What gets lost in this is the herculean effort OMB has made to assure OAR's authority administratively even without the consolidated account. Is this more confusing than ever? Probably...I'd be glad to talk with you more about it.

FYI: FY 97 numbers are looking very good on all fronts.

White House general counsel said no about the presidential seal.

Letterhead -- we obviously don't have a printing budget. I am sure it is possible to design something....I will speak with Kimberly (unless you have something designed already) that maybe can be done cheaply. I don't intend to ask too many questions about this -- I assume you want to use our address????

We'll get you an update soon.

DoD got us distracted on the National Commission update. We'll try for next week some time.

Talk to you soon.

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:22-FEB-1996 12:22:38.62

SUBJECT: video script

TO: Jeremy D. Benami (BENAMI_J) (WHO)

READ:22-FEB-1996 12:37:40.78

TEXT:
coming by fax as well

===== ATTACHMENT 1 =====

ATT CREATION TIME/DATE:22-FEB-1996 12:19:00.00

ATT BODYPART TYPE:p

ATT CREATOR: Jeffrey Levi

TEXT:
PRINTER FONT 24_POINT_COURIER
Centers for Disease Control and
Prevention

Video

PRINTER FONT 12_POINT_COURIER
? This video is for use at national and important local
meetings on HIV/AIDS prevention. It will be first used
at the opening of the Centers for Disease Control and
Prevention "HIV Prevention Community Planning Co

-Chairs
Meeting"

? The video allows the President to demonstrate the
Administration's strong commitment to AIDS prevention
and to partnership with states and communities.

? National and community leaders in AIDS prevention will
be present.

PRINTER FONT 24_POINT_COURIER
DRAFT
SCRIPT

PRINTER FONT 18_POINT_COURIER
Centers for Disease Control and
Prevention Video

PRINTER FONT 12_POINT_COURIER
The PRESIDENT: It's a pleasure to join you today to discuss
the critical issue of AIDS prevention. I'm
sorry I can't be there with you in person.

Let me first thank each and every one of you
for your work on the front lines of this

epidemic. In community after community across this great nation, you provide the leadership and the commitment needed to turn the tide in this epidemic.

As a nation, we have responded with compassion and commitment to protect our people from HIV. Those efforts have helped to reduce the number of new infections by nearly 50 percent. But you and I know that is not enough. Not when forty to eighty thousand Americans are still becoming infected every year. And not when more than one hundred of our fellow citizens are dying of AIDS every day.

We know that every HIV infection is a preventable infection. But to achieve that we have to do everything we can to empower our citizens.

I am proud of the work we have done together to respond to the critical needs created by this epidemic. A strong public

-private partnership has helped to support creative education programs that puts information in the hands of our people and gives them the skills they need to protect themselves and their loved ones.

In December, at the historic White House Conference on HIV and AIDS, I called on our public health professionals to work toward a very important goal -- to reduce the number of HIV infections each and every year until there are none.

THE PRESIDENT: It will take a national effort, beginning in communities like yours, to achieve that important goal. And we will need the help of businesses, schools, churches, and other community organizations to get there.

My Administration is committed to finding a cure for AIDS and a vaccine against HIV. We must provide comprehensive care for all those who are living with HIV and AIDS. And, of course, we must continue to reduce the number of HIV infections.

Together, I know that we can reach these goals and change the future of our country and our planet.

Thank you and God bless you.

===== END ATTACHMENT 1 =====

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Marsha Scott (SCOTT_M) (WHO)

CREATION DATE/TIME:22-FEB-1996 18:20:50.08

SUBJECT: You poor baby!!

TO: Jeffrey Levi (LEVI_J) (WHO)

READ:23-FEB-1996 09:06:02.65

TEXT:

You're doing good work. I have talked to Itzkowitz, Socarides and Hattoy. All three will spread the word. We'll reconvene tomorrow. Go home and have a good night's slepp.

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:22-FEB-1996 11:59:53.05

SUBJECT: today's 3 p.m. meeting

TO: Marilyn Yager (YAGER_M) (WHO)

READ:22-FEB-1996 12:18:35.05

TEXT:

Apologies...it doesn't look like Richard Sorian is going to be able to make it -- and I can't either ...this should be a supportive group -- hope this doesn't put you in a difficult position.

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:22-FEB-1996 12:24:04.39

SUBJECT: video request

TO: Jeremy D. Benami (BENAMI_J) (WHO)

READ:22-FEB-1996 12:43:19.41

TEXT:
also sent by fax

===== ATTACHMENT 1 =====

ATT CREATION TIME/DATE:22-FEB-1996 12:22:00.00

ATT BODYPART TYPE:p

ATT CREATOR: Jeffrey Levi

TEXT:

PRINTER FONT 12_POINT_ROMAN

VIDEO REQUEST PROPOSAL

Date: 02/22/96

☐ ACCEPT ☐ REJECT ☐ PENDING

TO: Stephanie Streett
Deputy Assistant to the President &
Director of Scheduling
Anne Walley
Deputy Assistant to the President &
Director of Scheduling

FROM: Carol H. Rasco, Assistant to the President
for Domestic Policy

REQUEST: Video message on HIV/AIDS prevention

PURPOSE: This video would be used at national and
important local conferences and events
centered on HIV/AIDS prevention to provide a
message about the President's leadership in
this area.

Most immediately, it would be shown at the
Centers for Disease Control and Prevention
"HIV Prevention Community Planning Co

-Chairs
Meeting," an annual meeting of 800+

participants from all 50 states.

DATE AND TIME: CDC conference opens March 7, 1996.

SOURCE OF PAYMENT: Centers for Disease Control and Prevention

BACKGROUND: Since the beginning of his Administration,

the President has made a priority of

responding to the HIV/AIDS epidemic. At the

Dec. 6, 1995, White House Conference on HIV

and AIDS, the President established a

national goal to reduce the number of HIV

infections each year until there are none.

This video would be used to convey that goal

and that message to national and local

organizations responding

to HIV/AIDS.

DURATION: Three minutes

REMARKS ATTACHED: Script is attached to the request.

STAFF CONTACT: Jeremy Ben Ami

ORIGIN OF PROPOSAL: Office of National AIDS Policy

===== END ATTACHMENT 1 =====

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:22-FEB-1996 11:20:27.69

SUBJECT: news

TO: Patsy Fleming (FLEMING_P) (WHO)

READ:22-FEB-1996 11:24:44.17

TEXT:

===== ATTACHMENT 1 =====

ATT CREATION TIME/DATE:22-FEB-1996 01:12:00.00

ATT BODYPART TYPE:E

ATT CREATOR: aidsnews

ATT SUBJECT: CDC AIDS Daily Summary 02/22/96

ATT TO: levi_j (levi_j@A1@CD)

TEXT:

AIDS Daily Summary
February 22, 1996

The Centers for Disease Control and Prevention (CDC) National AIDS Clearinghouse makes available the following information as a public service only. Providing this information does not constitute endorsement by the CDC, the CDC Clearinghouse, or any other organization. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC Clearinghouse should be cited as the source of this information.
Copyright 1996, Information, Inc., Bethesda, MD

"Approval of DaunoXome Set by European Countries"

"Patients' Groups Jump Into the Battle Over Proposals to Restructure the FDA"

"Genentech to Spin Off AIDS Research Unit"

"FDA Chief Warns Against Some Parts of Overhaul Legislation"

"Culture, et Cetera: Excuse Me"

"Singapore HIV Infection Rises 29 Percent in 1995"

"Teens Flush with Cash in Toilet Giveaway"

"HIV Antiviral Effects of Hyperbaric Oxygen Therapy"

"NIH Agrees to Temporary By-Pass of AIDS Office in Allocation of Grants"

"Continued Sexual Risk Behavior Among HIV Seropositive, Drug-Using Men: Atlanta, Washington D.C., San Juan, Puerto Rico"

"Approval of DaunoXome Set by European Countries"

Wall Street Journal (02/22/96) P. B4

NeXstar Pharmaceuticals Inc. has announced that 10 European Community countries including Austria, Belgium, Denmark, Germany, Greece, Ireland, Italy, Luxembourg, the Netherlands, and Portugal will allow the marketing of DaunoXome, a new drug used to treat Kaposi's sarcoma in AIDS patients. Sweden and the United Kingdom had earlier approved the drug. Food and Drug Administration approval for DaunoXome is currently pending in the United States.

"Patients' Groups Jump Into the Battle Over Proposals to Restructure the FDA"

Wall Street Journal (02/22/96) P. B5; McGinley, Laurie

Patients' groups are now joining the debate on reforming the Food and Drug Administration (FDA) but are taking positions on both sides of the issue. Defending the FDA is the Patients' Coalition, made up of more than 50 national nonprofit groups, including the American Cancer Society, the Arthritis Foundation, the National Hemophilia Foundation, AIDS Action Council, and Gay Men's Health Crisis. While this group says reform proposals would weaken the agency and put consumers at risk, other patient groups are pushing for change. Derek Link, a spokesman for the Patients' Coalition, objects to proposals that would place tight deadlines on drug approvals, which could require the FDA to use outside, private reviewers. But Ellen Stovall, of the National Coalition for Cancer Survivors, said the legislation is needed to require the agency to speed drug approvals and to allow companies to publish information on alternative, unapproved uses of approved drugs. The Patients' Coalition was formed after a number of nonprofit health groups disagreed with proposals that industry groups described as good for consumers. However, some AIDS groups--including the National AIDS Treatment Advocacy Project--claim that the coalition is too cautious.

"Genentech to Spin Off AIDS Research Unit"

Journal of Commerce (02/22/96) P. 5B

Genentech Inc. plans to create a new company, Genenvax Inc., to further develop a potential AIDS vaccine. Genentech has already spent \$100 million and 10 years on its gp120 vaccine. Donald Francis, who supervised early AIDS research at the Centers for Disease Control and Prevention, will head the new company.

"FDA Chief Warns Against Some Parts of Overhaul Legislation"

Washington Post (02/22/96) P. A23; Schwartz, John

FDA Commissioner David A. Kessler told members of the Senate Labor and Human Resources Committee on Wednesday that the agency was successfully reforming itself and that certain provisions of Sen. Nancy Kassebaum's (R-Kan.) reform bill could adversely affect public health. Under consideration was a portion of the bill that would require the FDA to take action within four months on applications for new drugs to treat life-threatening diseases or other conditions for which no treatment exists, and within six months for all other products. Kessler said that the agency is

already approving new drugs for AIDS and other life-threatening illnesses in less time than the Kassebaum bill stipulates. The session scheduled for Thursday will consider another portion of the bill that would permit drug manufactures to distribute to physicians peer-reviewed studies of unapproved uses of approved drugs. Related Story: Washington Times (02/22) P. B6

"Culture, et Cetera: Excuse Me"

Washington Times (02/22/96) P. A2; Barnicle, Mike

In a letter to the editor, reprinted in the Washington Times from the Boston Globe, columnist Mike Barnicle objects to President's Clinton's attempt to restore disability, retirement, and health benefits to HIV-infected military personnel who will be discharged under a new law. Barnicle argues that Clinton wants the protections because, although he signed the bill, "he can't stand the thought of a single person not liking him." Furthermore, he writes that, in light of current AIDS education efforts, "if you get the disease today due to sexual behavior or drug use, then you are either a complete moron or a degenerate junkie," and that taxpayers should not have to pay for benefits for such individuals.

"Singapore HIV Infection Rises 29 Percent in 1995"

Reuters (02/22/96)

Singapore reported that 111 new cases of HIV were reported in 1995, a 29 percent increase over 1994's figures. According to the Ministry of Health, 419 cases of HIV have been reported in Singapore since 1985, the year that statistics were first gathered. To date, 179 of these people have developed AIDS and 124 have died. All but one of the HIV-infections reported in 1995 were transmitted through sexual contact, 76 percent of which occurred through heterosexual transmission. Males accounted for 91 percent of the cases.

"Teens Flush with Cash in Toilet Giveaway"

Chicago Tribune (02/18/96) P. 16-5E; Horowitz, Donna

In Larkspur, Calif., teenage volunteers have raised \$7,050 for the Marin AIDS Project by giving away water-conserving toilets. The AIDS group provides services to people with AIDS and offers AIDS prevention education. To encourage people to conserve water, the Marin Municipal Water District underwrote the cost of the toilets, which reduce water bills and keep the costs down for importing water, while the teens organized and advertised the giveaways and collected the old toilets, which will be crushed and used for road construction. The teens received \$15 for each new toilet they distributed.

"HIV Antiviral Effects of Hyperbaric Oxygen Therapy"

Journal of the Association of Nurses in AIDS Care (01/96-02/96)

Vol.7, No.1, P. 43; Reillo, Michelle R.; Altieri, Raymond J.

Researchers have theorized that hyperbaric oxygen (HBO) therapy inhibits HIV. To test this theory, Reillo and Altieri conducted laboratory tests with HIV-infected plasma and peripheral blood mononuclear cells (PBMCs), comparing the viral load before and

after treatment. The viral load was lower after the treatment, and few viruses entered the uninfected PBMCs that were exposed to HBO. The therapy was also tested in patients and appeared to eliminate traceable HIV virus in their plasma. The therapy was found to relieve the fatigue associated with HIV infection without the toxic side effects brought on by antiviral drugs. The preliminary results offer evidence of HBO's potential to fight HIV in the laboratory and the body. Additional research is necessary to study the mechanism of the treatment.

"NIH Agrees to Temporary By-Pass of AIDS Office in Allocation of Grants"

Nature (02/08/96) Vol.379, No.6565, P. 475; Wadman, Meredith

In an effort to get AIDS research funding back on schedule after two government shutdowns, the National Institutes of Health (NIH) has made a preliminary decision to take away budget control held by the Office of AIDS Research (OAR). If the decision is made final, AIDS funding would go directly to the individual institutes. Officials from the Clinton Administration, which has supported the OAR, note that the decision is not final. A spokesman from the White House National AIDS Policy Office said the president is "absolutely and firmly" committed to keeping the OAR's budgetary role. AIDS activists claim that the decision would take away all the OAR's authority and would make the results of a forthcoming evaluation of the NIH's AIDS research efforts meaningless. The House voted in August to remove the OAR's budgetary authority, but the Senate voted to keep it. A temporary funding provision is unclear about the AIDS office's current role. Officials at the Department of Health and Human Services, NIH's parent agency, say they are still trying to reach a final decision. A spokesman for Rep. John Porter (R-Ill.), who chairs the appropriation subcommittee in charge of the NIH budget, says the committee thinks that "science, not politics, should make all judgments about scientific research."

"Continued Sexual Risk Behavior Among HIV Seropositive, Drug-Using Men: Atlanta, Washington D.C., San Juan, Puerto Rico" Morbidity and Mortality Weekly Report (02/23/96) Vol. 45, No. 7; Centers for Disease Control and Prevention

A new study looking at sexual practices of male drug-users who are infected with HIV underscores the need for intensified prevention efforts for this risk group. Previous research reveals that a number of infected men who use drugs continue to practice high-risk sexual behaviors. To look at factors that may contribute to these behaviors, this report compares two groups of HIV-positive, drug-using men--those who report unprotected sex and those who abstain or practice safer sex. The study found no significant differences in demographic characteristics, health status, or drug use behavior, but did identify an opportunity for improved prevention. Most of these men are linked to ongoing community programs which provide drug treatment, mental services, health care, and psychological support. The challenge is to ensure that these programs also address the critical need for these individuals to reduce risky sexual behaviors. This article

will be available tomorrow, February 23, from the Centers for
Disease Control and Prevention National AIDS Clearinghouse
World Wide Web page, <http://cdcnac.aspensys.com:86>, the CDC
National AIDS Clearinghouse listserv, and CDC NAC ONLINE.

===== END ATTACHMENT 1 =====

===== ATTACHMENT 2 =====

ATT CREATION TIME/DATE:22-FEB-1996 10:20:00.00

ATT BODYPART TYPE:D

TEXT:

RFC-822-headers:

Received: from storm.eop.gov (storm.eop.gov)

by PMDF.EOP.GOV (PMDf V5.0-4 #6879) id <0111IDVFJVU800JG4C@PMDf.EOP.GOV> for
levi_j@a1.eop.gov; Thu, 22 Feb 1996 10:18:39 -0400 (EDT)

Received: from aspensys ("port 45022"@aspensys.aspensys.com)

by STORM.EOP.GOV (PMDf V5.0-6 #6879) id <0111IDWUCFDW0000OS@STORM.EOP.GOV> for
levi_j@a1.eop.gov; Thu, 22 Feb 1996 10:19:48 -0700 (MST)

Received: by aspensys (5.0/SMI-SVR4) id AA29827; Thu, 22 Feb 1996 10:12:51 +0500

Errors-to: martha_vander_kolk@smtpinet.aspensys.com

Precedence: bulk

Originator: aidsnews@cdcnac.aspensys.com

X-Comment: CDC National AIDS Clearinghouse

X-Listprocessor-version: 6.0c -- ListProcessor by Anastasios Kotsikonas

===== END ATTACHMENT 2 =====

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeremy D. Benami (BENAMI_J) (WHO)

CREATION DATE/TIME:22-FEB-1996 11:53:02.87

SUBJECT: AIDS office video request

TO: Carol H. Rasco (RASCO_C) (WHO)

READ:22-FEB-1996 15:37:35.38

TO: Elizabeth E. Drye (DRYE_E) (OPD)

READ:22-FEB-1996 12:35:33.08

TO: Patsy Fleming (FLEMING_P) (WHO)

READ:22-FEB-1996 11:55:59.14

TO: Jeffrey Levi (LEVI_J) (WHO)

READ:22-FEB-1996 11:58:53.90

TEXT:

Have spoken to Scheduling and to Richard at the AIDS office. The request for a video will be reworked (in the next hour!!) into a more generic video and script that can be used for a range of different events including the town halls.

Decisions on videos will be made this afternoon and taping is on Monday.

Hope this is OK with everyone.

I also agreed with Richard that all scheduling and video requests would be run through me and I would then review with Carol/Elizabeth and work with the scheduling office.

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Ashley L. Raines (RAINES_A) (OA)

CREATION DATE/TIME:22-FEB-1996 15:09:18.56

SUBJECT: AIDS Policy Mission Statement

TO: Jeffrey Levi (LEVI_J) (WHO)

READ:22-FEB-1996 16:41:48.31

CC: Joseph G. Kouba (KOUBA_J) (OA)

READ:22-FEB-1996 15:47:57.56

TEXT:

Jeff,

We are working on the FY 1997 budget and we need a brief description of what your office does (like a mission statement). This will be included in the Office of Policy Development FY 1997 budget package in the briefing book for Frank Reeder who will be testifying before Congress on several EOP agency budgets.

Please provide this description to me early tomorrow, if possible. Thanks for your help.

RECORD TYPE: PRESIDENTIAL (EXTERNAL MAIL)

CREATOR: aidsnews@aspensys.com@INET@EOPMRX

CREATION DATE/TIME:23-FEB-1996 11:49:00.00

SUBJECT: CDC AIDS Daily Summary 02/23/96

TO: levi_j (levi_j@A1@CD) (WHO)

READ:23-FEB-1996 16:40:07.35

TEXT:

AIDS Daily Summary
February 23, 1996

The Centers for Disease Control and Prevention (CDC) National AIDS Clearinghouse makes available the following information as a public service only. Providing this information does not constitute endorsement by the CDC, the CDC Clearinghouse, or any other organization. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC Clearinghouse should be cited as the source of this information.
Copyright 1996, Information, Inc., Bethesda, MD

"Pa. Adds New AIDS Drug to Program"

"Airing Ads on AIDS"

"CDC Finds Some Drug Users Still Spreading AIDS"

"Health and Welfare Ministry in Japan Knew of Risk of AIDS in 1983"

"HHS Awards \$80 Million in Ryan White Funding to 42 Cities"

"Urine Therapy Devotees Flock to India"

"Survey Finds Keys to Secondary Prevention of AIDS"

"Serum Cortisol Levels Linked to Disease Progression in AIDS Patients"

"CDC Wants More Input Before Updating Post-Exposure Guidelines"

"Gay Physicians Group Offers Aid to HIV-Infected Doctors"

"Continued Sexual Risk Behavior Among HIV Seropositive, Drug-Using Men: Atlanta, Washington D.C., San Juan, Puerto Rico"

"Pa. Adds New AIDS Drug to Program"

Philadelphia Inquirer (02/23/96) P. B3; Collins, Huntly

The Pennsylvania Welfare Department announced Thursday that uninsured people will have access to the first of the protease inhibitors, a promising new class of anti-HIV drugs. The state will add the drug saquinavir, or Invirase, to the AIDS medicines it already provides to uninsured residents. The drug, along with others expected to be approved this spring, has shown the most potential yet to suppress HIV. The state now pays for 56 AIDS drugs for low- and moderate-income residents. A year's supply of the saquinavir costs about \$6,860.

"Airing Ads on AIDS"

Miami Herald (02/22/96) P. 1B; Smith, Stephen

Health Crisis Network, Dade County, Fla.'s largest provider of AIDS services, has contracted with the advertising firm Beber Silverstein & Partners to give a louder voice to AIDS education. Already, there are plans for billboards that show a condom and read: "The airbag for your other drive." The new campaign is also supposed to include free television commercials, but currently TV stations are only willing to air the tamest ad. This commercial features a group of men, women, and children who obtain services from Health Crisis Network, along with the message: "Every 13 minutes, someone in the United States is infected with HIV." Officials at Health Crisis Network say they are frustrated by the TV station's reluctance to air more provocative ads. "If we're going to talk about the transmission of HIV, you have to talk about sex," said Cathy Lynch, the organization's director.

"CDC Finds Some Drug Users Still Spreading AIDS"

Reuters (02/22/96); Cooper, Mike

A new study from the U.S. Centers for Disease Control and Prevention (CDC) shows that one third of HIV-infected men using illegal drugs continue to have unprotected sex, frequently with multiple partners. A total of 28 percent of the 116 men surveyed said they were having sex without a condom. The subjects reported an average of 4 sex partners and 14 sexual acts in the prior month, were more likely to trade sex for money or drugs, and were less likely to inform their partners that they had HIV. Dr. Judith Greenberg of the CDC's Division of Sexually Transmitted Diseases says that the results indicate that the drug counseling programs from which the subjects were selected may be neglecting to stress the importance of practicing safer sex.

"Health and Welfare Ministry in Japan Knew of Risk of AIDS in 1983"

Reuters (02/22/96)

As early as 1983, Japan's Health and Welfare Ministry considered a warning against the use of U.S.-produced blood products for hemophiliacs, but did nothing, according to documents disclosed Wednesday. Until recently, the Ministry said it could not confirm the existence of AIDS-related documents, in response to charges by hemophiliacs that it knew imported blood products were contaminated. A Ministry report in 1984 concluded that unheated products could continue to be used. More than 1,800 Japanese have been infected with HIV from the blood products so far.

"HHS Awards \$80 Million in Ryan White Funding to 42 Cities"

Reuters (02/21/96)

The Department of Health and Human Services (HHS) announced that it has released \$80 million in Ryan White funding to 42 cities.

HHS said that the cities received about half of the normal amount under the CARE Act, because Congress has not provided the full year's funding for the Ryan White Program, which provides medical and support services for HIV and AIDS patients

"Urine Therapy Devotees Flock to India"

Reuters (02/23/96); Graves, Nelson

Hundreds of doctors and scientists from 17 countries are attending the first World Conference on Auto-Urine Therapy, a controversial treatment for many diseases including AIDS. The three-day meeting, being held in the western Indian state of Goa, brings together proponents of the 5,000-year-old therapy, which involves drinking one's own urine. Former Indian Prime Minister Moraji Desai, who died at 99 last year, surprised the world when he revealed that he drank his own urine every day. Some doctors say urine contains hormones, enzymes, vitamins, and minerals that can cure diseases, and lessen AIDS patients' symptoms. But many mainstream doctors say that while small doses of urine are not harmful, they offer no therapeutic benefit.

"Survey Finds Keys to Secondary Prevention of AIDS"

Reuters (02/22/96)

A survey of more than 2,500 homosexual and bisexual men shows that when they recognize the importance of testing, therapy, and secondary prevention behaviors, HIV-infected patients tend to follow medical recommendations for treatment. Dr. Ron Stall and others at the University of California at San Francisco analyzed the surveys, which asked about preventive health habits, antiviral treatments, and perceptions about such treatment including benefits and toxicity, and use of alternative therapies. While one-third of the men did not know their HIV-status, three-quarters of the ones that knew they had HIV adhered to secondary prevention recommendations. According to Stall, prevention efforts can help guard against both primary infection and secondary problems related to treatment and disease progression.

"Serum Cortisol Levels Linked to Disease Progression in AIDS Patients"

Reuters (02/22/96)

A prospective study of adrenal function in 51 AIDS patients indicates that serum cortisol concentrations are negatively correlated with CD4 cell counts. In the Journal of Clinical Endocrinology and Metabolism, Dr. Loic Guillevin of Universite Paris-Nord speculated that either glucocorticoids can influence the immune system, or, that as the disease progresses, changes in the immune system influence cortisol concentrations. Guillevin also suggested that adrenal insufficiency may be increasing among AIDS patients.

"CDC Wants More Input Before Updating Post-Exposure Guidelines"
AIDS Alert (02/96) Vol.11, No.2, P. 13

The Centers for Disease Control and Prevention will gather health experts for a meeting this spring to consider whether to recommend the use of zidovudine for health care workers exposed to HIV. A case-control study, published recently in Morbidity and Mortality Weekly Report, showed that the drug, used in a prophylactic capacity, was beneficial to such workers. The current Public Health Service (PHS) recommendations, published in 1990, say there is not enough evidence to merit recommending post-exposure prophylaxis, although health care workers are to be informed of the option and left to make the decision themselves. The new study analyzed data from 31 health care workers that had been infected with HIV on the job and 679 others who were exposed to HIV between 1988 and 1994. Workers who took AZT after exposure were significantly less likely to become infected. If the PHS were to recommend AZT use for post-exposure prophylaxis, the Food and Drug Administration might expand its approved indication for the treatment. This could allow workers to receive insurance coverage for the drug. Also, workers who are not offered AZT might have legal standing. Worker interest in prophylaxis has increased since the study results were reported.

"Gay Physicians Group Offers Aid to HIV-Infected Doctors"
American Medical News (02/05/96) Vol.39, No.5, P. 22; Kent, Christina

San Francisco's Gay and Lesbian Medical Association (GLMA) created the Medical Expertise Retention Program in 1990 to assist HIV-infected health care workers. The group offers legal assistance, support groups, job counseling, psychiatric referrals, updated policy information, and advocacy services. The organization has provided services for family practice, psychiatric, and ophthalmology residents who were dismissed based on hospital lawyers' advice. The group has also helped an emergency doctor whose professional liability coverage was dropped, thus forcing him to stop practicing. In a 1991 survey of 200 HIV-positive or "high risk" health care workers, the GLMA found that 75 percent feared losing their jobs because of their HIV status. The majority of those who were not tested, but considered high-risk, said they would be less likely to get tested, because of the potential job-related conflicts.

"Continued Sexual Risk Behavior Among HIV Seropositive, Drug-Using Men: Atlanta, Washington D.C., San Juan, Puerto Rico"
Morbidity and Mortality Weekly Report (02/23/96) Vol. 45, No. 7; Centers for Disease Control and Prevention

A new study looking at sexual practices of male drug-users who are infected with HIV underscores the need for intensified prevention efforts for this risk group. Previous research reveals that a number of infected men who use drugs continue to practice high-risk sexual behaviors. To look at factors that may contribute to these behaviors, this report compares two groups of HIV-positive, drug-using men--those who report unprotected sex

and those who abstain or practice safer sex. The study found no significant differences in demographic characteristics, health status, or drug use behavior, but did identify an opportunity for improved prevention. Most of these men are linked to ongoing community programs which provide drug treatment, mental services, health care, and psychological support. The challenge is to ensure that these programs also address the critical need for these individuals to reduce risky sexual behaviors. This article will be available tomorrow, February 23, from the Centers for Disease Control and Prevention National AIDS Clearinghouse World Wide Web page, <http://cdcnac.aspensys.com:86>, the CDC National AIDS Clearinghouse listserv, and CDC NAC ONLINE.

===== ATTACHMENT 1 =====
ATT CREATION TIME/DATE:23-FEB-1996 11:52:00.00

ATT BODYPART TYPE:D

TEXT:

RFC-822-headers:

Received: from storm.eop.gov (storm.eop.gov)

by PMDF.EOP.GOV (PMDf V5.0-4 #6879) id <0111JVAHOZU800KFI6@PMDf.EOP.GOV> for
levi_j@a1.eop.gov; Fri, 23 Feb 1996 11:49:19 -0400 (EDT)

Received: from aspensys ("port 38208"@aspensys.aspensys.com)

by STORM.EOP.GOV (PMDf V5.0-6 #6879) id <0111JTK4W0Z2000MRE@STORM.EOP.GOV> for
levi_j@a1.eop.gov; Fri, 23 Feb 1996 10:58:29 -0700 (MST)

Received: by aspensys (5.0/SMI-SVR4) id AA11723; Fri, 23 Feb 1996 10:51:29 +0500

Errors-to: martha_vander_kolk@smtpinet.aspensys.com

Precedence: bulk

Originator: aidsnews@cdcnac.aspensys.com

X-Comment: CDC National AIDS Clearinghouse

X-Listprocessor-version: 6.0c -- ListProcessor by Anastasios Kotsikonas

===== END ATTACHMENT 1 =====

Withdrawal/Redaction Marker

Clinton Library

DOCUMENT NO. AND TYPE	SUBJECT/TITLE	DATE	RESTRICTION
006. email	From: Nancy-Ann Min, To: Jeffrey Levi, Re: ADAP Update [partial] (1 page)	02/23/1996	b(6)

COLLECTION:

Clinton Presidential Records
Automated Records Management System [Email]
WHO ([Jeffrey Levi...])
OA/Box Number: 500000

FOLDER TITLE:

[02/19/1996 - 02/23/1996]

2018-0759-F
jn397

RESTRICTION CODES

Presidential Records Act - [44 U.S.C. 2204(a)]

- P1 National Security Classified Information [(a)(1) of the PRA]
- P2 Relating to the appointment to Federal office [(a)(2) of the PRA]
- P3 Release would violate a Federal statute [(a)(3) of the PRA]
- P4 Release would disclose trade secrets or confidential commercial or financial information [(a)(4) of the PRA]
- P5 Release would disclose confidential advice between the President and his advisors, or between such advisors [(a)(5) of the PRA]
- P6 Release would constitute a clearly unwarranted invasion of personal privacy [(a)(6) of the PRA]

C. Closed in accordance with restrictions contained in donor's deed of gift.

PRM. Personal record misfile defined in accordance with 44 U.S.C. 2201(3).

RR. Document will be reviewed upon request.

Freedom of Information Act - [5 U.S.C. 552(b)]

- b(1) National security classified information [(b)(1) of the FOIA]
- b(2) Release would disclose internal personnel rules and practices of an agency [(b)(2) of the FOIA]
- b(3) Release would violate a Federal statute [(b)(3) of the FOIA]
- b(4) Release would disclose trade secrets or confidential or financial information [(b)(4) of the FOIA]
- b(6) Release would constitute a clearly unwarranted invasion of personal privacy [(b)(6) of the FOIA]
- b(7) Release would disclose information compiled for law enforcement purposes [(b)(7) of the FOIA]
- b(8) Release would disclose information concerning the regulation of financial institutions [(b)(8) of the FOIA]
- b(9) Release would disclose geological or geophysical information concerning wells [(b)(9) of the FOIA]

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Nancy-Ann E. Min (MIN_N) (OMB)

CREATION DATE/TIME:23-FEB-1996 20:14:01.91

SUBJECT: RE: ADAP update

TO: Jeffrey Levi (LEVI_J) (WHO)
READ:25-FEB-1996 21:40:32.37

CC: Marsha Scott (SCOTT_M) (WHO)
READ:26-FEB-1996 10:23:11.86

CC: Patsy Fleming (FLEMING_P) (WHO)
READ:26-FEB-1996 08:51:55.83

TEXT:

yes--but it is the level that greg told you about last week--i forget the number, but it is to get them up to something like \$20 or \$22 million in FY96, and then that number is continued in our 97 proposal. if i can find greg's earlier e-mail, i will send it. thanks for trying to help with nih. i got a meeting between the director and the secretary, and alice was very good, she pushed very hard. but the secretary says if you take out the clinical center, aids research is getting 1.7% increase, whereas the rest is getting 1.6%. alice tried to get her to ask harold to go up to 2.0% for aids, but she said he has threatened to resign, and if the potus is upset she will tell him to call harold.

(b)(6)

(b)(6) i think we will have
to emphasize the positive--she says that 40% of clinical center
devotes about 40% of its resources to AIDS.

[006]

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:23-FEB-1996 13:48:20.81

SUBJECT: Response to Hochberg

TO: Adam R. Kreisel (KREISEL_A) (WHO)

READ:23-FEB-1996 13:53:28.21

TEXT:

Attached is our standard response under Patsy's signature; I did not recast it for Mr. Panetta's signature since I assume there are stylistic things you will need to do as well. Hope this is helpful; let me know if there is more you need us to do.

Thanks.

===== ATTACHMENT 1 =====

ATT CREATION TIME/DATE:23-FEB-1996 13:46:00.00

ATT BODYPART TYPE:p

ATT CREATOR: Jeffrey Levi

TEXT:

PRINTER FONT 12_POINT_ROMAN

Dornan Amendment letter

[name and address]

Dear :

Thank you for your letter regarding the recently enacted National Defense Authorization Act of 1996.

As you know, at the urging of Congressman Robert Dornan, the Congress added a provision to this bill requiring the discharge within six months of enactment of all military personnel living with HIV. The President and I were strongly opposed to this provision and sought to have it removed from the final legislation. However, the Congress refused to drop this provision and included it in the legislation it sent to the President. Because the bill included items of concern to our national defense and because it was clear that the Congress would almost certainly override a veto, the President signed this legislation on February 10.

As the President has said, the Dornan Amendment "is blatantly discriminatory and highly punitive to service members and their families. People living with HIV can and do lead full and productive lives, provide for their families, and contribute to the well

-being of our Nation." The President and his Administration are moving aggressively on three fronts to repeal or ameliorate this provision. First, the President has declared that the Dornan Amendment is unconstitutional based on the 14th Amendment's guarantee of equal

treatment and a joint statement by Secretary of Defense William J. Perry and Chairman of the Joint Chiefs of Staff, General John M. Shalikashvili, that the Dornan Amendment is "unnecessary as a matter of sound military policy." The President also directed the Department of Justice not to defend the Dornan Amendment in court.

Second, the President has lent his full support to efforts in Congress to repeal the Dornan Amendment before a single member of the armed forces is discharged. Such legislation has already been introduced in the House and is expected to be introduced shortly in the Senate.

Finally, the President issued a memorandum to the Secretaries of Defense, Transportation, and Veterans Affairs directing them to develop a comprehensive package of benefits for these individuals and their families in the event that all efforts to block or expunge the Dornan Amendment fail.

With the strong support of the American people and members of

both major political parties, I am confident that the Dornan Amendment will be repealed. I appreciate your support on this matter.

Sincerely,

Patricia S. Fleming

Director, Office of National AIDS Policy

===== END ATTACHMENT 1 =====

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:23-FEB-1996 17:38:58.54

SUBJECT: RE: Followup Status on Microbicide Recommendations

TO: Weniger, Bruce (bgw2@NIP1.EM.CDC.GOV@INET@EOPMRX)
READ:NOT READ

CC: Thurman, Sandra (c/o Bauerly) (cbauerl@emory.edu@INET@EOPMRX)
READ:NOT READ

CC: Miramontes, Helen (UCSF) (Helen_Miramontes_at_S/N-MHCAN@ccmail.ucsf.edu@INET@EOPMRX)
READ:NOT READ

CC: Cade, Jerry (Nevada) (peacevisio@aol.com@INET@EOPMRX)
READ:NOT READ

CC: Greenberger, Phyllis (SAWHR) (sawhr@clark.net@INET@EOPMRX)
READ:NOT READ

CC: 'Hitt, R. Scott (Los Angeles)' (scotthitt@aol.com@INET@EOPMRX)
READ:NOT READ

TEXT:

In advance of the April meeting, everyone will be receiving a point by point response to the Council's recommendations -- following our discussions with the agencies. Presumably, you will not see any turf battles here, since if there are any, we will get them resolved before you get an answer.

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Marsha Scott (SCOTT_M) (WHO)

CREATION DATE/TIME:23-FEB-1996 14:16:09.86

SUBJECT: More Info

TO: Jeffrey Levi (LEVI_J) (WHO)

READ:23-FEB-1996 16:16:28.67

TEXT:

Part of the problem we are having on OAR is the rumor that our folks working on the '96 CR appropriations are not mentioning OAR. Noone has given me names but maybe we should have someone from Leg Affairs at the meeting. It should be someone who is actually cutting the deals. What do you think?

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:23-FEB-1996 16:17:05.88

SUBJECT: RE: More Info

TO: Marsha Scott (SCOTT_M) (WHO)

READ:26-FEB-1996 10:20:34.54

TEXT:

sounds fine...let me know who -- Nancy-Ann may know if this is true.

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Marsha Scott (SCOTT_M) (WHO)

CREATION DATE/TIME:23-FEB-1996 10:33:57.41

SUBJECT: Meeting

TO: Jeffrey Levi (LEVI_J) (WHO)

READ:23-FEB-1996 12:06:12.65

TEXT:

Good list. I know this is a tough one for you guys, but add Tom Sheridan. In or spirit of openness, this will help. Having it at OEOB is a good idea.

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:23-FEB-1996 09:49:06.82

SUBJECT: computers

TO: Patsy Fleming (FLEMING_P) (WHO)

READ:23-FEB-1996 11:59:22.46

TEXT:

===== ATTACHMENT 1 =====

ATT CREATION TIME/DATE:23-FEB-1996 09:21:00.00

ATT BODYPART TYPE:B

ATT CREATOR: Ashley L. Raines

ATT SUBJECT: RE: AIDS Policy Mission Statement

ATT TO: Jeffrey Levi (LEVI_J)

TEXT:

Thanks for the description!

I've been working on two things for you: computers and phones. I talked with IST yesterday and found out that your office is on the schedule to begin cabling on Monday (2/26) and will take approximately 2 days to complete. We're working on getting the software licenses needed. They're short on some of the mandatory licenses but they hope this won't delay the process of getting your office hooked up to the network and e-mail.

The only loose end is who needs e-mail accounts. This is what I have: Patsy, You, Carmena, Richard and Lahoma. We don't allow interns e-mail accounts, but will give them network accounts for word processing. Please let me know if I am missing someone. I'll fill out the OA-65's for each person unless this has already been done by your office.

As far as phones, I've been trying to track down the appropriate person in either Bell Atlantic or GSA to report the problems your office has been having and also to get the bills sent to me. This has been more difficult than I ever expected. I think I've talked to 10 people, but have finally found one person who is trying to help me. I'll get someone over there as soon as possible to do a site survey and discuss your office's needs with Carmena.

Just wanted you to know I haven't forgotten about you guys. Please let me know about the e-mail accounts. Thanks.

===== END ATTACHMENT 1 =====

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Ashley L. Raines (RAINES_A) (OA)

CREATION DATE/TIME:23-FEB-1996 09:30:13.62

SUBJECT: RE: AIDS Policy Mission Statement

TO: Jeffrey Levi (LEVI_J) (WHO)

READ:23-FEB-1996 09:48:44.09

TEXT:

Thanks for the description!

I've been working on two things for you: computers and phones. I talked with IST yesterday and found out that your office is on the schedule to begin cabling on Monday (2/26) and will take approximately 2 days to complete. We're working on getting the software licenses needed. They're short on some of the mandatory licenses but they hope this won't delay the process of getting your office hooked up to the network and e-mail.

The only loose end is who needs e-mail accounts. This is what I have: Patsy, You, Carmena, Richard and Lahoma. We don't allow interns e-mail accounts, but will give them network accounts for word processing. Please let me know if I am missing someone. I'll fill out the OA-65's for each person unless this has already been done by your office.

As far as phones, I've been trying to track down the appropriate person in either Bell Atlantic or GSA to report the problems your office has been having and also to get the bills sent to me. This has been more difficult than I ever expected. I think I've talked to 10 people, but have finally found one person who is trying to help me. I'll get someone over there as soon as possible to do a site survey and discuss your office's needs with Carmena.

Just wanted you to know I haven't forgotten about you guys. Please let me know about the e-mail accounts. Thanks.

Withdrawal/Redaction Marker

Clinton Library

DOCUMENT NO. AND TYPE	SUBJECT/TITLE	DATE	RESTRICTION
--------------------------	---------------	------	-------------

007. email	From: Dorothy Karayannis, To: Many Recipients, Re: Brian's Party (2 pages)	02/23/1996	Personal Misfile
------------	--	------------	------------------

COLLECTION:

Clinton Presidential Records
Automated Records Management System [Email]
WHO ([Jeffrey Levi...])
OA/Box Number: 500000

FOLDER TITLE:

[02/19/1996 - 02/23/1996]

2018-0759-F
jn397

RESTRICTION CODES

Presidential Records Act - [44 U.S.C. 2204(a)]

P1 National Security Classified Information [(a)(1) of the PRA]
P2 Relating to the appointment to Federal office [(a)(2) of the PRA]
P3 Release would violate a Federal statute [(a)(3) of the PRA]
P4 Release would disclose trade secrets or confidential commercial or financial information [(a)(4) of the PRA]
P5 Release would disclose confidential advice between the President and his advisors, or between such advisors [(a)(5) of the PRA]
P6 Release would constitute a clearly unwarranted invasion of personal privacy [(a)(6) of the PRA]

C. Closed in accordance with restrictions contained in donor's deed of gift.

PRM. Personal record misfile defined in accordance with 44 U.S.C. 2201(3).

RR. Document will be reviewed upon request.

Freedom of Information Act - [5 U.S.C. 552(b)]

b(1) National security classified information [(b)(1) of the FOIA]
b(2) Release would disclose internal personnel rules and practices of an agency [(b)(2) of the FOIA]
b(3) Release would violate a Federal statute [(b)(3) of the FOIA]
b(4) Release would disclose trade secrets or confidential or financial information [(b)(4) of the FOIA]
b(6) Release would constitute a clearly unwarranted invasion of personal privacy [(b)(6) of the FOIA]
b(7) Release would disclose information compiled for law enforcement purposes [(b)(7) of the FOIA]
b(8) Release would disclose information concerning the regulation of financial institutions [(b)(8) of the FOIA]
b(9) Release would disclose geological or geophysical information concerning wells [(b)(9) of the FOIA]

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:23-FEB-1996 17:52:40.85

SUBJECT: ADAP update

TO: Nancy-Ann E. Min (MIN_N) (OMB)

READ:23-FEB-1996 20:14:03.72

TO: Marsha Scott (SCOTT_M) (WHO)

READ:26-FEB-1996 10:21:02.89

CC: Patsy Fleming (FLEMING_P) (WHO)

READ:23-FEB-1996 18:07:03.08

TEXT:

AIDS Action is testifying before House Labor-HHS on Tuesday. They will be saying that they need \$75 million for the program (the drug companies who dominate the coalition on this issue would not go along with AIDS Action in going in from the start with our number)...but I have gotten a promise that when our number is officially out, they will endorse it and praise it -- and bless them if they can get more.

Another issue: are we including the AETCs as part of our add-backs?
thanks.

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:23-FEB-1996 12:06:47.24

SUBJECT: RE: Meeting

TO: Marsha Scott (SCOTT_M) (WHO)

READ:23-FEB-1996 12:53:59.44

TEXT:

fine to add Tom...and I will...but since when does he do NIH stuff?

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:23-FEB-1996 17:53:17.34

SUBJECT: More Weniger

TO: Patsy Fleming (FLEMING_P) (WHO)

READ:23-FEB-1996 18:07:50.50

TEXT:

===== ATTACHMENT 1 =====

ATT CREATION TIME/DATE:23-FEB-1996 11:14:00.00

ATT BODYPART TYPE:E

ATT CREATOR: Weniger, Bruce

ATT SUBJECT: Followup Status on Microbicide Recommendations

ATT TO: 'Levi, Jeff (ONAP, White House)' (LEVI_J@A1@CD)

ATT CC: Thurman, Sandra (c/o Bauerly) (cbauerl@emory.edu@INET@EOPMRX)

ATT CC: Miramontes, Helen (UCSF) (Helen_Miramontes_at_S/N-MHCAN@ccmail.ucsf.edu@INET@EOPMRX)

ATT CC: Cade, Jerry (Nevada) (peacevisio@aol.com@INET@EOPMRX)

ATT CC: Greenberger, Phyllis (SAWHR) (sawhr@clark.net@INET@EOPMRX)

ATT CC: 'Hitt, R. Scott (Los Angeles)' (scotthitt@aol.com@INET@EOPMRX)

TEXT:

Dear Jeff,

When you get a chance, can ONAP give us some feedback on the proposed PHS response to the recommendations on microbicides from our December meeting?

I hope this doesn't become an inter-agency rivalry issue with NIH and CDC fighting over turf (taking or avoiding responsibility) on the issue.

My unofficial personal opinion is the two agencies ought to work together on the conference/meeting we recommended, with CDC responsible for organizing the prevention policy guidelines aspects and NIH responsible for organizing the state-of-the-art science review session.

Thanks,
Bruce

===== END ATTACHMENT 1 =====

===== ATTACHMENT 2 =====

ATT CREATION TIME/DATE:23-FEB-1996 11:52:00.00

ATT BODYPART TYPE:D

TEXT:

RFC-822-headers:

Received: from storm.eop.gov (storm.eop.gov)

by PMDF.EOP.GOV (PMDf V5.0-4 #6879) id <0111JVAHOZU800KFI6@PMDf.EOP.GOV> for
LEVI_J@al.eop.gov; Fri, 23 Feb 1996 11:49:57 -0400 (EDT)

Received: from msmail ("port 42529"@msmail.em.cdc.gov)

by STORM.EOP.GOV (PMDf V5.0-6 #6879) id <0111JRR940UW000MRE@STORM.EOP.GOV> for
LEVI_J@al.eop.gov; Fri, 23 Feb 1996 10:06:55 -0700 (MST)

Received: from SmtOut.em.cdc.gov by msmail (5.0/SMI-SVR4) id AA12793; Fri,
23 Feb 1996 10:09:42 -0500

Received: by SmtOut.em.cdc.gov with Microsoft Mail id

<312D59D8@SmtOut.em.cdc.gov>; Fri, 23 Feb 1996 10:08:24 -0500 (EST)

===== END ATTACHMENT 2 =====

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:23-FEB-1996 09:10:01.02

SUBJECT: RE: You poor baby!!

TO: Marsha Scott (SCOTT_M) (WHO)

READ:23-FEB-1996 10:29:39.79

TEXT:

Everyone so far is being quite reasonable. I also put in a call to Mike Shriver...he used to call us all the time -- doesn't any more now that he is at NAPWA (something about the corporate culture there thinks we are irrelevant) -- to restart some dialogue with him.

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Marsha Scott (SCOTT_M) (WHO)

CREATION DATE/TIME:23-FEB-1996 12:54:41.01

SUBJECT: Sheridan

TO: Jeffrey Levi (LEVI_J) (WHO)

READ:23-FEB-1996 13:17:41.11

TEXT:

I don't know that he does per se. This is about community relations. It will be a good thing. Thanks

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Nancy-Ann E. Min (MIN_N) (OMB)

CREATION DATE/TIME:23-FEB-1996 15:54:56.56

SUBJECT: RE: Morin and ADAP \$

TO: Jeffrey Levi (LEVI_J) (WHO)

READ:23-FEB-1996 16:17:43.01

CC: Marsha Scott (SCOTT_M) (WHO)

READ:26-FEB-1996 10:20:12.29

TEXT:

thanks. as i said, i want them to support what the president is doing and give him credit. if in the end this thing has so much "lift" that members of Congress decide to push it through with a higher number, that would be fine. but our estimates are based on the best guesses anyone has at this point, based on projections of when these drugs would become available and how many people could benefit from them.

RECORD TYPE: PRESIDENTIAL (EXTERNAL MAIL)

CREATOR: bgw2@NIP1.EM.CDC.GOV@INET@EOPMRX

CREATION DATE/TIME:23-FEB-1996 18:08:00.00

SUBJECT: Re: Followup Status on Microbicide Recommendations

TO: Jeffrey Levi (LEVI_J@A1@CD) (WHO)

READ:25-FEB-1996 21:42:43.22

TEXT:

Thanks, Jeff.

Bruce

From: Jeffrey Levi

To: Weniger, Bruce

Cc: Thurman, Sandra (c/o Bauerly); Miramontes, Helen (UCSF); Cade, Jerry (Nevada); Greenberger, Phyllis (SAWHR); 'Hitt, R. Scott (Los Angeles)'

Subject: RE: Followup Status on Microbicide Recommendations

Date: Friday, 23 February 1996 17:37

In advance of the April meeting, everyone will be receiving a point by point response to the Council's recommendations -- following our discussions with the agencies. Presumably, you will not see any turf battles here, since if there are any, we will get them resolved before you get an answer.

===== ATTACHMENT 1 =====

ATT CREATION TIME/DATE:23-FEB-1996 18:10:00.00

ATT BODYPART TYPE:D

TEXT:

RFC-822-headers:

Received: from storm.eop.gov (storm.eop.gov)

by PMDF.EOP.GOV (PMDf V5.0-4 #6879) id <0111K8LLRGGW00LJS7@PMDf.EOP.GOV> for LEVI_J@a1.eop.gov; Fri, 23 Feb 1996 18:08:44 -0400 (EDT)

Received: from msmail ("port 64752"@msmail.em.cdc.gov)

by STORM.EOP.GOV (PMDf V5.0-6 #6879) id <0111K8N2R1BI000MRE@STORM.EOP.GOV> for LEVI_J@a1.eop.gov; Fri, 23 Feb 1996 18:09:56 -0700 (MST)

Received: from SmtOut.em.cdc.gov by msmail (5.0/SMI-SVR4) id AA11942; Fri, 23 Feb 1996 18:13:56 -0500

Received: by SmtOut.em.cdc.gov with Microsoft Mail id

<312DCB5D@SmtOut.em.cdc.gov>; Fri, 23 Feb 1996 18:12:45 -0500 (EST)

===== END ATTACHMENT 1 =====

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Carol H. Rasco (RASCO_C) (WHO)

CREATION DATE/TIME:23-FEB-1996 16:39:32.63

SUBJECT: URGENT!

TO: Carol H. Rasco (RASCO_C) (WHO)
READ:23-FEB-1996 16:39:35.13

TO: Jeremy D. Benami (BENAMI_J) (WHO)
READ:23-FEB-1996 17:03:37.25

TO: Jennifer L. Klein (KLEIN_J) (OPD)
READ:23-FEB-1996 17:41:55.37

TO: Cathy R. Mays (MAYS_C) (OPD)
READ:23-FEB-1996 16:51:34.19

TO: Rosalyn A. Miller (MILLER_RA) (OPD)
READ:26-FEB-1996 11:03:22.14

TO: Bruce N. Reed (REED_B) (WHO)
READ:23-FEB-1996 17:05:24.41

TO: Michael T. Schmidt (SCHMIDT_MT) (OPD)
READ:23-FEB-1996 16:41:47.26

TO: Stephen C. Warnath (WARNATH_S) (OPD)
READ:23-FEB-1996 16:54:28.52

TO: Paul J. Weinstein, Jr (WEINSTEIN_P) (OPD)
READ:23-FEB-1996 16:43:17.08

TO: Patsy Fleming (FLEMING_P) (WHO)
READ:23-FEB-1996 17:02:23.83

TO: Janet B. Abrams (ABRAMS_J) (VPO)
READ:23-FEB-1996 19:17:54.42

TO: Julie E. Demeo (DEMEO_J) (OPD)
READ:26-FEB-1996 08:25:47.68

TO: Diana M. Fortuna (FORTUNA_D) (OPD)
READ:23-FEB-1996 17:00:13.33

TO: Christopher C. Jennings (JENNINGS_C) (WHO)
READ:23-FEB-1996 17:02:13.85

TO: Jeffrey Levi (LEVI_J) (WHO)
READ:23-FEB-1996 16:40:13.87

TO: Gaynor R. McCown (MCCOWN_G) (OPD)
READ:23-FEB-1996 16:56:22.45

TO: Molly Brostrom (BROSTROM_M) (WHO)
READ:23-FEB-1996 18:07:15.52

TO: Dorothy L. Karayannis (KARAYANNIS_D) (OPD)
READ:23-FEB-1996 16:41:34.65

TO: Deborah L. Fine (FINE_D) (OPD)
READ:23-FEB-1996 16:45:37.44

TO: Dennis Burke (BURKE_D) (OPD)
READ:23-FEB-1996 17:26:15.49

TO: Patricia E. Romani (ROMANI_P) (WHO)
READ:23-FEB-1996 16:45:29.60

TO: Denise Ricketson (RICKETSON_D) (OPD)
READ:23-FEB-1996 16:49:09.89

TO: Pamela Cicetti (CICETTI_P) (WHO)
READ:23-FEB-1996 17:29:59.41

TO: Elizabeth E. Drye (DRYE_E) (OPD)
READ:23-FEB-1996 17:00:10.61

TEXT:

OH, that URGENT was just to get your attention.

Staff meeting will start as promptly as possible Monday at 9:30 a.m. I have to be back in West Wing by 9:40 but do have a couple of things I want to go over with you and then Jeremy and Elizabeth will carry forward.

You are hereby ordered to have a great weekend! (That is the more urgent part!)

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:23-FEB-1996 13:44:12.82

SUBJECT: Morin and ADAP \$

TO: Nancy-Ann E. Min (MIN_N) (OMB)

READ:23-FEB-1996 15:56:54.95

TO: Marsha Scott (SCOTT_M) (WHO)

READ:23-FEB-1996 14:08:31.48

TEXT:

I spoke with Steve Morin about our plans for the budget amendment for ADAP, after hearing that he is pushing \$75 million. I explained that we were doing \$52 million -- and convinced him that it would NOT be helpful to have the groups pushing for a different number. He agreed to speak with his contacts to be sure that adjust their strategy. (AIDS Action is already on board with our approach.)